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Due to the increasing incidence of antibiotic resistant strains, the use of novel 
antimicrobials, such as bacteriocins, has become an ever more likely prospect. Lacticin 3147 
(of which there are two components, Ltnα and Ltnβ) and nisin belong to the subgroup of 
bacteriocins called the lantibiotics, which has attracted much attention in recent years. The 
lantibiotics are antimicrobial peptides that contain unusual amino acids resulting from a 
series of enzyme-mediated post translational modifications. Given that there have been 
relatively few examples of lantibiotic-specific resistance; these antimicrobials appear to 
represent valid alternatives to classical antibiotics. However, the fact that lantibiotics are 
naturally only produced in small amounts often hinders their commercialisation. In order to 
overcome this bottleneck, several approaches can be employed. For example, we can create 
a situation that reduces the quantity of a lantibiotic required to inhibit a target by 
combining it with other antimicrobials. Here, following an initial screen involving lacticin 
3147 and several classical antibiotics, it was observed between lacticin 3147 and the 
commercial antibiotics polymyxin B/E function synergistically. This reduced the amounts of 
the individual antimicrobials required for kill and broadened the spectrum of inhibition of 
both agents. Upon combination with polymyxins, lacticin 3147, which has been associated 
with Gram positive targets only, actively targeted Gram negative species such as Escherichia 
coli and Cronobacter sp. An alternative means of addressing problems associated with 
lantibiotic yield is to better understand how production is regulated, and ultimately use this 
information to enhance peptide levels. With this in mind the regulation of lacticin 3147 
production from the promoter Pbac was investigated using a green fluorescent protein (GFP) 
Abstract 
expression reporter system. This revealed that elements within both of the divergent 
operons of the lacticin 3147 gene cluster are involved in Pbac regulation. That is, LtnR, 
already established as a negative regulator of itself and the lacticin 3147 associated 
immunity genes, also acts as an activator of Pbac transcription. In contrast, an enhanced level 
of expression is observed in the absence of the lacticin 3147 structural genes, ltnA1 and 
ltnA2, indicating that these genes/gene products are involved in Pbac repression. In fact, 
through complementation of the ltnA2 gene, it was revealed that this regulation is more 
likely to be dependent on the presence of the gene transcript rather that the corresponding 
prepropeptide or modified Ltnβ.  
It may be that if lacticin 3147 production is successfully enhanced, the ability of the 
producing cell to protect itself may become an issue. To prepare for such a possibility a 
bioengineered derivative of the lacticin 3147 immunity protein LtnI (LtnI I81V) which 
provides enhanced protection was discovered through an in depth investigation involving 
the site and saturation mutagenesis of this protein. In addition, the creation of truncated 
forms of LtnI allowed the identification of important and essential regions of this immunity 
protein. Finally, as mentioned, self-immunity is essential to prevent self-killing. However the 
discovery of nisin U immunity and regulatory gene homologues (spiFEGRR’K) within the 
pathogenic strain S. infantarius subsp. infantarius is a cause for concern as it represents an 
example of immune mimicry, a form of lantibiotic-specific resistance. The ability of spiFEG to 
confer protection was apparent when they successfully provided protection to nisin A, F, Z, 
Q and U when expressed heterologously in the nisin sensitive L. lactis HP host.  
As a consequence of the studies presented in this thesis, it is likely that strategies 
will emerge that will facilitate the production of greater levels of lacticin 3147 production 
and lead to enhanced immunity in lactococcal backgrounds. Alternatively the need for 
enhanced production could be avoided through the use of antimicrobial combinations. In 
addition, providing awareness of the threats of the emergence of resistance through 
immune mimicry can allow researchers to develop strategies to prevent this phenomenon 
from leading to the dissemination of lantibiotic resistance. 
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Due to the increasing incidence of antibiotic resistant strains, the use of 
novel antimicrobials, such as bacteriocins, has become an ever more likely 
prospect. Lacticin 3147 (of which there are two components, Ltnα and Ltnβ) and 
nisin belong to the subgroup of bacteriocins called the lantibiotics, which has 
attracted much attention in recent years. The lantibiotics are antimicrobial peptides 
that contain unusual amino acids resulting from a series of enzyme-mediated post 
translational modifications. Given that there have been relatively few examples of 
lantibiotic-specific resistance; these antimicrobials appear to represent valid 
alternatives to classical antibiotics. However, the fact that lantibiotics are naturally 
only produced in small amounts often hinders their commercialisation. In order to 
overcome this bottleneck, several approaches can be employed. For example, we 
can create a situation that reduces the quantity of a lantibiotic required to inhibit a 
target by combining it with other antimicrobials. Here, following an initial screen 
involving lacticin 3147 and several classical antibiotics, it was observed between 
lacticin 3147 and the commercial antibiotics polymyxin B/E function synergistically. 
This reduced the amounts of the individual antimicrobials required for kill and 
broadened the spectrum of inhibition of both agents. Upon combination with 
polymyxins, lacticin 3147, which has been associated with Gram positive targets 
only, actively targeted Gram negative species such as Escherichia coli and 
Cronobacter sp. An alternative means of addressing problems associated with 
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lantibiotic yield is to better understand how production is regulated, and ultimately 
use this information to enhance peptide levels. With this in mind the regulation of 
lacticin 3147 production from the promoter Pbac was investigated using a green 
fluorescent protein (GFP) expression reporter system. This revealed that elements 
within both of the divergent operons of the lacticin 3147 gene cluster are involved 
in Pbac regulation. That is, LtnR, already established as a negative regulator of itself 
and the lacticin 3147 associated immunity genes, also acts as an activator of Pbac 
transcription. In contrast, an enhanced level of expression is observed in the 
absence of the lacticin 3147 structural genes, ltnA1 and ltnA2, indicating that these 
genes/gene products are involved in Pbac repression. In fact, through 
complementation of the ltnA2 gene, it was revealed that this regulation is more 
likely to be dependent on the presence of the gene transcript rather that the 
corresponding prepropeptide or modified Ltnβ.  
It may be that if lacticin 3147 production is successfully enhanced, the ability 
of the producing cell to protect itself may become an issue. To prepare for such a 
possibility a bioengineered derivative of the lacticin 3147 immunity protein LtnI 
(LtnI I81V) which provides enhanced protection was discovered through an in depth 
investigation involving the site and saturation mutagenesis of this protein. In 
addition, the creation of truncated forms of LtnI allowed the identification of 
important and essential regions of this immunity protein. Finally, as mentioned, 
self-immunity is essential to prevent self-killing. However the discovery of nisin U 
immunity and regulatory gene homologues (spiFEGRR’K) within the pathogenic 
strain S. infantarius subsp. infantarius is a cause for concern as it represents an 
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example of immune mimicry, a form of lantibiotic-specific resistance. The ability of 
spiFEG to confer protection was apparent when they successfully provided 
protection to nisin A, F, Z, Q and U when expressed heterologously in the nisin 
sensitive L. lactis HP host.  
As a consequence of the studies presented in this thesis, it is likely that 
strategies will emerge that will facilitate the production of greater levels of lacticin 
3147 production and lead to enhanced immunity in lactococcal backgrounds. 
Alternatively the need for enhanced production could be avoided through the use 
of antimicrobial combinations. In addition, providing awareness of the threats of 
the emergence of resistance through immune mimicry can allow researchers to 
develop strategies to prevent this phenomenon from leading to the dissemination 
of lantibiotic resistance. 
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Summary 
The dramatic rise in the incidence of antibiotic resistance demands that new 
or varied treatments will have to be developed. One potentially interesting class of 
antimicrobials are the modified bacteriocins termed lantibiotics, bacterially 
produced post-translationally modified, lanthionine/methyl-lanthionine containing 
peptides. This is in part due to the low levels of resistance reported for lantibiotics 
as compared with commercial antibiotics. Given that there are very few examples 
of naturally occurring lantibiotic resistance, the deliberate induction of such 
phenotypes and/or the creation of deletion mutations in resistance genes have 
been used to investigate this phenomenon. Mechanisms that hinder the action of 
lantibiotics are often innate systems that react to the presence of any cationic 
peptides/proteins, or which result from cell well damage, rather than being 
lantibiotic specific. Such resistance mechanisms often arise due to altered gene 
regulation following detection of antimicrobials/cell wall damage by sensory 
proteins at the membrane. This facilitates alterations to the cell wall or changes in 
the composition of the membrane. Other general forms of resistance include the 
formation of spores or biofilms, which are a common mechanistic response to 
many classes of antimicrobials. In rare cases bacteria have been shown to possess 
specific anti-lantibiotic mechanisms. These are often species specific and include 
the nisin lytic protein nisinase and the phenomenon of immune mimicry.  
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Introduction 
Lantibiotics are ribosomally-synthesised antimicrobial peptides produced by 
Gram positive bacteria. They undergo post-translational modification which results 
in the presence of unusual amino acids such as dehydroalanine (Dha) and 
dehydrobutyrine (Dhb) as well as the eponymous lanthionine/methyllanthionine 
residues. Lantibiotics are subclassified on the basis of their biosynthetic machinery 
and the amino acid sequence of the structural peptide (Rea et al., 2011). The most 
characterised lantibiotic is nisin (subclass 1), which has been used in the dairy and 
food industry for decades. It is a 3353 Da cationic, linear peptide of 34 amino acids 
produced by Lactococcus lactis subsp. lactis that contains five intramolecular ring 
structures. It has a dual mode of action, both preventing cell wall biosynthesis and 
also forming pores in the cell membrane of susceptible cells (Wiedemann et al., 
2001). Lantibiotics have been frequently suggested to have the potential to be 
utilised in a wide range of medical applications (see reviews (Cotter et al., 2005a; 
Cotter et al., 2013; Piper et al., 2009). One of these reasons is that, in comparison 
to commercial antibiotics, resistance to lantibiotics is relatively rare. However, 
resistance has been induced in laboratory settings and this, in addition to the innate 
resistance characteristics of the bacterial cell, is the subject of this review. 
 
Mode of action 
In order to appreciate the various mechanisms by which bacteria are, or 
become resistant, to lantibiotics, it is first necessary to understand their mode of 
action. In the case of many cationic lantibiotics, or lantibiotics with cationic 
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domains, there is an initial attraction to the anionic cell membrane of target 
microbes (Asaduzzaman et al., 2006; Deegan et al., 2010; Moll et al., 1996). 
Notably, changes in lantibiotic charge as a result of genetic engineering alters the 
efficacy of such lantibiotics, presumably due to reduced attraction/interaction with 
the cell membrane (Deegan et al., 2010; Kraaij et al., 1997). Once at the membrane, 
lantibiotics such as nisin, mersacidin, epidermin, plantaricin C and lacticin 3147 
(Ltnα) bind and form a complex with a docking molecule, lipid II (Breukink et al., 
1999; Brotz et al., 1998a; Brotz et al., 1998b; Wiedemann et al., 2006a; Wiedemann 
et al., 2006b). Lipid II is a precursor of cell wall peptidoglycan and is found at the 
outer leaflet of the bacterial membrane, and so the lantibiotic: lipid II complex 
inhibits peptidoglycan synthesis. Nisin binds the pyrophosphate linker of lipid II 
(Hsu et al., 2004), as does plantaricin C and lacticin 3147 (Ltnα) (Wiedemann et al., 
2006a; Wiedemann et al., 2006b). Mersacidin and members of the mersacidin 
group of lantibiotics target the N-acetylglucosamine (GlcNAc) moiety and most 
probably the sugar and phosphate residues of lipid II (Bierbaum & Sahl, 2009). Lipid 
I has also been identified as a target of nisin and epidermin (Brotz et al., 1998b); 
lipid I is essentially lipid II before the acquisition of the GlcNAc moiety. However, 
binding to lipid II has a more pronounced effect. It should be noted that lipid I or 
lipid II are not the target of all lantibiotics and the targets of some lantibiotics are 
yet to be found, such as those of Pep5 and epilancin K7 (Pag et al., 1999). For some 
lantibiotics that bind lipid II, including nisin, this binding not only inhibits cell wall 
biosynthesis but also facilitates pore formation and leads to the release of ions and 
molecules from the target bacteria (Benz et al., 1991; Bierbaum & Sahl, 2009). Two-
component lantibiotics, such as lacticin 3147, are thought to function through the 
9 
 
formation of a three member complex, with the α peptide targeting lipid II and then 
sequestering the β peptide for pore formation (Wiedemann et al., 2006b). There 
are a few models which describe how the structural conformation of lantibiotics 
within the membrane leads to pore formation. This includes the barrel-stave 
mechanism described by Sahl (Sahl, 1991), the wedge model (Driessen et al., 1995) 
and a model described by Chikindas (Chikindas et al., 1995). However, not all 
lantibiotics form pores. Mersacidin, actagardine and cinnamycin (all members of 
the globular subclass II lantibiotics) only block cell wall/membrane synthesis by 
binding to receptors, i.e. lipid II or phosphatidylethanolamine (Brotz et al., 1995; 
Machaidze & Seelig, 2003). Gallidermin (and related peptides) is unusual in that, 
while it possesses the same putative lipid II binding motif as nisin, it is considerably 
shorter (22 amino acids, compared to the 34 of nisin). As a result, the ability of 
gallidermin to form pores depends on the membrane thickness of the target cell 
and, thus, against some target cells it is the interaction with lipids I and II alone, and 
not pore formation, that is responsible for inhibiting these targets. The superior 
activity of gallidermin over nisin in a cell wall biosynthesis assay would seem to 
explain its high killing potency even in situations where it doesn’t form pores 
(Bonelli et al., 2006). 
Another activity that has been attributed to a number of lantibiotics, 
including nisin, subtilin and sublancin, is the ability to prevent spore outgrowth by 
Bacillus and Clostridium species (Hurst, 1981; Paik et al., 1998). An in depth study 
into the mechanism of action in B. anthracis identified that the initiation of 
germination is essential for the action of nisin. The action of nisin is governed by 
two events during the outgrowth of spores: the establishment of metabolism and 
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the shedding of the external spore structures (Gut et al., 2008). In L. lactis, 
truncated nisin A mutants lacking rings D and E were unable to form pores in the 
membranes or cause a disruption of the membrane potential, but were still able to 
inhibit the outgrowth of Bacillus subtilis spores (Rink et al., 2007). In contrast, 
mutants in the hinge region of nisin (N20P/M21P and M21P/K22P) which retained 
the ability to bind lipid II, but were unable to form pores, had antimicrobial activity 
against vegetative cells of B. anthracis but did not inhibit spore outgrowth. 
Therefore in B. anthracis, at least, pore formation is essential to limit spore 
outgrowth, which suggests that nisin utilizes lipid II as the germinated spore target 
during outgrowth inhibition and that nisin-mediated membrane disruption is 
essential to inhibit spore development into vegetative cells (Gut et al., 2011). 
It should be noted that there are a number of specific antimicrobial 
activities associated with individual lantibiotics (Asaduzzaman et al., 2006). In 
addition, related peptides referred to as lanthipeptides have functions other than 
as antimicrobial agents (Arnison et al., 2013). The morphogenetic peptides SapB 
and SapT from Streptomycetes act in such a manner (Kodani et al., 2005). These 
peptides are believed to function as biosurfactants during the formation of aerial 
hyphae (Willey et al., 2006). 
 
The Role of Cell Wall Modifications in Resistance 
Lipid II 
In addition to many lantibiotics, a number of other antibiotics also interact 
with lipid II (e.g. vancomycin), albeit through different parts of the target molecule. 
Lipid II is the precursor of cell wall biosynthesis found at the outer leaflet of the 
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bacterial membrane. The main structural component of the bacterial cell wall 
consists of peptidoglycan which is a polymer of a repeating N-acetylmuramic acid 
(MurNAc) and GlcNAc motif, cross-linked via peptides attached to MurNAc. The 
final steps in the maturation are catalysed by a penicillin-binding protein (PBP), a bi-
functional enzyme which catalyses polymerization of the sugar units 
(glycosyltransfer), as well as peptide cross-linking (transpeptidation), utilizing Lipid 
II as substrate (Schwartz et al., 2001). Lipid II, as the corresponding monomer, 
consists of a single disaccharide pentapeptide bound to a polyisoprenoid anchor 
called undecaprenyl by a pyrophosphate linker. Binding of antimicrobial substances 
to lipid II interferes with peptidoglycan biosynthesis by physically sequestering the 
compound and preventing its utilization by transpeptidase and transglycosylase 
enzymes that install the cross-linked network of the bacterial cell wall (Lazar & 
Walker, 2002).  
Recently, it was shown that nisin and gallidermin also bind to other 
intermediates of the wall teichoic acid (WTA) biosynthesis pathway, including lipid 
III (undecaprenol-pyrophosphate-N-acetylglucosamine) and lipid IV (undecaprenol-
pyrophosphate-N-acetylglucosamine-N-acetyl-mannosamine), with the specific 
interaction with WTA precursors promoting pore formation in artificial lipid bilayers 
(Müller et al., 2012).   
Despite the importance of lipid II to the activity of many lantibiotics, 
quantification of the levels of lipid II in nisin-sensitive Micrococcus flavus, nisin-
sensitive Listeria monocytogenes and their nisin-resistant variants indicated that 
nisin resistance was independent of lipid II levels (Kramer et al., 2004). 
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DltA 
Bacterial membranes usually have an overall negative net charge. 
Bacteriocins, including the lantibiotics, resemble a considerable proportion of the 
antimicrobial molecules associated with human, vertebrate, invertebrate and plant 
host defence systems in that they have cationic properties that confer a high 
affinity for the anionic bacterial cell envelope (Weidenmaier et al., 2003). The Gram 
positive bacterial cell wall comprises a thick peptidoglycan fabric as well as 
polymers of alternating phosphate and alditol groups called teichoic acids. Teichoic 
acids are classified in two groups: WTA (as mentioned previously), which are 
phosphodiester-linked via a linkage unit to muramic acid residues of peptidoglycan 
(Hancock & Baddiley, 1985; Ward, 1981), and lipoteichoic acids (LTA), which are 
macroamphiphiles anchored hydrophobically through the fatty acid residues of 
their glycolipid component in the outer layer of the cytoplasmic membrane 
(Fischer, 1988). The dlt (D-alanyl-lipoteichoic acid) operon is responsible for D-
alanine esterification of both LTA and WTA (Fig. 1(a)) (Perego et al., 1995). The dlt 
operon has been characterized across many species and contains four genes 
required for functionality: dltABCD (Neuhaus & Baddiley, 2003). The role of DltA is 
to act as a D-alanine-D-alanyl carrier protein ligase (Dcl), which activates D-alanine 
by hydrolysis of ATP and transfers it to the phosphopantetheine co-factor of a 
specified-alanine carrier protein (Dcp), encoded by dltC (Heaton & Neuhaus, 
1992). The hydrophobic DltB, which may have a transmembrane location, is 
required for D-alanine incorporation into teichoic acids, possibly through the 
transfer of activated D-alanine across the cytoplasmic membrane (Perego et al., 
1995). It is thought that DltD transfers D-alanine from the membrane carrier to 
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teichoic acids, as indicated by the apparent presence of an N-terminal signal 
peptide. The dltABCD gene sequence and organization is highly conserved across a 
range of species (Peschel et al., 1999). In Streptococcus agalactiae, however, in 
addition to these genes, two regulatory genes of the dlt operon, designated dltR 
and dltS are located upstream of dltA (Poyart et al., 2001). In C. difficile, a putative 
regulatory protein (CD2850) is thought to negatively regulate the dlt operon 
(McBride & Sonenshein, 2011a).  
As a result of the D-alanylation of teichoic acids, positive charges are 
incorporated into the cell wall. Hence, cationic antimicrobial peptides (CAMPs) such 
as nisin and gallidermin are repelled from the cell envelope of target 
microorganisms such as L. monocytogenes, B. cereus, Clostridium difficile, S. 
pneumoniae and S. aureus (Abachin et al., 2002; Khattar et al., 2009; Kovacs et al., 
2006; McBride & Sonenshein, 2011a; Peschel et al., 1999). This is a form of innate 
lantibiotic resistance and becomes particularly evident in the presence of 
antimicrobial peptides that trigger a signalling pathway that up-regulates the 
process (Peschel et al., 1999). This phenomenon was first reported by Peschel et al., 
who determined that a dltA mutant of S. aureus and dltA, dltB, and dltD mutants of 
Staphylococcus xylosus did not produce D-alanine esters in their teichoic acids, and 
that these conditions increased their sensitivity to CAMPs, including the lantibiotic 
gallidermin. Additionally this study showed that wild-type strains of Staphylococcus 
bearing additional copies of the dlt operon contained greater amounts of D-
alanylated teichoic acids, and hence repelled cationic proteins more effectively and 
were less sensitive to gallidermin (Peschel et al., 1999). It was also notable that 
spontaneously nisin-resistant mutants of L. lactis IL1403 expressed the dlt and gal 
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operons at a higher level (Kramer et al., 2006). The relevance of the gal operon, 
associated with the Leloir pathway (Grossiord et al., 2003), is that galE encodes a 
UDP-glucose 4-epimerase that is responsible for the synthesis of α-galactose, which 
is transported across the membrane to become a substituent of LTA. This 
observation led to further studies in L. lactis MG1363, which established that L. 
lactis MG1363ΔgalAMK was twice as sensitive to nisin as the wild-type, suggesting 
that α-galactose incorporation has an effect on LTA structure and thus is important 
in nisin resistance. In addition the LTA of the resistant strain contains twice as much 
α-galactose as the wild-type, which could indicate a more densely packed LTA, and 
ultimately making the cell-wall barrier less negatively charged due to the action of 
DltA (Kramer et al., 2006). Nisin-resistant cells also appeared to have more 
lipoteichoic acid than nisin-sensitive cells. In addition de-esterified lipoteichoic acids 
from nisin-resistant cells migrated more slowly through a polyacrylamide gel than 
those from nisin-sensitive cells. These results indicated that lipoteichoic acids could 
be modified to increase the resistance of Streptococcus bovis to nisin (Mantovani & 
Russell, 2001). LTA alanylation also seems to affect the susceptibility 
of Streptococcus pneumoniae to nisin (Kovacs et al., 2006) 
In the absence of dltA, Abachin et al. discovered that L. monocytogenes was 
severely impaired in a mouse infection model (4 log increase in the LD50) and, in 
vitro, the adherence of the mutant to various cell lines was impaired, although the 
amounts of surface proteins associated with virulence (ActA, InlA and InlB) 
remained unaffected. These results show that the D-alanylation of the LTAs 
contributes to the virulence of the intracellular pathogen L. monocytogenes 
(Abachin et al., 2002). However, to date, the contrary has not been identified where 
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increased levels of DltA may contribute to virulence. So whether such a mechanism 
could enhance virulence due to sensing increased levels of DltA as well as 
enhancing the lantibiotic resistance of a strain has yet to be determined. 
 
Penicillin-Binding Proteins 
Multi-modular penicillin-binding proteins (PBPs) are responsible for 
peptidoglycan assembly. They are subcategorized as class A or B, depending on the 
structure and the catalytic activity of their N-terminal module. The C-terminal of the 
penicillin-binding protein modules of both classes catalyse peptide cross-linking 
between two adjacent glycan chains through their transpeptidase activity (Goffin & 
Ghuysen, 1998). The N-terminal module of PBPs belonging to class A are 
responsible for the glycosyltransferase activity leading to glycan chain elongation 
(Terrak et al., 1999), whereas in class B PBPs this domain is responsible for 
interactions with other proteins during septation and also regulates the shape of 
bacterial cells (Marrec-Fairley et al., 2000). 
There have been a number of instances in which a relationship between 
lantibiotic resistance and PBPs has been noted. First, the expression level of a 
putative PBP was found to be significantly increased in a spontaneous nisin-
resistant strain of L. monocytogenes compared to the wild-type non-resistant strain 
(Gravesen et al., 2001). This strain was also slightly more resistant to mersacidin but 
was sensitive to a variety of different beta-lactam antibiotics. Similarly, expression 
of the gene encoding PBP2A (class B PBP) was higher in a nisin-resistant mutant of 
L. lactis IL1403 than in the corresponding wild-type strain, leading to speculation 
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that resistance was provided by a thicker and more densely packed cell wall 
(Kramer et al., 2006).  
The class A penicillin-binding protein PBP4 (encoded by lmo2229) of L. 
monocytogenes has been implicated in nisin resistance as disruption of the 
encoding gene enhanced nisin sensitivity, with a 1.66-fold decrease in MIC (Guinane 
et al., 2006). It was also observed that increased expression of LiaS, a histidine 
kinase element which regulates PBP2229 (PBP4), resulting in increased levels of PBP 
and nisin resistance in Listeria (Gravesen et al., 2004). Gravesen et al. suggest that 
PBP2229 mediates enhanced nisin resistance by shielding lipid II and in addition 
reduces the extracellular lipid II concentration (Gravesen et al., 2004). This 
hypothesis is in accordance with previous studies that suggest nisin sensitivity is 
affected by the accessibility of lipid II (Breukink et al., 1999; Gravesen et al., 2001). 
Curiously, mutation of another histidine kinase element, LisK, results in enhanced 
nisin resistance despite reducing expression of both pbp2229 and liaS (Cotter et al., 
2002).  
 
IrpT/RmlD 
Another novel gene involved in nisin resistance is irpT, disruption of which 
leads to an increased level of resistance. While IrpT is not directly involved in nisin 
resistance, it has a role in gene regulation. In the absence of IrpT, the gene rmlD 
and four others are up-regulated in Lactococcus lactis subsp. lactis N8 (Xuanyuan et 
al., 2010). RmlD is involved in the synthesis of dTDP-l-rhamnose, which is a 
precursor involved in cell wall polysaccharides backbone production (Tsukioka et 
al., 1997). The importance of RmlD was confirmed when it was established that 
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overexpression of the corresponding gene in L. lactis MG1363 enhanced nisin 
resistance (Xuanyuan et al., 2010). 
 
Resistance of Spores to Lantibiotics 
Bacterial spores are extremely resistant to biocides, thanks in particular to 
their thickly layered proteinaceous spore coat (for review see (Leggett et al., 2012)). 
Although they do not kill spores, lantibiotics such as nisin can be sporostatic, 
preventing spore outgrowth. An investigation of nisin resistant mutants of 
Clostridium botulinum created through continuous exposure to the lantibiotic 
resulted in resistant mutants (both spores and vegetative cells) which had the 
ability to germinate in levels of nisin that reduced the parental strain by 7-8 log 
cycles (Mazzotta et al., 1997). Although the mechanism by which the action of nisin 
is circumvented in these resistant mutants is unknown, it appears that it is not a 
nisin specific phenomenon as resistance was observed to a variety of bacteriocins, 
across a range of classes.  
 
Cell Membrane Modifications 
Lipopolysaccharide (LPS) 
Lantibiotics are generally produced by Gram positive bacteria and are most 
active against other Gram positive strains. Gram negative target microorganisms 
are usually very resistant to lantibiotics as the architecture of their outer membrane 
prevents the penetration of the lantibiotics (with sizes of approximately 1800–4600 
Da) to the cytoplasmic membrane (Fig. 1(f)) (Brotz & Sahl, 2000; Schved et al., 1994; 
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Stevens et al., 1991). The outer layer of the outer membrane serves as the site of 
attachment for lipid A, an anionic dimer of glucosamine linked to fatty acid chains 
and flanked by polar phosphate groups. Lipid A is covalently bonded to a core 
polysaccharide and a specific O-chain consisting of repeating oligosaccharide units. 
This complex is referred to as lipopolysaccharide (LPS), unless it lacks the O-chain, 
in which case it is named lipooligosaccharide (LOS) (Rietschel et al., 1994). Chelating 
agents such as EDTA as well as the application of sublethal stresses such as heating 
or freezing can disrupt the LPS barrier leading to an increased sensitivity among 
enterobacteria to lantibiotics (Boziaris & Adams, 2000; Kalchayanand et al., 1992; 
Stevens et al., 1991). Even without such treatments some lantibiotics possess 
limited activity against Gram negative targets. Microbisporicin, which selectively 
blocks peptidoglycan biosynthesis causing cytoplasmic UDP-linked precursor 
accumulation, has some activity against Gram negative species (such as E. 
coli, Moraxella catarrhalis, Neisseria spp., and Haemophilus influenza), which is 
unseen in other lantibiotics (Castiglione et al., 2008). However, the mechanistic 
basis for this enhanced activity has yet to be elucidated. Some bioengineered nisin 
mutants, altered at serine residue 29, are also exceptional by virtue of their 
enhanced activity against Gram negative strains such as Cronobacter sakazakii, E. 
coli and Salmonella Typhimurium (Field et al., 2012).   
 
Lipid Composition  
The lipid composition of the bacterial cell membrane also impacts on the 
levels of resistance. Membranes contain phospholipids whose composition and 
relative abundance vary profoundly, both between species and under various 
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environmental conditions and growth phases (DiRusso & Nystrom, 1998; Ratledge 
& Wilkinson, 1988). The most common bacterial phospholipids are 
phosphatidylglycerol (PG) and diphosphatidylglycerol (cardiolipin), whose head 
groups are negatively charged (Huijbregts et al., 2000). Others, such as 
phosphatidylethanolamine (PE) (a zwitterion), are found in enterobacteriaceae 
(Matsumoto, 2001) and bacilli (De Mendoza et al., 1993) but not in Staphylococcus 
(Nahaie et al., 1984) or Listeria species (Fischer & Leopold, 1999). In a nisin-resistant 
variant of L. monocytogenes Scott A increased levels of PG over cardiolipin was 
identified as the mechanism of resistance (Verheul et al., 1997). There are 
corroborating reports that nisin has a greater propensity to penetrate membranes 
composed of cardiolipin over PG, PE, phostaphatidylcholine (PC), 
monogalactisyldiacylglycerol (MGDG) and digalactisyldiacylglycerol (DGDG) (Demel 
et al., 1996). Decreased levels of the  anionic phospholipids PG and cardiolipin and 
increased levels of the neutrally charged PE were also associated with nisin 
resistance in L. monocytogenes ATCC 700302 (Crandall & Montville, 1998). Such a 
phospholipid composition results in a decrease in membrane net negative charge 
and hence diminishes the ability of nisin to interact with the membrane (Fig. 1(b)). 
Nisin resistant cells have been reported to have decreased levels of phospholipids 
and to have a greater ration of straight-chained:branch-chained fatty acids than 
parental cells (Fig. 1(c)) (Ming & Daeschel, 1995). Reduced membrane fluidity has 
also been associated with nisin resistance, with increased long-chain fatty acids and 
reduced ratios of C15/C17 fatty acids contributing to a more rigid membrane 
conformation (Martinez & Rodriguez, 2005; Mazzotta & Montville, 1997; Ming & 
Daeschel, 1993). 
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MprF 
Lysine esterification of one of the two hydroxyl groups of PG results in the 
free amino groups imparting a net positive charge on PG, creating lysyl-
phosphatidylglycerol (L-PG)  (Peschel et al., 2001; Ratledge & Wilkinson, 1988). The 
presence of L-PG and the process of lysinylation has been described in several 
bacterial pathogens, including S. aureus (Nahaie et al., 1984; Peschel et al., 2001), L. 
monocytogenes (Fischer & Leopold, 1999; Thedieck et al., 2006) and 
Mycobacterium tuberculosis (Maloney et al., 2009), as well as some soil organisms 
such as Bacillus species (Samant et al., 2009; Staubitz & Peschel, 2002). This 
lysinylation process is performed by MprF (multiple peptide resistance factor) 
which catalyses the transfer of lysine residues from lysyl-tRNAs to PG (Gould & 
Lennarz, 1967; Lennarz et al., 1966; Staubitz et al., 2004) and which appears to have 
a major role in resistance to antimicrobial peptides (Fig. 1(e)). Identification of the 
protein responsible has led to the corresponding gene being detected in a 
considerable number of Gram positive and Gram negative genomes (Weidenmaier 
et al., 2003). In fact, sequence comparisons with known PG synthase sequences 
allowed the identification of mprF homologues in 347 microorganisms, including 31 
genera of Gram positive bacteria (mostly Firmicutes and Actinobacteria), 59 genera 
of Gram negative bacteria (mostly Proteobacteria), and in three species of Archaea 
within the genus Methanosarcina (Roy, 2009).  
MprF proteins are integral membrane proteins with two separable 
functional domains; a well-conserved hydrophilic cytoplasmic domain at the             
C terminus that synthesizes L-PG and a large hydrophobic domain at the N terminus 
that facilitates the flipping of L-PG (Ernst et al., 2009). Both domains of MprF are 
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necessary for the resistance phenotype. The C-terminal domain and six of the 
fourteen proposed transmembrane segments of MprF are sufficient for the full 
synthesis of L-PG, but they do not lead to an efficient resistance phenotype, since 
most of the L-PG remains in the inner layer of the cytoplasmic membrane. 
However, full resistance is achieved when the N-terminal domain is co-expressed 
with the L-PG synthase domain and the L-PG is translocated to the outer layer of 
the membrane (Ernst et al., 2009). L-PG-deficient mutants exhibit increased 
susceptibilities to many cationic peptides. This was first noted when a mutant 
of S. aureus devoid of L-PG was found to be more susceptible to gallidermin and 
nisin (Peschel et al., 2001). Comparable effects due to loss of L-PG synthesis were 
observed for L. monocytogenes, with the corresponding deletion mutant being 
significantly more susceptible to gallidermin and the α-defensins HNP-1 and HNP-2 
(Thedieck et al., 2006). 
Some Gram positive bacteria, such as Clostridium perfringens SM101, 
possess two mprF homologous genes (mprF1 and mprF2). While mprF2 encodes a 
lysyl-phosphatidylglycerol synthase (L-PGS), mprF1 encodes an alanyl 
phosphatidylglycerol synthase (A-PGS). The formation of alanyl 
phosphatidylglycerol (A-PG) and L-PG was shown to be tRNA-dependent using Ala-
tRNAs and Lys-tRNAs as substrates, respectively (Roy & Ibba, 2008; Staubitz et al., 
2004). In E. faecalis, mprF1 and mprF2 homologues have been identified, although 
only MprF2 is involved in aminoacylation and formation of L-PG, A-PG, and R-PG 
(Bao et al., 2012), a task also carried out by a single MprF protein found in E. 
faecium (Roy & Ibba, 2009). Aminoacylation of PG with glycine and ornithine has 
also been described (Gould & Lennarz, 1967; Houtsmuller & van, 1963). By 
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producing the MprF A-PGS protein of C. perfringens in an S. aureus mprF deletion 
mutant, it was established that the production of A-PG rather than L-PG production 
did not affect susceptibility to antimicrobials such as nisin and gallidermin or to the 
antibiotic daptomycin (Slavetinsky et al., 2012). This indicates that the zwitterion A-
PG is just as effective as the cationic L-PG in protecting the cell and maintaining 
resistance. A-PG contributes up to 6% to the overall lipid content of Pseudomonas 
aeruginosa. A-PG deficiency (due to deletion of an mprf homologue) leads to 
increased susceptibility to β-lactam antibiotics (ampicillin, oxacillin, and cefsulodin), 
the lipopeptide antibiotic daptomycin and other antimicrobials (protamine sulfate, 
poly-l-lysine, and polymyxin E) as well as chromium ions (Arendt et al., 2012; Klein 
et al., 2009), indicating that MprF contributes to reducing the antimicrobial 
susceptibility in both Gram positive and Gram negative microorganisms. 
A similar protective mechanism has been identified in M. tuberculosis. In 
these bacteria, the lysX gene, encoding the two-domain lysyl-transferase (MprF)-
lysyl-tRNA synthetase (LysU) protein, is responsible for L-PG production. A lysX 
deletion mutant shows sensitivity to cationic antibiotics and antimicrobial peptides. 
This mutant also shows altered membrane potential compared to the wild-type 
strain and an increased association with lysosome-associated membrane protein–
positive vesicles. This indicates that the lysX mutant strain is not as adept at 
preventing fusion of phagosomes with lysosomes, a process which is partly required 
to allow intramacrophage replication (Maloney et al., 2009). It is interesting to note 
that the expression of the mprF fragment of lysX alone does not lead to the 
production of L-PG. This is notable since two lysU genes are encoded in M. 
tuberculosis, one is a cytosolic essential gene, the other as a domain of lysX. It 
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therefore appears that unlike other bacteria, the cytosolic LysU and the membrane-
bound MprF do not cooperate to produce L-PG (Maloney et al., 2009). 
In conclusion, the presence of these aminoacylated PGs provides a way for bacteria 
to shield themselves from the action of lantibiotics, and CAMPs in general. The 
extent of this protection can be considerable ranging from a 1.5 fold increase in the 
amount of gallidermin required to inhibit L. monocytogenes (Thedieck et al., 2006), 
to a 7- and 28- fold increase in resistance to gallidermin and nisin, respectively, in S. 
aureus (Peschel et al., 2001).  
 
fab Operon 
In a nisin resistant L. lactis strain, the operon fabDG1G2Z1Z2 is expressed to 
a lower extent than in the sensitive wild-type (Kramer et al., 2006). This operon is 
involved in membrane synthesis via saturation and elongation of phospholipids 
(Heath & Rock, 1995). The decreased expression of the fab operon might lead to a 
reduced amount of saturated fatty acids and less elongated fatty acids in the 
membrane, making it less densely packed. Such alterations in cytoplasmic 
membrane composition might influence the ability for nisin to interact with the 
membrane and thus increase resistance. However, further investigations are 
required to definitively establish the contribution of this operon in providing 
protection against lantibiotics. 
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Two Component Systems Associated With Lantibiotic Resistance 
Two-component systems (TCS) are thought to function as a monitor that 
allows the cell to adapt to specific environmental conditions. It contains a sensor 
that encodes a sensory histidine-kinase (HK) and a regulator that encodes a cognate 
response regulator. In addition, an intramembrane-sensing HK (IM-HK) lack an 
extracytoplasmic domain, indicative for a sensing process at or from within the 
membrane interface. Two major groups are found in Firmicutes linked to 
maintaining cell envelope integrity, mediating antibiotic resistance, or 
detoxification processes and can be differentiated based on sequence similarity and 
genomic context: (1) BceS-like IM-HK that are functionally and genetically linked to 
ABC transporters, and (2) LiaS-like IM-HK, as part of three-component systems (Fig. 
2).  
 
1. BceRS-like Two Component Systems  
BceRS of B. subtilis 
BceS-like IM-HKs possess two transmembrane helices but lack any 
extracellular sensory domains. They are functionally and genetically linked to ABC 
transporters named BceAB (Dintner et al., 2011; Mascher, 2006). They are almost 
exclusively found in Firmicutes, with 80% of the transporters associated with a 
BceRS-like TCS (Dintner et al., 2011). It would appear that the presence of 
antimicrobial peptides cannot be detected by these histidine kinases alone, but 
rather that this resistance module relies on the transporters for stimulus 
recognition i.e. in the presence of an antimicrobial peptide, the transporter 
somehow communicates with the sensor kinase. It is believed that this involves 
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direct contact between the transporter and histidine kinase (Dintner et al., 2011; 
Falord et al., 2012). However, the mechanism by which signalling occurs is as yet 
unknown. This communication leads to the activation of the cognate response 
regulator and, subsequently, an induction of transporter gene expression. 
Importantly, ATP hydrolysis by the transporter, and therefore active transport, are 
required for the signalling process (Fig. 2) (Hiron et al., 2011; Rietkotter et al., 
2008).  
Experimental evidence from a number of homologous systems from B. 
subtilis, Staphylococcus aureus, Streptococcus mutans, and Lactobacillus casei 
confirms that this signalling pathway is a general characteristic of the Bce-type 
modules and, on a number of occasions has been associated with lantibiotic 
resistance (Falord et al., 2012; Hiron et al., 2011; Ouyang et al., 2010; Revilla-
Guarinos et al., 2013; Rietkotter et al., 2008; Staron et al., 2011). For example in L. 
lactis, a homologue named LlrG/KinG, is found encoded either side of a VanZ-like 
protein. VanZ is found in E. faecium and confers resistance to teicoplanin (Arthur et 
al., 1995). Downstream from llrG/kinG, the ABC transporter ysaBC is located. The 
expression of this transporter is induced by nisin and consequently confers 
resistance to this lantibiotic (Kramer et al., 2006). 
The BceAB-type transporters are well characterised and have been classified 
within the peptide-7 exporter (Pep7E) family in the Transport Classification 
Database (TCDB) (Saier et al., 2009). These transporters are composed of an ATPase 
(BceA) and a permease (BceB) component with 10 transmembrane helices and a 
characteristic, large, extracellular domain of approximately 200 amino acids 
between helices VII and VIII. These transporters contribute to B. subtilis bacitracin 
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and lantibiotic resistance. With the obseved MIC of bacitracin for the bceAB mutant 
reduced ∼30 fold and resistance to actagardine and mersacidin reduced ∼2- to 4-
fold (Mascher et al., 2003; Ohki et al., 2003; Rietkotter et al., 2008; Staron et al., 
2011). Through random mutagenesis, the specific functions of the transporter were 
found to be primarily associated with the C-terminal region of the permease, BceB, 
and particularly in the eighth transmembrane helix. Furthermore, although 
signalling and resistance are functionally interconnected, several mutations 
identified had stronger effects over one than the other (Kallenberg et al., 2013). 
The co-occurrence and coevolution of Pep7E transporters and the BceRS-like TCS  
has led to the hypothesis that a functional link always exists between these 
systems, in which they cooperate in both signalling and detoxification (Dintner et 
al., 2011). In addition to BceRS-AB, there are two further paralogous peptide-
sensing and detoxification (ABC transporter) modules present within the B. subtilis 
genome i.e. YxdJK-LM and PsdRS-AB (formerly YvcPQ-RS). The YxdJK-LM system 
responds to the human antimicrobial peptide LL-37 (Pietiainen et al., 2005) and the 
PsdRS-AB system responds primarily to lipid II-binding lantibiotics, such as nisin, 
gallidermin, subtilin, and actagardine (strongest inducer) as well as the lipid II-
binding lipopeptide, enduracidin. Other lantibiotics, including Pep5, mersacidin 
sublancin and duramycin, as well as for lipid II-binding antibiotics vancomycin and 
ramoplanin, are not inducers (Staron et al., 2011). On the basis of these findings, 
and the different lipid II-associated motifs that these peptides target, it would seem 
that PsdRS induced expression is linked to antimicrobials with an N-terminal lipid II-
binding motif, referred to as a pyrophosphate cage. A range of TCSs were 
characterised in L. casei BL23, insertional mutations identified that of these TC09 
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and TC12, which are homologous to the three paralogous TCS of B. subtilis, BceRS, 
PsdRS, and YxdJK were responsible for nisin resistance. Of the remaining mutated 
TCSs identified, some showed more or even greater sensitivity to nisin and one 
(T04) showed more resistance (Alcantara et al., 2011).  
 
BraRS of S. aureus 
A BceRS-like (IM-HK) TCS associated with S. aureus, BraRS, has been shown 
to be essential for resistance to bacitracin, nisin and nukacin ISK-1 (Hiron et al., 
2011; Kawada-Matsuo et al., 2013b; Kolar et al., 2011; Yoshida et al., 2011). As a 
consequence of having been identified in three separate studies, this TCS is also 
referred to as BceRS (Yoshida et al., 2011) and NsaRS (Blake et al., 2011). The name 
BraRS (bacitracin resistance associated) is representative of its characteristics and 
so has been chosen for further referral (Hiron et al., 2011). Through use of a lacZ 
reporter–gene fusion, it has been demonstrated that braRS expression is up-
regulated by a variety of cell-envelope-damaging antibiotics, including 
phosphomycin, ampicillin, nisin, gramicidin, carbonyl cyanide m-
chlorophenylhydrazone and penicillin G (Kolar et al., 2011). Immediately 
downstream of braRS are the genes which encode the ABC transporter BraDE (an 
example of the BceAB type transporters discussed above), which is also of key 
importance to bacitracin and nisin resistance through sensing and signalling 
through BraRS. BraRS also activates transcription of the detoxification ABC 
transporter, vraDE (Hiron et al., 2011) (Fig. 3). Highly conserved imperfect 
palindromic sequences have been identified upstream from the braDE and vraDE 
promoter sequences that are essential for transcriptional activation by BraRS (Hiron 
28 
 
et al., 2011). Microarray analysis revealed that the transcription of 245 genes is 
altered in a ΔbraS mutant (the majority being down-regulated). These 245 genes 
include several that are involved in transport, drug resistance, cell envelope 
synthesis, transcriptional regulation, amino acid metabolism and virulence (Kohler 
et al., 2009). Thus BraRS has an important resistance role in S. aureus and functions 
to reprogram gene expression to modify cell envelope architecture, facilitating 
adaptation and survival. 
The extent of the contribution of BraRS to antimicrobial resistance, relative 
to other TCSs, has been assessed through the creation and analysis of a number of 
mutants. When a S. aureus ΔbraRS mutant was co-cultured with a nukacin ISK-1 or 
nisin A producer, a significant decrease in numbers was observed, which was not 
apparent for the parental S. aureus strain. In contrast, ΔvraSR and ΔgraRS (GraRS is 
yet another TCS) mutants were more moderately affected, thus establishing the 
greater importance of BraRS, and its associated transporters (Kawada-Matsuo et 
al., 2013b). Interestingly, through screening of a bank of nisin resistant mutants, a 
single mutation was identified in braS (A20E) that conferred an 8-16 fold increase in 
nisin resistance (Blake et al., 2011). It is thus apparent that changes to BraRS can 
provide a means via which S. aureus can attain enhanced resistance to lantibiotics. 
 
GraRS of S. aureus 
Overexpression of a second IM-HK identified in S. aureus and its associated 
response regulator, named GraRS, has been linked with the vancomycin-
intermediate S. aureus (VISA) phenotype. This TCS is also referred to as vraCA (Li et 
al., 2007a)) and closely resembles bceRS of B. subtilis (Cui et al., 2005). GraRS 
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induces expression of the adjacently located genes vraFG that encode an ABC 
transporter (Meehl et al., 2007), which is known to be overexpressed in strains 
exhibiting increased vancomycin resistance (Kuroda et al., 2000). This transporter is 
revealed to be involved in antimicrobial sensing and signalling through GraSR 
(Falord et al., 2012). A recent study identified an upstream gene whose product, 
GraX, appears to be a cytosolic accessory protein which acts by signalling through 
the GraS kinase and also effectively interacts with VraF and VraR. GraXRS-VraFG has 
been defined as a five-component system involved in cationic antimicrobial peptide 
sensing and signal transduction to promote resistance to these peptides in S. aureus 
(Fig. 3) (Falord et al., 2012). It has also been suggested that GraRS may regulate 
more than just vraFG. Analysis of graR and graS mutants highlighted alterations in 
overall surface charge, with charge becoming more negative than that of wild-type 
cells (Meehl et al., 2007). It has also been discovered that these cell surface changes 
are due to the regulation of dlt and mprF by GraRS (Li et al., 2007a; Matsuo et al., 
2011). GraRS are also thought to contribute to tolerance of high temperatures, 
survival upon exposure to oxidative stress and the regulation of pathogenicity 
(Falord et al., 2011).  
 With respect to lantibiotic resistance/sensitivity, it has been noted that 
a graRS negative mutant exhibits a greater susceptibility to nukacin ISK-1 than nisin 
A, while no susceptibility to bacitracin is observed (Kawada-Matsuo et al., 2013b). A 
previous study found a graR mutant had increased susceptibility to vancomycin and 
polymyxin B. Interestingly single or multiple amino acid changes within GraR have 
been associated with enhanced resistance, such changes include S197N (Cui et al., 
2005; Meehl et al., 2007). Expression of graR transcripts were not found to increase 
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upon exposure of the cell to nukacin ISK-1 or nisin (Kawada-Matsuo et al., 2013b). 
This supports the model proposed in the same study which details the co-ordinated 
effort achieved by GraRS and BraRS, upon exposure of S. aureus to a relatively high 
level of nisin A or nukacin ISK-1 or such cationic antimicrobials. That is, GraRS is 
seen as important for resistance until significant induction of VraDE expression by 
BraRS occurs. In conclusion S. aureus is defined to possess three distinct class-I-
bacteriocin-resistance systems, implemented through the independent action of 
VraSR (an LiaRS-like TCS) and the co-ordinated function of the two TCS mentioned 
above (Fig. 3) (Kawada-Matsuo et al., 2013b). S. epidermidis also harbours a GraRS 
equivalent named ApsRS that has been found to be induced by nisin and other 
antimicrobials (Li et al., 2007b).  
 
AnrAB Transporter of L. monocytogenes 
AnrAB was named on the basis of its role; i.e. ABC transporter involved 
in nisin resistance. The permease component of the transporter was discovered as a 
result of screening a mariner transposon bank of L. monocytogenes EGD-e mutants 
for nisin sensitivity and was found to be a BceAB-like transporter. Examination of a 
subsequently generated ΔanrB deletion mutant also revealed an associated 
increased sensitivity to the lantibiotic gallidermin, to bacitracin and to a large 
number of β-lactam antibiotics (Collins et al., 2010a). Based on these results it was 
proposed that AnrAB is a multidrug resistance (MDR) transporter that contributes 
to the innate antimicrobial resistance of L. monocytogenes. The TCS VirRS and RpoN 
(σ54) are responsible for regulation of anrAB (Arous et al., 2004; Mandin et al., 
2005). It has been proposed that Lmo1746-47 (a BceAB-like ABC transporter 
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downstream from VirR), along with AnrAB and VirRS, may form an antimicrobial 
sensing and detoxification module similar to the VraDE-BraRS-BraDE network in S. 
aureus (Gebhard & Mascher, 2011). 
Interestingly, AnrAB, which is a BceAB-like transporter, is most similar to an 
ABC transporter in Streptococcus pneumoniae D39 (Sp0912-Sp0913), which was 
found to contribute to the innate resistance of this strain to nisin, bacitracin, 
gramicidin (all cell envelope-active antimicrobials), and lincomycin (a protein 
synthesis inhibitor). Furthermore, expression of sp0912 is induced by up to 13-fold 
upon treatment with nisin or bacitracin (Majchrzykiewicz et al., 2010) and, more 
recently, has been found to be regulated by a TCS designated Rr01-Hk01 (Dintner et 
al., 2011).  
 
2. LiaRS and LiaRS-like Two Component Systems 
Most members of the phylum Firmicutes harbour a TCS, generally referred 
to as LiaRS (formerly yvqEC), which is involved in the response to cell envelope 
stress elicited by inhibitors of the lipid II cycle (Fig. 2(b)). Upon the addition of 
vancomycin or bacitracin, LiaRS autoregulates the genes liaIHGFSR, which are 
organised across two operons liaIH and Lia(G)FSR. Across the Firmicutes liaG is only 
present in Bacillus spp. closely related to B. subtilis (Wolf et al., 2010). Systematic 
deletion of the operon has revealed the functions of each gene product. LiaF is a 
potent negative regulator of LiaR-dependent gene expression. As the sequence and 
genomic location of the liaF gene is conserved in the Firmicutes, it would seem that 
LiaFRS is a common three component system, with both positive and negative 
feedback loops that sense and respond to cell envelope stress signals. LiaH, a 
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homolog of E. coli phage shock protein A, responds through damage sensing. In 
silico analysis could not predict the role of liaI or liaG, though the fact that they 
harbour two or one trans-membrane domains, respectively, is indicative of 
membrane localization. However, LiaI seems to be involved in sensing and 
counteracting membrane damage (Jordan et al., 2006; Wolf et al., 2010). In 
addition to characterisation of the genes within the operon the promoter of the lia 
operon and the cis-acting sequences necessary for antibiotic-inducible gene 
expression were also identified (Mascher et al., 2004). This promoter responded 
strongly to a subset of cell wall-active antibiotics that interfere with the lipid II 
cycle, such as bacitracin, ramoplanin, vancomycin and nisin (Mascher et al., 2004). 
A detailed analysis strongly suggests that the stimulus sensed by the LiaRS system is 
some aspect of interference with cell wall biosynthesis by such antimicrobials, 
rather than directly sensing their presence. In that instance LiaRS acts as a damage-
sensing and signal-transducing system, and thus contrasts with BceRS-AB which is 
thought to function through direct drug sensing and signal transduction (Wolf et al., 
2012).  
The role of LiaRS in L. monocytogenes has been investigated (Collins et al., 
2012; Fritsch et al., 2011; Gravesen et al., 2004). LiaRS-mediated signal transduction 
is also negatively regulated by LiaF in a similar fashion to that described for B. 
subtilis (Fritsch et al., 2011). LiaFRS in B. subtilis is seen to regulate expression of 
itself and liaIH (Wolf et al., 2010), and as seen in L. monocytogenes sv1/2a EGD this 
occurs in response to exposure to the cell wall-active antibiotics vancomycin and 
bacitracin. In L. monocytogenes, however, the expression of 27 genes (Fritsch et al., 
2011), including penicillin-binding protein (PBP) (Gravesen et al., 2001) and telA, 
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which encodes a protein involved in toxic ion resistance are also regulated (Collins 
et al., 2010b). Collins et al. have reported that a ΔliaS strain grew more successfully 
than the corresponding wild-type in the presence of nisin. A mutant lacking another 
histidine kinase, ΔlisK, which also has a nisin-resistant phenotype, was previously 
reported to alter liaS and PBP expression. With this in mind, the nisin resistance of 
3 mutants ΔliaS, ΔliaS/ΔlisK and ΔlisK was compared and it was discovered that the 
ΔlisK mutant is 2-fold more resistant than the wild-type and that the ΔliaS and 
ΔliaS/ΔlisK mutants are a further 2-fold more resistant. On the basis of the nisin-
resistant phenotype of these mutants, it was postulated that these phenotypes 
were attributable to the increased production of the corresponding PBP, the 
expression of which was also increased in the ΔliaS mutant (Collins et al., 2012). In 
contrast, mutation of the corresponding response regulator, ΔliaR, in seven wild-
type strains of L. monocytogenes resulted in an average decrease in cell density of 
5.2 ± 0.7 log10 CFU ml-1 after 24 hr for the 7 ΔliaR strains compared to the wild-type 
on exposure to nisin (Bergholz et al., 2013). Furthermore, this study established 
that lmo1746, a gene downstream from virR (a response regulator) encoding an 
ABC transporter permease, contributed to LiaR-mediated nisin resistance (Bergholz 
et al., 2013). A Group B Streptococcus ΔliaR mutant has also been found to be more 
susceptible to cell wall-active antibiotics (vancomycin and bacitracin) and to 
antimicrobial peptides (polymyxin B, colistin, and nisin) than the parent strain. In 
the absence of LiaR this strain also became avirulent, no longer causing sepsis and 
pneumonia in mouse models (Klinzing et al., 2013). The different consequences of 
mutating LiaS and LiaR most likely reflect the inactivation of different members of 
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the three-component system, with deletion of LiaS potentially resulting in the 
cross-activation of LiaR by other histidine kinases. 
The LiaFSR system of S. mutans has also been characterised and is known to 
regulate genes encoding membrane- and cell wall-associated proteases and 
chaperones as well as genes encoding proteins involved in cell envelope biogenesis 
and remodelling (Suntharalingam et al., 2009). LiaRS has also been identified to 
upregulate dltA expression in Streptococcus gordonii (McCormick et al., 2011).  
CesSR (also referred to as TCS-D (Mascher et al., 2004; O'Connell-Motherway et al., 
2000)) is a LiaRS homologue found in L. lactis. Upstream of cesSR is llmg1650, a liaF 
homologue. A L. lactis ΔcesR mutant was found to be approximately twofold more 
sensitive to nisin, plantaricin C and bacitracin than the corresponding parent strain. 
It has also been established that the bacteriocins lactococcin 972 and plantaricin C, 
as well as bacitracin, and vancomycin, act as inducers of the llmg1650 promoter in a 
concentration-dependent manner, but that nisin did not induce this promoter 
(Martinez et al., 2007). 
 
VraSR of S. aureus 
To date four two-component systems involved in both cell wall synthesis 
and drug resistance have been identified in S. aureus;  WalKR, BraRS, GraRS and 
VraSR. While WalKR is more specifically involved in cell wall metabolism and its 
regulation, the other three TCSs contribute significantly to antimicrobial resistance 
(Dubrac et al., 2007; Mascher, 2006). The vraSR genes are homologous to liaRS of B. 
subtilis. VraSR, vancomycin resistance associated sensor/regulator, contributes to 
resistance to cell-wall-targeting agents such as lantibiotics, and has been shown to 
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protect against cell damage by modulating components of the peptidoglycan 
biosynthesis pathway. Through microarray analysis of S. aureus strain N315 and 
its vraSR null mutant, Kuroda et al. discovered that of 139 transcripts induced by 
exposure of the parent strain to vancomycin, 46 were no longer transcribed in the 
mutant strain  (Kuroda et al., 2003). Among the genes regulated by VraSR are those 
encoding SgtB (a monofunctional glycosyltransferase involved in the polymerization 
of peptidoglycan), PBP2 (penicillin-binding protein 2 also involved in peptidoglycan 
polymerization) and MurZ (UDP-N-acetylglucosamine enolpyruvyl transferase 
required for murein monomer precursor synthesis); all involved in cell-wall 
biosynthesis. A number of genes previously associated with β-lactam, as well as 
glycopeptide resistance in S. aureus have also been identified to be under the 
control of VraSR. Among them is vraDE, which encodes an ABC transporter that is 
linked with bacitracin and nisin resistance. This transporter is also regulated by 
another S. aureus TCS, BraRS (Hiron et al., 2011). It has been demonstrated that 
overproduction of PBP2 significantly increases resistance to the lipid II cycle 
disrupting antibiotic teicoplanin (Hanaki et al., 1998). Therefore, the significant 
reduction in teicoplanin resistance observed in vraSR null mutants agrees well with 
the loss of PBP2 induction. Konuda et al. also revealed that over-expression 
of vraSR via a high-copy-number plasmid alone did not increase transcription 
of pbp2 and sgtB (Kuroda et al., 2003). Induction thus requires exposure to the cell-
wall synthesis inhibitors in the presence of VraSR. In other words, resistance is 
dependent on attack in the form of inhibition of cell-wall synthesis, which in turn 
activates the VraS sensor kinase. In addition, VraSR is independently activated upon 
inhibition of cell wall biosynthesis, such as was observed through the action of 
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mersacidin, daptomycin and vancomycin (Kawada-Matsuo et al., 2013b; Sass et al., 
2008). However, a study by Muthaiyan et al., revealed that unlike daptomcin and 
vancomycin in the previous study, nisin treatment did not induce vraSR expression 
(Muthaiyan et al., 2008). This was confirmed by a second study that demonstrated 
that the lantibiotic nukacin-ISK1 had such induction properties; this difference was 
attributed to their differing structures and modes of action (Kawada-Matsuo et al., 
2013b).  
In the absence of VraSR, S. aureus shows a significant increase in 
susceptibility against various cell wall synthesis inhibitors and antimicrobials, 
including nukacin-ISK1, oxacillin, cefoxitin, tunicamycin, cycloserine daptomycin, 
vancomycin and bacitracin (Kawada-Matsuo et al., 2013b; Kuroda et al., 2003; 
McCallum et al., 2011). The vraSR genes have been found to be more highly 
expressed in some vancomycin intermediately resistant S. aureus (VISA) compared 
to vancomycin susceptible S. aureus (VSSA). In fact, VraSR has been proposed to be 
involved in the VISA-type resistance mechanism via contribution to cell wall 
thickening which prevents antimicrobials from reaching their target molecules, as is 
the case for vancomycin and lipid II (Fig. 1(d)). Although mersacidin also has the 
same target molecule, it does not bind to the D-alanyl-D-alanine terminus. In the 
case of the thickened cell wall, increased free amounts of false such target sites are 
present, leading to reduced diffusion velocity of vancomycin through the cell wall. 
Resistance to mersacidin is not hindered in such a manner but is still observed to 
induce the VraSR TCS (Kuroda et al., 2000; McAleese et al., 2006; Sass et al., 2008). 
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3. Other Two Component Systems 
LisRK of L. monocytogenes 
LisRK is a TCS associated with a significant role in the virulence potential 
of L. monocytogenes. Originally identified in the strain LO28 it has since been 
revealed that in addition to its major contribution in responding to ethanol, pH, and 
hydrogen peroxide stresses, LisRK is involved in the cell’s tolerance to 
antimicrobials  including nisin and the cephalosporin family of antibiotics (Cotter et 
al., 1999; Kallipolitis & Ingmer, 2001). A ΔlisK mutant showed a large reduction in 
the expression of three genes. One is thought to encode a penicillin-binding protein 
that shows homology to PBP2a of Streptococcus pneumoniae and PBP1a of Bacillus 
subtilis, both of which are high-molecular-weight PBPs possessing 
glycosyltransferase and transpeptidase domains (Cotter et al., 2002). The other 
LisK-regulated genes encode another histidine kinase that is homologous to LiaR of 
B. subtilis and a protein of unknown function with homology to B. subtilis YvlB 
(Cotter et al., 2002).  
 
VirRS of L. monocytogenes 
In almost all cases, genes encoding two-component systems are contiguous 
on the chromosome. This is not the case for virR (regulator) and virS (HK), which are 
separated by three genes. L. monocytogenes transcriptomic analysis of both 
the virR::Tn917 and ΔvirS mutants revealed that VirR positively controlled 12 genes 
and that, while VirS also regulated these genes, it also regulated a further 108 
genes in both a positive and a negative manner. The simplest explanation of this 
difference would be that the VirS histidine kinase is able to interact with one or 
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several other response regulators, leading to the activation/repression of the 
transcription of these genes (Mandin et al., 2005). The putative VirR DNA-binding 
site, a palindromic region of 16 bases, was found upstream of transcriptional units 
commonly regulated by VirR and VirS. The palindrome was highly conserved 
between the different promoter regions and showed a common organization 
(Mandin et al., 2005). 
The VirR/VirS system was originally identified as being involved in L. 
monocytogenes virulence, with in vivo up-regulation of VirR mediated by the major 
virulence regulator PrfA  (Camejo et al., 2009). With respect to genes known to 
contribute to innate nisin resistance, it is notable that dltA, mprF and anrB have 
been shown to be VirRS-regulated in L. monocytogenes (Collins et al., 2010a; 
Mandin et al., 2005). This strongly suggests that a significant role of the VirR/VirS 
system is to regulate resistance of L. monocytogenes to cationic peptides.  
 
CprRK of C. difficile 
The CprK sensor kinase and an orphan response regulator CprR, encoded 
elsewhere on the chromosome, are responsible for the resistance of Clostridium 
difficile to cationic antimicrobial peptides, including lantibiotics such as nisin and 
gallidermin (Suarez et al., 2013). The lantibiotics nisin, gallidermin, subtilin, mutacin 
1140 and cinnamycin were found to activate the CprK-CprR system, while 
sublancin, cytolysin, and actagardine did not. It was proposed by Suarez et al. that a 
combination of the (methyl-)lanthionine groups along with proline and glycine 
residues form a  motif that interacts with CprK and leads to activation of the CprK-
CprR two-component system. CprK and CprR are both expressed at low levels prior 
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to lantibiotic exposure, but CprK expression is markedly induced upon activation, 
while CprR expression is not (Suarez et al., 2013). The separate locations of the cprR 
and cprK transcripts may explain the fact that they are not co-ordinately regulated. 
The genes encoding the ABC transporter CprABC are regulated by CprK-CprR and 
found adjacent to cprK on the genome. Insertional disruption of one of the 
transporter genes resulted in significant decreases in resistance to both nisin and 
gallidermin (McBride & Sonenshein, 2011b). Hence, this TCS and ABC transporter 
pair, contribute to the resistance of C. difficile to many lantibiotics. 
 
NsrRS and LcrRS of S. mutans 
In S. mutans, two novel two-component systems, NsrRS and LcrRS, are 
associated with resistance to nisin A, lacticin 481 and nukacin ISK-1. NsrRS regulates 
the expression of NsrX, a protein which shares homology with several 
acetyltransferases, including those of the TraX family, which is associated with F 
pilin acetylation in E. coli. Nisin-binding studies revealed that more nisin bound to 
cells that had a complemented ΔnsrX mutation than the mutant. Thus, it was 
determined that NsrX (or an as-yet-unidentified factor modified through NsrX) is 
involved in binding nisin A and preventing its interaction with lipid II. LcrRS 
regulates the expression of the ABC transporter LctFEG. Mutation of the genes lcrRS 
and lctFEG results in increased susceptibility to nukacin ISK-1 (and lacticin 481 with 
respect to ΔlcrRS)  (Kawada-Matsuo et al., 2013a).  
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Other Resistance Elements 
Biofilms 
A biofilm is a population or community of bacteria living in organized 
structures at a liquid interface. Within a biofilm, each bacterium occupies a specific 
microenvironment, which is determined by surrounding cells, proximity to a 
channel (both of which determine the pH and availability of nutrients and oxygen) 
and the extracellular polymeric substance (EPS) matrix. The structuring of biofilms 
in micro-colonies and water channels has been shown to be influenced by fluid 
flow, nutrient composition and intercellular small messenger molecules, or 
quoromones (acylated homoserine lactones, AHLs), that are used for bacterial 
communication. Cells in biofilms are more resistant to antimicrobials than 
planktonic (free-living) cells, providing protection against many antimicrobials, 
including lantibiotics, and against protozoan grazing and host defences (Anderson & 
O'Toole, 2008; Mah & O'Toole, 2001; Matz & Kjelleberg, 2005).  
All biofilms contain an extracellular matrix that holds cells together. This 
matrix is often composed of a polysaccharide biopolymer along with other 
components such as proteins or DNA (Branda et al., 2005). The nature of the matrix 
exopolysaccharide greatly varies depending on growth conditions, medium and 
substrates, and also varies amongst bacterial strains. Cells in biofilms also employ 
adhesive proteins. For instance, S. aureus matrix harbours Biofilm-
Associated Proteins (termed Bap) that are required for biofilm formation. Anchored 
to the cell wall of S. aureus, these proteins serve to hold cells together within the 
biofilm, probably by interacting with other proteins on the surface of adjacent cells. 
In addition to the exopolysaccharides and proteins, extracellular DNA (eDNA) also 
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provides structural integrity to the biofilm. S. aureus biofilms, for example, have 
eDNA in the matrix, providing added stability to the biofilm. It is thought that this 
eDNA is caused by cell lysis and the release of genomic DNA (Rice et al., 2007). 
Increased resistance to environmental stresses as observed in biofilms 
appears to be as a result an increase in the portion of persister cells, which neither 
grow nor die in the presence of bactericidal agents, and thus exhibit multidrug 
tolerance (Spoering & Lewis, 2001). Persister cells have been proposed to be 
protected from the action of antibiotics because of their dormant nature and the 
requirement of active targets by antibiotics. Persister cells express toxin–antitoxin 
systems which lead to this dormant state. The toxin typically is a protein that 
inhibits important cellular functions such as translation or replication, and forms an 
inactive complex with the antitoxin (for review see (Hayes & Van Melderen, 2011)). 
Overproduction of chromosomally-encoded "toxins" such as RelE, an inhibitor of 
translation, or HipA, the first validated persister/multi drug tolerence gene, causes 
a sharp increase in persisters and an increase in antimicrobial tolerance (Correia et 
al., 2006; Keren et al., 2004). Deletion of the hipBA module produces a sharp 
decrease in persisters in both stationary and biofilm cells (Keren et al., 2004). 
Extracellular matrices also act as a diffusion barrier to small molecules. The reduced 
diffusion of nutrients, vitamins, or cofactors in biofilms results in the presence of 
metabolically inactive cells within the bacterial community. In addition, as a 
consequence of being confined to a restricted space, the rate of bacterial growth is 
limited (Stewart & Franklin, 2008). Hence, bacteria in biofilms are naturally in a 
stationary phase of growth, resulting in the production of secondary metabolites 
such as antibiotics, pigments, and other small-molecules (Martin & Liras, 1989). 
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These secondary metabolites also function as signalling molecules to initiate the 
process of biofilm formation (Lopez & Kolter, 2010). Thus the physical protection 
provided by biofilms, their compact nature and the reduced rates of cellular 
growth, bacteria within biofilms are less susceptible to the action of antimicrobials. 
Indeed, cells in biofilms have been shown to exhibit a 10- to 1000- fold greater 
antimicrobial resistance than the corresponding cells when grown planktonically 
and with notably great cell densities (Davies, 2003). A study of the antibiotics 
amoxicillin, doxycycline and metronidazole revealed that the MICs increased 
markedly when planktonic populations of Porphyromonas gingivalis were tested at 
cell densities equal to those found in biofilm populations (107–108 cells/ml) (Larsen, 
2002). 
 The resistance of biofilms to lantibiotics has been investigated and it is clear 
that, like many other antimicrobials, lantibiotics can be effective in preventing the 
formation of biofilms but are less successful at killing microorganisms present in 
established biofilms. In one instance, the lantibiotic gallidermin and the well-
studied biofilm-forming S. aureus SA113 and S. epidermidis O47 strains were the 
subject of investigation (Saising et al., 2012). When used at MIC levels as 
determined with planktonic cells, gallidermin was completely unable to form a 
biofilm. In the case of S. aureus, a biofilm-inhibiting effect was evident even when 
in the sub-MIC range. It was particularly notable that the transcription levels of a 
gene involved in primary adhesion (the major autolysin, atl) and another involved in 
exopolysaccharide production (the intercellular adhesin, ica) were significantly 
decreased in the presence of gallidermin. In contrast, when biofilm-associated 
staphylococci were treated with 8 × MIC of gallidermin, colony forming units (CFUs) 
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were decreased by 3 logs in the 24hr biofilms and by only 1 to 2 logs in the 5-day 
biofilms (Saising et al., 2012). The activity of the two peptide lantibiotic, lacticin 
3147, against S. mutans in biofilms has also been tested. At 2 X MIC (6.25µmol l-1), 
lacticin 3147 reduced S. mutans biofilm formation by   ̴90%. However, when 50 
µmol l-1 lacticin 3147 was tested against 1-day old biofilms of S. mutans, only a 24-
50% reduction was apparent (Dobson et al., 2011). It is worth noting that many S. 
mutans strains are capable of producing lantibiotics and/or other bacteriocins, 
known as mutacins. The production of these antimicrobials may allow these strains 
to compete within the dental biofilm and to persist when nutrients become limited 
in the dental plaque (Nguyen et al., 2009). Similarly, nisin has been shown to 
prevent biofilm formation of 25 S. aureus strains at minimum growth inhibitory 
concentrations, however at subinhibitory concentrations biofilm formation was not 
prevented (Sudagidan & Yemenicioglu, 2012). 
A recent study compared the potential of lantibiotics nisin A, nukacin ISK-1 
and the class II bacteriocin lacticin Q to inhibit 24 hr established methicillin-
resistant S. aureus biofilms (Okuda et al., 2013). Despite targeting lipid II, nukacin 
ISK-1 has a bacteriostatic mode of action only, inhibiting cell wall synthesis but not 
forming pores (Asaduzzaman et al., 2009). Lacticin Q functions by forming toroidal 
pores in target membranes (Yoneyama et al., 2009). From this study, it would 
appear that pore formation leading to ATP efflux is important for bactericidal 
activity against biofilm cells. Of the antimicrobials tested, nisin A most closely fits 
this requirement, with ATP efflux observed through the action of nisin A at 0.25× 
MIC (0.625 μM), whereas 1× MIC (5.0 μM) lacticin Q was required. Nukacin ISK-1 
had no effect on ATP efflux even at 8× MIC (96 and 80 μM) (Okuda et al., 2013).  
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Nisin has been encapsulated within liposomes (nisin-liposome) in order to 
prolong the inhibition of S. mutans strain 10449b glucan-biofilms on microplates. 
While unencapsulated nisin lost its potency within 6 hr, only 76% of the nisin within 
nisin-liposomes was released within this time, thus prolonging the inhibitory effects 
(Yamakami et al., 2013). Nisin has also been combined with sodium fluoride to 
provide a stronger bactericidal effect on S. mutans. The observed synergy revealed 
through checkerboard and survival assays was also more effective in preventing 
biofilm formation over 4 hr and 16 hr  as compared with sodium fluoride alone 
(Tong et al., 2011). Nisin also functions synergistically with daptomycin and 
ciprofloxacin with respect to inhibiting established (24 hr) MRSA biofilms. Time-kill 
assays using the minimum biofilm-eradication concentrations of the antimicrobials 
demonstrate a 3-log reduction in CFU of an MRSA control and two clinically 
obtained MRSA biofilms occurred even within 4 hr when used in combination, the 
individual antimicrobials never obtaining such level of kill even at 24 hr post 
application (Dosler & Mataraci, 2013).  
The immobilization of nisin, via a poly(ethylene glycol) (PEG(1000)) linker, to 
multi-walled carbon nanotubes significantly enhanced the antimicrobial and anti-
biofilm properties of the nanotubes by up to 7-fold (Qi et al., 2011). Similarly, nisin 
has been covalently bound to stainless steel surfaces to the same effect, reducing 
adhesion of bacteria and thus biofilm formation (Hequet et al., 2011). Incorporating 
different concentrations (0.1%, 0.5% and 1%) of nisin into poly-ethylene-co-vinyl 
acetate (EVA) films reduced biofilm formation on these surfaces, with the beneficial 
effects being more evident against a strain of S. epidermidis than against 
representative L. monocytogenes or S. aureus strains (Nostro et al., 2010). A very 
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recent breakthrough involves acyldepsipeptides, which have been shown to 
effectively assist in the kill of persisters as a result of uncontrolled activation of a 
subunit (ClpP) of the protease enzyme Clp. This activation causes a dramatic 
increase in the size of the central pore in ClpP allowing access for peptides and 
proteins to the proteolytic chamber, resulting in an increase in protein degradation 
and ultimately cell death (Conlon et al., 2013). 
 
Nisin Resistance Protein 
A 35-kDa nisin resistance protein (NSR) has been found to be produced by 
some strains of L. lactis. Originally nsr was observed as a specific nisin resistance 
gene located on a 60-kb plasmid in the nisin non-producer L. lactis 
subsp. diacetylactis DRC3 (Froseth & McKay, 1991). Since then, several groups have 
isolated nisin-resistant lactococcal strains containing nsr on a plasmid (Liu et al., 
1997; Sun et al., 2009; Yun et al., 2006). The mechanism by which NSR confers 
resistance is proposed to involve the proteolytic degradation of nisin, mediated by a 
C-terminal conserved tail-specific protease (TSPc) domain at the C terminus of NSR 
(Chatterjee et al., 2005; O'Driscoll et al., 2006). TSPc efficiently cleaves substrates 
that have apolar residues and a free alpha-carboxylate at the C terminus and have 
been identified and characterised in a range of species, including E. coli (Keiler et 
al., 1995). Such proteases contain a conserved PDZ domain adjacent to the TSPc 
domain, which is indispensable for binding of the TSPc with nonpolar C-termini of 
its peptide substrates and thus for the catalytic activity (Beebe et al., 2000; Spiers et 
al., 2002). However, NSR does not possess a PDZ domain. NSR also differs from 
other TSPc containing proteins in that it harbours charged and polar residues (Lys, 
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His, and Ser) at the C terminus (Keiler & Sauer, 1996). More detailed analyses have 
revealed that NSR and purified NSRSD (a version of NSR without the predicted N-
terminal signal peptide sequence) proteolytically inactivates nisin by cleaving the 
peptide bond between MeLan28 and Ser29. This truncated nisin (nisin1-28) showed a 
noticeably reduced affinity for the lactococcal membrane, a significantly reduced 
effectiveness in pore formation in the target membrane and a 100-fold-lower 
bactericidal activity against L. lactis MG1363, compared to whole nisin (Sun et al., 
2009). An nsr gene has also been identified in S. agalactiae ATCC 13813, the gene 
product of which is referred to as SaNSR. A plasmid expressing this resistance gene 
was shown to confer a 20-fold increase in resistance to the host strain. In silico 
screening for nsr-like genes revealed their presence across a range of species 
including Corynebacterium casei and Corynebacterium ammoniagenes, and various 
strains of Leuconostoc mesenteroides, Leuconostoc carnosum, Enterococcus 
faecium, Staphylococcus epidermis, Streptococcus ictaluri, Streptococcus sanguinis, 
Streptococcus dysgalactiae and Streptococcus agalactiae. These genes were found 
within operons that also contained genes encoding an ABC transporter, named 
NsrFP and a TCS NsrRK. It is proposed that these genes confer nisin resistance in 
these strains (Khosa et al., 2013). 
 
Nisinase 
In a study dating back to 1967, anti-nisin activity was detected in extracts of 
bacilli and endospores of organisms that had a lytic mechanism for rupture of the 
spore coat (type L), which was not detectable in spores which ruptured the spore-
coat mechanically (type M). Further investigation of cell-free extracts of Bacillus 
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cereus and B. polymyxa revealed that the anti-nisin phenotype was not as a result 
of proteolytic activity, was somewhat specific as it did not affect polymyxin, 
gramicidin or bacitracin, but did inactivate nisin and subtilin (Jarvis, 1967). Nisinase 
was isolated from several Bacillus sp. and was shown to be a dehydropeptide 
reductase, as it specifically reduced the C-terminal dehydroalanyl-lysine of nisin to 
alanyl-lysine (Jarvis, 1970). Nisinase activity has also been associated 
with Lactobacillus plantarum (Kooy, 1952), S. thermophilus (Alifax & Chevalier, 
1962), C. botulinum (Rayman et al., 1983), L. lactis subsp. cremoris, E. faecalis and S. 
aureus (Carlson & Bauer, 1957).  
 
Gad System 
In L. monocytogenes, several systems help to withstand low pH stress, but 
the glutamate decarboxylase (GAD) system is probably the most important (Cotter 
et al., 2001a; Cotter et al., 2001b; Cotter et al., 2005b). Of the five gad 
genes, gadD1, gadD2, and gadD3 encode decarboxylases that catalyse the 
conversion of glutamate to γ-amino butyrate (GABA) and carbon dioxide 
(CO2). gadT1 and gadT2 encode antiporters, which import glutamate and export 
GABA. Deletion of gadD1 impairs the ability of a strain to tolerate exposure to both 
sublethal and lethal levels of nisin (Begley et al., 2010). It was discovered that the 
intracellular ATP levels were reduced in the ΔgadD1 mutant, being only 
approximately 60% of those of the parent, suggesting that GadD1 contributes 
significantly to ATP pools and hence tolerance of nisin (Begley et al., 2010).  
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arc Operon 
The arc genes are involved in the breakdown of arginine via the arginine 
deiminase pathway. This pathway is responsible for the breakdown of arginine into 
ornithine, ammonium, and carbon dioxide. Arginine deiminase (ArcA), ornithine 
carbamoyltransferase (ArcB), and carbamate kinase (ArcC) are the three enzymes 
responsible for this degradation process (Poolman et al., 1987). The arc operon is 
thought to contribute to acquired nisin resistance as a fourfold overexpression of 
the genes arcAC1C2DT2 was observed in a L. lactis nisin resistant strain compared 
to the corresponding wild-type strain. The conversion of arginine into ammonium 
might result in a locally less acidic pH at the outer side of the cytoplasmic 
membrane, preventing nisin from attaching to the lipid II molecule (Kramer et al., 
2006). 
 
TelA 
The tellurite resistance gene, telA, was identified from the screening of 
a mariner random mutant bank for nisin-sensitive L. monocytogenes mutants. 
The telA gene encodes a toxic ion resistance transporter that also plays a role in 
resistance to cell wall-acting antibiotics. LiaR has been reported to regulate telA 
expression under salt-induced nisin resistance conditions (Bergholz et al., 2013). 
The telA gene also forms a two-gene operon with xpaC, which encodes a putative 
member of the halogen hydrol superfamily. This same genetic organization is 
conserved across many members of the Firmicutes and Proteobacteria phyla. The 
creation of a nonpolar deletion mutant of telA confirmed its involvement in 
resistance as the strain was found to be 4-fold-more sensitive to nisin and, in 
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addition, the ΔtelA strain was also 8-fold-more susceptible to gallidermin and 2-
fold-more susceptible to bacitracin, cefuroxime, cefotaxime, and tellurite (Collins et 
al., 2010b). 
 
PurR 
Three mutations within the gene purR (encoding a purine operon repressor) 
were identified in a nisin resistant mutant of S. aureus SH1000. However, this gene 
does not seem to be essential for resistance as it is intact in other cases of 
spontaneous nisin resistance in S. aureus (Blake et al., 2011). The fact however, that 
the three mutations (G228E, V229G and E184STOP) were retrieved from 
independently selected nisin resistant mutants of SH1000 strongly suggests that 
this locus is involved in resistance in this strain. 
 
IreK-IreP-IreB 
One of mechanisms employed by E. faecalis to survive therapeutic 
concentrations of cephalosporins may also be involved in determining resistance to 
lantibiotics. This means of resistance involves a signalling system comprised of a 
eukaryotic-like serine/threonine kinase (IreK) and phosphatase (IreP) pair that 
antagonistically regulate cephalosporin resistance (Kristich et al., 2007). A third 
protein, IreB, is modulated by IreK-dependent phosphorylation and, although its 
role is unknown, it has been found to contribute to negative regulation of 
resistance and to be an endogenous substrate of both IreK and IreP (Hall et al., 
2013). Homologues of these three proteins are found in the genomes of nearly all 
Gram positive bacteria. A strain bearing a deletion in ireK exhibited reduced 
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resistance to sodium cholate (a detergent found in bile) and to nisin (Hall et al., 
2013; Kristich et al., 2007). In addition, a double mutant lacking ireK and ireB 
showed enhanced resistance to both these bactericidal agents (Hall et al., 2013; 
Kristich et al., 2007).  
 
Sigma Factors 
One important mediator of the stress response in many Gram positive 
bacteria is the alternative sigma factor SigB. In B. subtilis SigB activity is regulated 
by a complex network of protein-protein interactions governed by a variety of 
environmental or metabolic stresses such as heat shock, osmotic shock, ethanol 
treatment, or entry into stationary growth phase (Boylan et al., 1993). The growth 
of a L. monocytogenes EGDe sigB mutant is noticeably reduced in the presence of 
nisin or lacticin 3147 relative to its parental strain (Begley et al., 2006). It was 
hypothesised that SigB regulates general stress proteins or proteins involved in 
extrusion of antimicrobials out of the cell. Indeed, SigB binding sites are located 
upstream of htrA (lmo0292), which encodes a putative molecular chaperone shown 
to be involved in tolerance of penicillin G (Stack et al., 2005). Another SigB binding 
site is upstream of mdrL (lmo1409), encoding an antibiotic efflux pump (Mata et al., 
2000).  
Another alternative sigma factor, SigL, also contributes to antimicrobial 
resistance. Nisin survival assays show that both SigB and SigL affect the sensitivity 
of L. monocytogenes 10403S to nisin in broth survival assays. Contrary to the 
findings of Begley et al. (2006), the ΔsigB mutant was seen to be more resistant to 
nisin. The differences observed were attributed to class of peptide, the strain, initial 
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number of bacteria, growth phase, and the assay used for evaluation (Palmer et al., 
2009). Interestingly, a sigB null mutation was revealed to sensitize the cell in a ΔsigL 
background, leading to reduced nisin resistance (Palmer et al., 2009). In addition, 
Butcher et al. have proposed that the extracytoplasmic function (ECF) sigma factors 
σM, σX and σW all contribute to antibiotic resistance in B. subtilis (Butcher & 
Helmann, 2006). A B. subtilis sigX deletion mutant has been found to be more 
sensitive to nisin than the wild-type. Furthermore, most genes under σX control 
processes contribute to the biosynthesis or metabolism of the cell envelope, and 
include the dlt operon and pbpX (penicillin-binding protein) amongst many others 
(Cao & Helmann, 2004). σM was found to contribute to bacitracin resistance via 
regulation of the bcrC (ywoA) gene, encoding a putative bacitracin transport 
permease (Bernard et al., 2005; Cao & Helmann, 2002). With respect to nisin 
resistance, the major contribution of σM is expression of ltaSa, encoding a stress-
activated lipoteichoic acid synthase. Lipoteichoic acid (LTA) adsorbs cations from 
the environment, including antimicrobials such as nisin. Binding of such cations to 
LTA may inhibit their transit through the cell wall, and thereby increase resistance 
(Kingston et al., 2013). Together, σM and σX regulate cell envelope structure to 
decrease access of nisin to its lipid II target. SigW has been linked with increased 
rigidity and decreased fluidity of the membrane (Kingston et al., 2011; Lee et al., 
2012) and has been directly linked with lantibiotic resistance. The σW-dependent 
operons, such as the B. subtilis resistance module yqeZ-yqfAB, are seen as critical 
for sublancin resistance. The membrane-integrated protease encoded within this 
operon, YqeZ, is thought to degrade lantibiotics that integrate into the membrane 
(Butcher & Helmann, 2006). In terms of nisin resistance, the σW associated SppA 
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appears to be the only signal peptide peptidase in B. subtilis that makes a 
contribution. In addition, σW regulates expression of the phage shock proteins PspA 
and YvlC, which enhance membrane stability and thus provide resistance 
specifically against the membrane-perturbing and pore forming activity of nisin 
(Kingston et al., 2013). Tellurite resistance related proteins (YceGHI) are also 
regulated by σW, with the protein YceG homologous to TelA found in L. 
monocytogenes (Collins et al., 2010b; Kingston et al., 2013). These self-protective 
mechanisms also provide resistance to other lantibiotics such as mersacidin, 
gallidermin and subtilin (Kingston et al., 2013). 
 
Immune Mimicry 
Lantibiotic self-immunity mechanisms are the means by which lantibiotic 
producers protect themselves against their own bactericidal agents. Immunity 
specific proteins (LanI) or specific self-protection ABC transporters (LanFE(G)) are 
found alone or in combination, providing specific resistance to lantibiotic self-
producers. Cross immunity is extremely rare between lantibiotic producers and 
these immunity mechanisms are specific to the particular lantibiotic produced by 
the cell (for review see (Draper et al., 2008)). An unusual means of resistance has 
been recently revealed, in which non-lantibiotic producing bacteria were shown to 
possess genes homologous to the lantibiotic immunity genes. With respect to 
lacticin 3147, functional immunity homologues were found in E. faecium DO and B. 
lichiniformis DSM 13. The B. licheniformis BliI protein has 37% identity with the 
lacticin 3147 immunity protein LtnI, and when bliI is expressed constitutively in a 
lacticin 3147-sensitive strain, L. lactis MG1363, the resistance of the strain was 
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increased by 20-fold (Draper et al., 2009). A similar result was seen when genes 
encoding the LtnFE ABC transporter homologue, EfdFE, from E. faecium DO were 
also expressed in the MG1363 background. The protection provided was specific in 
that no resistance to the distantly related one peptide lantibiotic nisin was apparent 
(Draper et al., 2009). This phenomenon appears to extend beyond lacticin 3147 
resistance as genes encoding immunity homologues have been found in 
Streptococcus infantarius subsp. infantarius BAA-102. The genes, spiFEG, encode an 
ABC transporter with >50% identity to that associated with immunity in the nisin U 
operon. Interestingly genes homologous to the individual components of the nisin 
two-component system known as NisRK (or NsuRK in the case of nisin U), referred 
to as spiRR’K are co-located with the spiFEG genes. While these regulatory genes 
did not confer a nisin U resistant phenotype when co-expressed with spiFEG, 
protection was provided when spiFEG was expressed constitutively in the nisin U 
sensitive Lactococcus lactis subsp. cremoris HP (Draper et al., 2012).  
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Conclusions 
The emergence of antimicrobial resistance represents a Grand Challenge to 
humanity; understanding how and by what means bacteria become resistant 
facilitates the development of new therapeutic treatments. In tandem it allows for 
the reassessment of current antimicrobials and the potential to improve on current 
therapeutic regimes. With low levels of naturally occurring lantibiotic resistance, 
these modified peptides serve as a credible alternative to commercial antibiotics. 
As some lantibiotics have a dual mode of action by forming pores and also inhibiting 
cell wall biosynthesis they represent a significant challenge to the target cell. A 
detailed classification of the known means of lantibiotic resistance is summarised in 
Table 1.  Such and future characterisation may allow for further tailoring of genetic 
variants of lantibiotic peptides that could circumvent resistance issues, and will 
inform the development of appropriate therapeutic regimes to overcome such 
issues if and when lantibiotics are deployed in clinical settings. 
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Tables and Figures 
Table 1. 
 
 
 
Cell wall/membrane altering mechanisms 
Name Species Regulated by Resistance to lantibiotics 
Mprf S. aureus  
L. monocytogenes 
VirRS/GraRS Nisin, Gallidermin 
DltA Streptococcus sp.  
Staphylococcus sp. 
L. monocytogenes  
L. lactis 
B. subtilis 
C. difficile 
VirRS/Sigma factors Nisin, Gallidermin 
gal operon L. lactis  Nisin 
Penicillin-binding protein L. monocytogenes  
L. lactis 
S. aureus 
LiaRS LisRK, VraSR, Sigma 
factors 
Nisin 
Lipid composition incl. 
the fab operon 
L. monocytogenes 
L. lactis 
 Nisin 
Miscellaneous resistance mechanisms 
Name Species Regulated by Resistance to lantibiotics 
Nisin resistance protein* L. lactis  
Corynebacterium sp. 
Leuconostoc sp.   
Enterococcus sp.   
Streptococcus sp. 
 Nisin 
Nisinase* S. thermophilus 
Lb. plantarum 
C. botulinum 
L. lactis  
E. faecalis  
S. aureus 
Bacillus sp. 
 Nisin, Subtilin 
Gad L. monocytogenes  Nisin 
NsrX S. mutans NsrRS Nisin 
arc operon L. lactis  Nisin 
PurR S. aureus   Nisin 
IreK-IreP-IreB E. faecalis  Nisin 
Sigma factors 
L. monocytogenes 
B. subtilis  
Nisin, Sublancin, 
Mersacidin,  Subtilin 
Gallidermin  
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Table 1. (continued) 
Transporters 
Name Species Regulated by Resistance to lantibiotics 
VraFG S. aureus GraXRS Nisin, Nukacin ISK-1 
CprABC C. difficile CprRK Nisin, Gallidermin 
AnrAB L. monocytogenes VirRS Nisin 
VraDE S. aureus BraRS, VraSR Nisin 
YsaBC L. lactis LlrG/KinG Nisin 
BraDE S. aureus BraRS Nisin 
Lmo1746-47 L. monocytogenes VirRS, LiaRS Nisin 
BceAB B. subtilis BceRS Actagardine, Mersacidin 
PsdAB  B. subtilis PsdRS Nisin, Gallidermin, Subtilin, Actagardine 
Sp0912-Sp0913 S. pneumoniae Rr01-Hk01 Nisin 
LctFEG S. mutans LcrRS Nukacin ISK-1, Lacticin 481 
NsrFP Corynebacterium sp. 
Leuconostoc sp.  
Enterococcus sp.  
Streptococcus sp. 
NsrRK Nisin 
TelA L. monocytogenes LiaRS Nisin, Gallidermin 
EfdFE* E. faecium  Lacticin 3147 
SpiFEG* S. infantarius  SpiRR’K ? Nisin 
Two Component Systems 
Name Species Resistance to lantibiotics 
TC09 & TC12 L. casei Nisin 
GrsRS S. aureus Nisin, Nukacin ISK-1 
BraRS S. aureus Nisin, Nukacin ISK-1 
PsdRS B. subtilis Nisin, Gallidermin, Subtilin, Actagardine 
LlrG/KinG L. lactis Nisin 
ApsRS S. epidermidis Nisin 
BceRS Bacillus sp. Actagardine, Mersacidin 
LiaRS Bacillus sp. 
Streptococcus sp. 
L. monocytogenes 
Nisin 
NsrRS S. mutans Nisin, Lacticin 481, Nukacin-ISK1 
LcrRS S. mutans Nukacin ISK-1, Lacticin 481 
VraSR S. aureus Nisin, Mersacidin, Nukacin-ISK1 
LisRK L. monocytogenes Nisin 
CesSR L. lactis Nisin, Plantaricin C 
VirRS L. monocytogenes Nisin 
CprRK C. difficile Nisin, Gallidermin, Subtilin, Mutacin 1140, Cinnamycin 
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Table 1. Summary of lantibiotic resistance methods. Listed are the strains in which 
lantibiotic resistance has been observed and the lantibiotics to which this resistance 
is conferred. Not included in the table are the general resistance mechanism 
inferred by the Gram negative cell wall and that of spore and biofilm formation. 
Lantibiotic specific resistance methods are indicated with an asterisk. 
 
 
 
 
 
 
 
 
94 
 
 
  
Fig. 1. Mechanisms of lantibiotic resistance which relate to the cell wall and 
membrane. D-alanylation of lipoteichoic acids (LTA) and wall teichoic acids (WTA) 
by the dltABCD operon which infers a positive charge (a); changes in phospholipid 
composition (b); changes in membrane fatty acid composition (c); cell wall 
thickening (d); lysine esterification of one of the two hydroxyl groups of 
phosphatidylglycerol (PG) by Mprf (e); the Gram negative outer cell membrane 
containing lipopolysaccharide (LPS) (f). 
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Fig. 2. Two main types of two component systems (TCS) are responsible for 
lantibiotic resistance. These incorporate the Bce-like TCSs (a) and the Lia-like TCSs 
(b). The presence of antimicrobials such as lantibiotics or the cell damage incurred 
as a result of their presence causes these TCSs to mediate the transcription of 
genes whose products infer a resistance phenotype.  
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Fig. 3. In S. aureus three main two component systems (TCS) are responsible for 
lantibiotic/antimicrobial resistance. These include two Bce-like TCSs, BraRS and 
GraRS and a Lia-like TCSs, VraSR. A co-ordinated resistance effort results from the 
action of these TCSs, causing upregulation of genes whose products alter the 
composition of the cell wall and membrane, and also encode ABC transporters 
which expel antimicrobials from the cell. 
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Summary 
The emergence of bacterial drug resistance encourages the re-evaluation of 
the potential of existing antimicrobials. Lantibiotics are post-translationally 
modified ribosomally synthesised antimicrobial peptides with a broad spectrum 
antimicrobial activity. Here, we focussed on expanding the potential of lacticin 
3147, one of the most studied lantibiotics and one which possesses potent activity 
against a wide range of Gram positive species including many nosocomial 
pathogens. More specifically, our aim was to investigate if lacticin 3147 activity 
could be enhanced when combined with a range of different clinical antibiotics. 
Initial screening revealed that polymyxin B and polymyxin E (colistin) exhibited 
synergistic activity with lacticin 3147. Checkerboard assays were performed against 
a number of strains, including both Gram positive and Gram negative species. The 
resultant fractional inhibitory concentration (FIC) index values established that, 
while partial synergy was detected against Gram positive targets, synergy was 
obvious against Gram negative species, including Cronobacter and E. 
coli. Combining lacticin 3147 with low levels of a polymyxin could provide a means 
of broadening target specificity of the lantibiotic, while also reducing polymyxin use 
due to the lower concentrations required as a result of synergy. 
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Introduction 
The challenge presented by the emerging problem of antibiotic resistance is 
a significant one. One approach has been to identify new bactericidal agents while 
another has involved a re-examination of the potential of previously identified 
antimicrobials. With this latter route in mind, there has been a particular focus on 
assessing and enhancing the benefits of applying lantibiotics in clinical settings 
(Cotter et al., 2013; Piper et al., 2009a). Lantibiotics are ribosomally synthesised 
antimicrobial peptides that are subjected to post-translational modification, 
resulting in the presence of unusual amino acids including intramolecular 
lanthionine and β-methyl lanthionine bridges. These bridges are formed through a 
two-step process that is initiated by the dehydration of serine and threonine 
residues to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively. The 
subsequent reaction of these modified amino acids with intrapeptide cysteines 
results in the formation of lanthionine (Ala-S-Ala; in the case of dha) or β-methyl-
lanthionine (Abu-S-Ala; in the case of dhb) bridges (for review see (Bierbaum & 
Sahl, 2009; Chatterjee et al., 2005; Suda et al., 2012)). Lacticin 3147 is a two peptide 
lantibiotic which exhibits broad spectrum activity against Gram positive targets. The 
two lacticin 3147 peptides, Ltnα and Ltnβ, work synergistically in a 1:1 ratio 
(Morgan et al., 2005; Suda et al., 2012). Ltnα first binds to the precursor of 
peptidoglycan production, lipid II, with Ltnβ subsequently interacting with this 
complex. The net effect is the inhibition of peptidoglycan synthesis and the 
formation of a membrane depolarising pore (Wiedemann et al., 2006).  
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Some lantibiotics are active at single nanomolar levels against particular 
targets and several lantibiotics inhibit drug–resistant Gram positive pathogens, 
including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant enterococci (VRE) (Cotter et al., 2013; Piper et al., 2009a). Lantibiotics are 
highly stable, resistance is rare and activity can be enhanced through genetic 
alteration and, thus, they are considered to be viable alternatives to traditional 
antibiotics (Cotter et al., 2013). Lacticin 3147 inhibits many Gram positive 
pathogens including Listeria monocytogenes, Staphylococcus aureus and 
Clostridium difficile as well as a variety of streptococci, enterococci and 
mycobacteria (Carroll et al., 2010; Iancu et al., 2012; Rea et al., 2007). However, to 
date, the inhibition of Gram negative species by lacticin 3147 has not been 
reported. This is most often attributed to the presence of the outer membrane, 
which prevents access of the lantibiotic to the cytoplasmic membrane.  
There are many potential benefits associated with identifying antibiotics 
that function synergistically with lacticin 3147. While antibiotic resistance has 
become a major obstacle, significant resistance to lacticin 3147 has yet to be 
reported and thus the use of antibiotic-lacticin 3147 combinations may 
prevent/overcome the emergence of resistance. Furthermore, certain antibiotic-
lacticin 3147 combinations may allow for a broader range of species to be targeted. 
Here we assess the impact of combining lacticin 3147 with a variety of clinical 
antibiotics and establish that lacticin 3147 exhibits synergistic activity in 
combination with either polymyxin B or polymyxin E. 
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Methods 
Cultures and growth conditions 
Salmonella Typhimurium UK1, Salmonella Typhimurium LT2, Escherichia coli 
0157:H-, E. coli EC101, E. coli DH5α (University College Cork (UCC) culture 
collection) and Cronobacter sakazakii 6440 (Dairy Products Research Centre (DPC) 
culture collection) were grown in Luria-Bertani (LB) broth and agar at 37°C, while 
Bacillus cereus 8079 (DPC culture collection) and Enterococcus faecium strains DO 
(Arduino et al., 1994), EC538, EC295 and EC725 (British Society for Antimicrobial 
Chemotherapy (BSAC)) were grown in Brain Heart Infusion (BHI) broth and agar at 
37°C. Staphylococcus aureus strains ST528, ST523, ST530, ST291, ST534 (BSAC) and 
5247 (DPC culture collection) was also grown at 37°C but with aeration in cation 
supplemented Mueller Hinton broth and Mueller hinton agar. Lactococcus lactis 
MG1363 (UCC culture collection) was grown at 30˚C without aeration in M17 broth 
(Oxoid Ltd., Basingstoke, Hampshire, England) supplemented with 0.5% (wt/vol) 
glucose (GM17).  
Antimicrobials 
Cefoperazone, cefaclor, teicoplanin, bacitricin, colistin sulphate (polymyxin 
E), polymyxin B, oxacillin and fusidic acid antimicrobial susceptibility discs were 
purchased from Oxoid. Polymyxin B and colistin sulphate (polymyxin E) were 
obtained from Sigma-Aldrich while lacticin 3147 was purified using the following 
procedure: TYG media (tryptone, 2.5 g l-1; yeast extract, 5.0 g l-1; glucose, 10 g l-1; β-
glycerophosphate, 19.0 g l-1; MgSO4 x 7H2O, 0.25 g l-1; MnSO4.4H2O, 0.05 g l-1) was 
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passed through 500 g XAD-16 beads (Sigma-Aldrich Company Ltd., Dorset, England) 
in order to remove all hydrophobic components. An overnight culture of L. lactis 
MG1363.pMRC01.pOM02 (Cotter et al., 2006) was then used to inoculate 1 L of the 
modified TYG broth (1% inoculum) and incubated at 30˚C overnight. The cells were 
subsequently harvested by centrifugation (7,000 g for 20 min) and resuspended in 
250 ml 70% propan-2-ol, pH2.0 (adjusted to pH2.0 with addition of conc. HCl). 
Following stirring at 4˚C for four hours the cell debris was removed by 
centrifugation and the supernatant was subjected to rotary evaporation (50 mbar 
at 40˚C) to reduce the volume to ~60 ml via removal of propan-2-ol. The resultant 
preparation was applied to a 10 g 60 ml-1 Strata C-18E Giga-Tube (Phenomenex, 
Cheshire, UK) after pre-equilibration with 60 ml methanol followed by 60 ml water. 
The column was subsequently washed with 120 ml of 30% ethanol and the 
lantibiotic was then eluted from the column via addition of 100 ml of 70% propan-
2-ol, pH2.0. From the 100 ml preparation, 20 ml volumes were subjected to rotary 
evaporation in order to reduce them to ~1.7 ml through removal of propan-2-ol. 
Aliquots of 1,800 µl were then applied to a Phenomenex (Phenomenex, Cheshire, 
UK) C12 reverse phase (RP)-HPLC column (Jupiter 4µ 90Å 250×10.0 mm, 4 µm) 
previously equilibrated with 25% propan-2-ol containing 0.1% trifluoroacetic acid 
(TFA). The column was then developed in a gradient of 30% propan-2-ol containing 
0.1% TFA to 60% propan-2-ol containing 0.1% TFA in 4 to 40 min at a flow rate of 
1.2 ml min-1. Fractions containing Ltnα and Ltnβ were collected after each HPLC run 
and stored under nitrogen gas. The Ltnα and Ltnβ containing fractions were pooled 
separately and subsequently subjected to rotary evaporation to remove all propan-
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2-ol before freeze-drying of the peptides. The Ltnα and Ltnβ peptides were 
weighed in µg quantities using a Mettler UMT2 micro-balance.  
Antibiotic disc-based assessment of antimicrobial sensitivity and synergy 
The sensitivities of S. Typhimurium LT2, C. sakazakii 6440, S. aureus, and E. 
faecium strains to a variety of antibiotics were determined by antibiotic disc 
diffusion assays as described previously (Collins et al., 2010). Briefly, stationary-
phase cultures (16 h) were diluted to 107 CFU ml-1 and swabbed onto Mueller 
Hinton, LB or BHI agar plates. Six mm antibiotic discs (Oxoid) infused with specific 
antibiotics were placed on the agar plates. On the same plate lacticin 3147 (1.2, 1.9 
or 2.5 µg) was added to a second antibiotic-containing disc and to a blank disc 
(control). Following overnight incubation (16 hr) at 37°C, the resultant zones of 
inhibition were measured. The antibiotic discs employed included cefotaxime, 
novobiocin, cefoperazone, teicoplanin, ceftazidime, cefaclor, cephradine, cefaclor 
(30 μg), bacitracin, imipenem, fusidic acid (10 μg), penicillin G (5 μg), and oxacillin (1 
μg), colistin sulphate (polymyxin E) (25 μg) and polymyxin B (300 U). 
Minimum inhibitory concentrations 
Minimum inhibitory concentration (MIC) determinations were carried out in 
triplicate in 96 well microtitre plates as described by Wiedemann et al., 2006. 
Briefly, bacterial strains were grown overnight in the appropriate conditions and 
medium, subcultured into fresh broth and allowed to grow to an OD600 of ~0.5. 
Serial two-fold dilutions of the lacticin 3147, polymyxin B or colistin sulphate were 
made in the growth medium of the respective strain. Bacteria were then added 
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diluted to a final concentration of 105 cfu ml−1 in each a 0.2 ml MIC test well. After 
incubation for 16 hr at 37°C, the MIC was read as the lowest peptide concentration 
causing inhibition of visible growth.  
Checkerboard assay for combining antimicrobials 
In order to analyse combinations of two different antimicrobials (e.g. X and 
Y), the minimum inhibitory concentration of each antimicrobial has to be defined 
against a specific strain. Once this is known a 2-fold serial dilution of X is made 
horizontally in 50 µl in a microtitre plate beginning at 8 x MIC for X. In a second 
microtitre plate, a similar dilution of Y is created and then 50 µl of this is added 
vertically to the original microtitre plate containing the dilution of X.  Bacteria were 
then added in the same fashion as performed for to the singular peptide minimum 
inhibitory assays described previously. Fractional inhibitory Concentration (FIC) 
index is defined by the following equation: FIC = [FICX + FICY] = [(X/MICX) + 
(Y/MICY)]. Where (X) is the lowest level of antimicrobial X in combination with 
another to achieve an inhibitory effect, while (MICx) is the MIC of that antimicrobial 
alone for the bacterial strain under investigation. FIC index results are interpreted 
as follows: FIC ≤ 0.5 is synergy, 0.5 <FIC ≤ 0.75 is partial synergy, 0.75< FIC ≤ 1.0 is 
additive, FIC >1.0 is indifferent and FIC > 4 is antagonistic (Neu, 1977).          
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Results 
Sensitivity of bacteria to lacticin 3147 and antibiotics in combination. 
To determine whether lacticin 3147 could work synergistically with a variety 
of clinically utilised antibiotics, we used antibiotic discs assays to assess the potency 
of individual antibiotics (cefotaxime, novobiocin, cefoperazone, teicoplanin, 
ceftazidime, cefaclor, cephradine, cefaclor (30 μg), bacitracin, imipenem, fusidic 
acid (10 μg), penicillin G (5 μg), oxacillin (1 μg), colistin sulphate (polymyxin E) (25 
μg) and polymyxin B (300 U)), in the presence and absence of lacticin 3147. It was 
evident that lacticin 3147 had the ability to enhance the activity of a number of the 
antibiotics tested (data not shown) but the benefits of combining lacticin 3147 with 
polymyxin B or polymyxin E were particularly obvious (Fig. 1). In the case of the 
representative Gram positive and negative strains, E. faecium DO and E. coli EC101, 
the diameters of the zones of inhibition were increased by over 180% and by over 
121%, respectively. Indeed, in the case of E. faecium DO, combining sub-inhibitory 
concentrations of the individual antimicrobials resulted in the formation of a zone 
of clearing (Fig. 1). Based on these preliminary experiments it was apparent that the 
benefits of combining lacticin 3147 with either polymyxin B or E merited further 
examination. We used broth based microtitre plate assays to determine MICs and 
combined FICs against a range of Gram negative and representative Gram positive 
strains (Table 1). It was apparent that a combination of lacticin 3147 and polymyxin 
B or E had an indifferent effect (FIC = 1.25 and 1.125 respectively) against 
Salmonella Typhimurium UK1 and an antagonistic effect (FIC > 4) was observed in 
the case of the LT2 strain. However, combining these antimicrobials against other 
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targets gave more positive results. Indeed, a high level of synergy was observed 
against Cronobacter sakazakii strain 6440, with an FIC index corresponding to 0.250 
for a lacticin 3147 and polymyxin B combination and 0.062 for a lacticin 3147 and 
polymyxin E combination. FIC values here were determined on the basis of the 
reduction in MIC values for the polymyxins alone as an MIC value for lacticin 3147 
could not be determined as it is not active against C. sakazakii, even at the highest 
level tested (924 µg ml-1). However, it can be established that the FIC is <0.312 for 
lacticin 3147 in combination with polymyxin B and <0.125 when combined with 
polymyxin E.  
Corresponding studies with three E. coli strains again revealed synergism 
between lacticin 3147 and the polymyxins. An FIC index value of 0.248 was 
obtained when lacticin 3147 and polymyxin B were combined against 0157:H- while 
the corresponding lacticin 3147 and polymyxin E FIC value was 0.188. When lacticin 
3147 and polymyxin B were combined against E. coli DH5α and EC101 FIC indices of 
0.188 and 0.5 were obtained, respectively. In addition an FIC index of 0.188 was 
determined when lacticin 3147 and polymyxin E were combined for these two 
target strains. 
A number of additional assays were carried out in order to determine if the 
benefits of combining lacticin 3147 and the polymyxins in broth extended to Gram 
positive targets. For this purpose Bacillus cereus 8079, Enterococcus faecium DO 
and Staphylococcus aureus 5247 were selected as representative indicator strains. 
It was established that, while some partial synergy between lacticin 3147 and 
polymyxin B was observed with respect to B. cereus 8079 and S. aureus 5247 (FIC = 
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0.62 and 0.75, respectively), the other combinations resulted in an additive or 
indifferent outcome.  
Given that the most notable outcome from the study was the synergistic 
activity of lacticin 3147 and the polymyxins against some Gram negative targets, 
further investigations were carried out to determine how the respective 
components of lacticin 3147, i.e. Ltnα and Ltnβ, perform individually in the 
presence of polymyxin B/E. Selecting the sensitive strain E. coli 0157:H- as a target, 
we were able to evaluate the contribution of the individual α and β peptides to this 
phenomenon (Table 3). Taking into consideration the molecular weights and 1:1 
ratio at which α and β are combined, we can derive the relative amount (µg ml-1) of 
each individual peptide present when lacticin 3147 (Ltnα and Ltnβ combined in a 
1:1 ratio) is synergistic with polymyxin B/E. With this information we can compare 
the action of α and β alone to the same amount of each peptide present in whole 
lacticin 3147 in each case of synergy. Although various degrees of synergy exist due 
to the different combinations and concentrations assessed, only those that yielded 
the greatest synergy with respect to lacticin 3147 are listed in Table 1. Obtaining 
such a high degree of synergy was not possible with the single peptides, Ltnα and 
Ltnβ. For this reason additional synergy values/FIC data for lacticin 3147 in 
combination with polymyxin B and E has been included in Table 2. This provides a 
means by which the contribution of the individual lacticin 3147 components can be 
derived by focusing on a fixed level of polymyxin B/E in each case of synergy. 
Hence, it is apparent that, when combined with a set concentration of polymyxin B 
and E, 6 times more Ltnα alone is required to achieve the level of synergy obtained 
when both Ltnα and Ltnβ are present. In contrast, only 4.7 times Ltnβ alone is 
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required to achieve a corresponding level of activity in the absence of Ltnα. 
Interestingly the reverse is seen when you consider the individual action of Ltnα 
and Ltnβ alone, in the absence of polymyxin. In this situation only 1.5 times the 
amount of Ltnα is required, while 4.7 times Ltnβ is needed to achieve an MIC 
relative to their contribution when both lacticin 3147 peptides are present. 
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Discussion 
We undertook a series of investigations to determine whether lacticin 3147 
acts synergistically with a range of clinically important antibiotics. Antibiotics 
encompassing many families and modes of action were chosen, including 
cephalosporins, polypeptides, glycopeptides, carbenems, and quinolones. Following 
this initial screen, it became clear that lacticin 3147 and the polymyxins acted 
synergistically. 
Polymyxins are a group of polypeptide antibiotics that exclusively target 
Gram negative microorganisms. The five distinct members of this group, polymyxin 
A-E, were discovered in 1947 and are produced non-ribosomally by different 
Bacillus polymyxa species (Storm et al., 1977). Polymyxin B and polymyxin E, also 
referred to as colistin, have been used in clinical practice for decades in otic and 
ophthalmic solutions (Nakajima, 1965; Ohzawa, 1965). Polymyxins are decapeptide 
antibiotics which consist of a heptapeptide ring, with polymyxin E differing from 
polymyxin B only by the presence of D-Leu in lieu of a D-Phe. This ring is linked to a 
tripeptide side-chain which carries an aliphatic chain attached via an amide bond to 
the amino terminus (Velkov et al., 2010). The polymyxins carry five positive charges 
due to the presence of L-α-γ-diaminobutyric acids (Storm et al., 1977) and it has 
been established that the amphiphilic nature of this molecule gives it the ability to 
interact, bind and traverse the Gram negative outer membrane. The target 
molecule is lipopolysaccharide (LPS) (Vaara, 1992), and specifically the lipid A 
component (Morrison & Jacobs, 1976; Srimal et al., 1996). The polymyxins 
dissociate protective divalent cations from their association with anionic LPS. This 
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displacement permeabilises the Gram negative outer membrane to allow the 
polymyxins, or other cationic peptides, to form pores (Hancock, 1997). It should be 
noted, however, that the use of polymyxins in clinical settings has been restricted 
to use only where drug resistant pathogens have been encountered. This is due to 
the toxicity, primarily nephro- and neuro-toxicity, associated with its use (Falagas & 
Kasiakou, 2006), although this toxicity has been suggested to be dose dependent 
(Evans et al., 1999). Nonetheless, the polymyxins are, in many cases, the only 
antibiotics capable of overcoming specific drug resistant pathogens, such as 
Pseudomonas aeruginosa and Acinetobacter baumannii in cystic fibrosis patients 
(for review see (Falagas & Kasiakou, 2005; Yuan & Tam, 2008; Zavascki et al., 2007). 
For this reason the polymyxins cannot be ignored, but strategies that could reduce 
the dose needed for these antibiotics to be effective are highly desirable. 
A numbers of studies have investigated the consequences of combining 
various antibiotics with polymyxins. Antimicrobial agents such as miconazole 
(Pietschmann et al., 2009), rifampicin (Giamarellos-Bourboulis et al., 2001; 
Giamarellos-Bourboulis et al., 2003) meropenem, ampicillin-sulbactam, 
ciprofloxacin, piperacillin-clavulanic acid, imipenem, amikacin, and gentamicin 
(Kasiakou et al., 2005) ciprofloxacin (Hoiby et al., 2005) trimethoprim, 
trimethoprim-sulfamethoxazole, and vancomycin (Vidaillac et al., 2012), to name 
but a few, have been the focus of studies to assess if they can work synergistically 
with polymyxins (also see Yahav et. al., for a review of compounds synergistic with 
polymyxin E (Yahav et al., 2012)). To date the only lantibiotic to have been 
investigated in this way is nisin, which displays synergy with polymyxin B and 
polymyxin E against Listeria and E. coli (Naghmouchi et al., 2010; Naghmouchi et al., 
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2011). Nisin has also been shown to function synergistically when combined with 
polymyxin E (and clarithromycin) against Pseudomonas aeruginosa (Giacometti et 
al., 1999). Combination studies have also recently revealed that lacticin 3147 and 
the lactoperoxidase system (LPOS) successfully inhibited growth of Cronobacter 
spp. in rehydrated infant formula (Oshima et al., 2012). Lacticin 3147, like nisin, is a 
food grade bactericidal agent obtained from the GRAS organism Lactococcus lactis. 
Notably, however, it differs from nisin with respect to its target specificity and its 
greater potency against a number of species (Iancu et al., 2012). Also the 
mechanism of action contrasts from the single nisin peptide, in that it requires the 
interaction of two peptides, Ltnα and Ltnβ, for optimal bactericidal activity.   
Here we report the first study to investigate whether synergy can occur 
between polymyxin(s) and a two-component lantibiotic. Not only do we reveal that 
synergy is apparent against a range of strains tested, we also investigated the 
individual contributions of Ltnα and Ltnβ. We established that, when combined 
with polymyxin B/E, the levels of lacticin 3147 required to inhibit Gram negative 
species are equivalent or lower than the levels of lacticin 3147 alone against many 
Gram positive targets. Thus, in the presence of 0.3125 µg ml-1 polymyxin B/E, the 
concentration of lacticin 3147 required to inhibit Cronobacter sp. is less than the 
lacticin 3147 MIC for Mycobacterium avium subsp. paratuberculosis (MAP) ATCC 
19698 or Mycobacterium kansasii CIT11/06 (Carroll et al., 2010). Similarly the MIC 
of lacticin 3147 (alone) against many S. aureus (which includes many of the 
nosocomial pathogens: methicillin-resistant S. aureus (MRSA), S. aureus with 
intermediate resistance to vancomycin (VISA), S. aureus with heterogenous 
vancomycin intermediate resistance (hVISA)) (Iancu et al., 2012; Piper et al., 
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2009b), is greater than that required to inhibit E. coli species when in the presence 
of a polymyxin. It is also important to note that synergy with lacticin 3147 may 
provide a means of reducing the dose of polymyxins required to inhibit specific 
targets, thereby addressing polymyxin-associated toxicity issues. For example, 8-
fold and 16-fold lower levels of the polymyxins are required to inhibit E. coli and 
Cronobacter when in the presence of lacticin 3147. Furthermore a recent study by 
Naghmouchi et al., has shown that in addition to its role in providing synergy with 
polymyxin E,  the lantibiotic nisin appears, at certain concentrations, to eliminate its 
toxicity, as seen in Vero cell lines (Naghmouchi et al., 2013). Having established the 
role lacticin 3147 has in polymyxin synergy, further investigations are warranted in 
order to ascertain if such toxicity preventing attributes are common amongst 
lantibiotics. 
As with previous studies (Gales et al., 2001), the solo activities of polymyxin 
B and polymyxin E against the strains tested here are very similar. With respect to 
the dual action of lacticin 3147 and polymyxins, it appears that the lacticin 3147-
polymyxin B combination has the greater potency against Gram positive targets but 
that the lacticin 3147-polymyxin E combination has a greater effect against Gram 
negative strains. Thus, the single amino acid difference between the two polymyxin 
peptides appears to have an impact on its bactericidal action and target specificity 
when combined with lacticin 3147. It was also notable that the lacticin 3147 
sensitivity of Gram positive microorganisms such as Enterococcus faecium DO, 
which is already highly sensitive to lacticin 3147, is not enhanced by the presence of 
the polymyxins. However, in the case of the strains that are relatively more lacticin 
3147 resistant, the benefits of adding polymyxin B (especially with respect to Gram 
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positive strains) and polymyxin E (especially for Gram negative strains) is most 
apparent. It is interesting to note that this phenomenon does not correlate with 
results obtained during the initial agar based disc assay screen, where the opposite 
pattern was observed. However, it is acknowledged that the agar-based screen is a 
much cruder assay, and in that instance polymyxin concentrations were fixed and 
only lacticin 3147 concentrations were altered. Moreover, no FIC data can be 
derived and so increased zone sizes may not represent the optimal combination of 
the antimicrobials as obtained through checkerboard assays. The mechanism by 
which this synergy occurs with respect to Gram negative targets is presumably 
based in the action of polymyxin permeabilising the outer membrane to allow 
lacticin 3147 to gain access to the cytoplasmic membrane and its lipid II target 
(Hermsen et al., 2003). However, a phenomenon concerning the synergy between 
polymyxin B/E and the singular peptides Ltnα and Ltnβ is also unveiled during this 
study. Considering the action of the singular peptides in the absence of polymyxin, 
a greater quantity of Ltnβ alone, than Ltnα alone, is required to inhibit E. coli (4.7 
times versus 1.5 times respectively). This is logical in that Ltnα has been shown to 
have greater solo activity, and can bind to lipid II and prevent peptidoglycan 
synthesis (Wiedemann et al., 2006). However, in the presence of polymyxin B/E, 
Ltnα needs to be added at a 6 times greater concentration to bring about an 
inhibitory effect equal to that achieved by Ltnα:Ltnβ combined. In contrast, Ltnβ 
only needs to be added at a 4.7 fold greater concentration to compensate for the 
absence of Ltnα and thus Ltnβ seems more potent than Ltnα in the presence of 
either polymyxin. It is not clear if this is due to the potency of Ltnα being slightly 
compromised by the activity of the polymyxins or is a reflection of a particularly 
114 
 
beneficial interaction between these antibiotics and Ltnβ. Additional studies will be 
required in order to investigate this further.  
Regardless of the mechanism involved, this study documents a means by 
which lacticin 3147 can be combined with polymyxins in order to effectively inhibit 
some Gram negative species. There are a number of practical implications to these 
findings but these will require in vivo analysis. One outcome may be to ultimately 
facilitate the use of lower concentrations of polymyxins in situations where the 
levels currently employed are of concern from a toxicity perspective. Alternatively, 
enhancing the spectrum of lacticin 3147 to include Gram negative targets could 
have benefits with respect to, for example, the treatment of bovine mastitis. While 
lacticin 3147 has been established as being effective with respect to controlling 
bovine mastitis caused by Gram positive microorganisms, reducing levels of S. 
aureus, Streptococcus dysgalactiae or Streptococcus uberis (Klostermann et al., 
2010; Ryan et al., 1998), mastitis can also be caused by Gram negative species and 
in particular by E. coli species (Schukken et al., 2012; Shpigel et al., 2008), against 
which lacticin 3147 has limited efficacy. E. coli can be considered the quintessential 
environmental pathogen with respect to mastitis. Infections tend to result in acute 
and often severe clinical mastitis and account for as many as 30% to 40% of clinical 
mastitis cases (Hogan & Smith, 1987). Combining lacticin 3147 with low levels of a 
polymyxin could provide a means of broadening target specificity, for example in 
the treatment of mastitis, while keeping the concentrations of antimicrobial 
employed to a minimum.  
 
115 
 
Acknowledgements 
This work was supported by the Irish Government under the National Development 
Plan, through Science Foundation Ireland Investigator award (10/IN.1/B3027).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
References 
 
 
Arduino, R. C., Murray, B. E. & Rakita, R. M. (1994). Roles of Antibodies and 
Complement in Phagocytic Killing of Enterococci. Infection and Immunity 62, 987-
993. 
 
Bierbaum, G. & Sahl, H. G. (2009). Lantibiotics: mode of action, biosynthesis and 
bioengineering. Current pharmaceutical biotechnology 10, 2-18. 
 
Carroll, J., Draper, L. A., O'Connor, P. M., Coffey, A., Hill, C., Ross, R. P., Cotter, P. 
D. & O'Mahony, J. (2010). Comparison of the activities of the lantibiotics nisin and 
lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents. 
 
Chatterjee, C., Paul, M., Xie, L. & van der Donk, W. A. (2005). Biosynthesis and 
mode of action of lantibiotics. Chem Rev 105, 633-684. 
 
Collins, B., Curtis, N., Cotter, P. D., Hill, C. & Ross, R. P. (2010). The ABC transporter 
AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, 
bacitracin, and various beta-lactam antibiotics. Antimicrob Agents Chemother 54, 
4416-4423. 
 
Cotter, P. D., Draper, L. A., Lawton, E. M., McAuliffe, O., Hill, C. & Ross, R. P. 
(2006). Overproduction of wild-type and bioengineered derivatives of the 
lantibiotic lacticin 3147. Appl Environ Microbiol 72, 4492-4496. 
 
117 
 
Cotter, P. D., Ross, R. P. & Hill, C. (2013). Bacteriocins - a viable alternative to 
antibiotics? Nat Rev Microbiol 11, 95-105. 
 
Evans, M. E., Feola, D. J. & Rapp, R. P. (1999). Polymyxin B sulfate and colistin: old 
antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 
33, 960-967. 
 
Falagas, M. E. & Kasiakou, S. K. (2005). Colistin: the revival of polymyxins for the 
management of multidrug-resistant Gram-negative bacterial infections. Clin Infect 
Dis 40, 1333-1341. 
 
Falagas, M. E. & Kasiakou, S. K. (2006). Toxicity of polymyxins: a systematic review 
of the evidence from old and recent studies. Critical care 10, R27. 
 
Gales, A. C., Reis, A. O. & Jones, R. N. (2001). Contemporary assessment of 
antimicrobial susceptibility testing methods for polymyxin B and colistin: review of 
available interpretative criteria and quality control guidelines. J Clin Microbiol 39, 
183-190. 
 
Giacometti, A., Cirioni, O., Barchiesi, F., Fortuna, M. & Scalise, G. (1999). In-vitro 
activity of cationic peptides alone and in combination with clinically used 
antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 44, 
641-645. 
 
118 
 
Giamarellos-Bourboulis, E. J., Xirouchaki, E. & Giamarellou, H. (2001). Interactions 
of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn 
Microbiol Infect Dis 40, 117-120. 
 
Giamarellos-Bourboulis, E. J., Sambatakou, H., Galani, I. & Giamarellou, H. (2003). 
In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas 
aeruginosa. Journal of chemotherapy 15, 235-238. 
 
Hancock, R. E. (1997). The bacterial outer membrane as a drug barrier. Trends 
Microbiol 5, 37-42. 
 
Hermsen, E. D., Sullivan, C. J. & Rotschafer, J. C. (2003). Polymyxins: pharmacology, 
pharmacokinetics, pharmacodynamics, and clinical applications. Infectious disease 
clinics of North America 17, 545-562. 
 
Hogan, J. S. & Smith, K. L. (1987). A Practical Look at Environmental Mastitis. Comp 
Cont Educ Pract 9, F341-F346. 
 
Hoiby, N., Frederiksen, B. & Pressler, T. (2005). Eradication of early Pseudomonas 
aeruginosa infection. Journal of cystic fibrosis : official journal of the European 
Cystic Fibrosis Society 4 Suppl 2, 49-54. 
 
Iancu, C., Grainger, A., Field, D., Cotter, P., Hill, C. & Ross, R. P. (2012). Comparison 
of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and 
Vancomycin Against Gram-Positive Bacteria. Probiotics & Antimicro Prot 4, 108-115. 
 
119 
 
Kasiakou, S. K., Michalopoulos, A., Soteriades, E. S., Samonis, G., Sermaides, G. J. 
& Falagas, M. E. (2005). Combination therapy with intravenous colistin for 
management of infections due to multidrug-resistant Gram-negative bacteria in 
patients without cystic fibrosis. Antimicrob Agents Chemother 49, 3136-3146. 
 
Klostermann, K., Crispie, F., Flynn, J., Meaney, W. J., Paul Ross, R. & Hill, C. (2010). 
Efficacy of a teat dip containing the bacteriocin lacticin 3147 to eliminate Gram-
positive pathogens associated with bovine mastitis. J Dairy Res 77, 231-238. 
 
Morgan, S. M., O'Connor P, M., Cotter, P. D., Ross, R. P. & Hill, C. (2005). 
Sequential actions of the two component peptides of the lantibiotic lacticin 3147 
explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents 
Chemother 49, 2606-2611. 
 
Morrison, D. C. & Jacobs, D. M. (1976). Binding of polymyxin B to the lipid A 
portion of bacterial lipopolysaccharides. Immunochemistry 13, 813-818. 
 
Naghmouchi, K., Drider, D., Baah, J. & Teather, R. (2010). Nisin A and Polymyxin B 
as Synergistic Inhibitors of Gram-positive and Gram-negative Bacteria. Probiotics & 
Antimicro Prot 2, 98-103. 
 
Naghmouchi, K., Belguesmia, Y., Baah, J., Teather, R. & Drider, D. (2011). 
Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E 
against resistant variants of Listeria monocytogenes and Escherichia coli. Res 
Microbiol 162, 99-107. 
 
120 
 
Naghmouchi, K., Baah, J., Hober, D., Jouy, E., Rubrecht, C., Sane, F. & Drider, D. 
(2013). Synergistic effect between colistin and bacteriocins in controlling Gram-
negative pathogens and their potential to reduce antibiotic toxicity in mammalian 
epithelial cells. Antimicrob Agents Chemother 57, 2719-2725. 
 
Nakajima, S. (1965). [Clinical use of colimycin F otic solution]. Jibi inkoka 
Otolaryngology 37, 693-697. 
 
Neu, H. C. (1977). Mecillinam--an amidino penicillin which acts synergistically with 
other beta-lactam compounds. J Antimicrob Chemother 3 Suppl B, 43-52. 
 
Ohzawa, R. (1965). [The use of colimycin ear drops]. Jibi inkoka Otolaryngology 37, 
585-590. 
 
Oshima, S., Rea, M. C., Lothe, S. & other authors (2012). Efficacy of organic acids, 
bacteriocins, and the lactoperoxidase system in inhibiting the growth of 
Cronobacter spp. in rehydrated infant formula. J Food Prot 75, 1734-1742. 
 
Pietschmann, S., Hoffmann, K., Voget, M. & Pison, U. (2009). Synergistic effects of 
miconazole and polymyxin B on microbial pathogens. Veterinary research 
communications 33, 489-505. 
 
Piper, C., Cotter, P. D., Ross, R. P. & Hill, C. (2009a). Discovery of medically 
significant lantibiotics. Curr Drug Discov Technol 6, 1-18. 
 
121 
 
Piper, C., Draper, L. A., Cotter, P. D., Ross, R. P. & Hill, C. (2009b). A comparison of 
the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus 
and Enterococcus species. J Antimicrob Chemother 64, 546-551. 
 
Rea, M. C., Clayton, E., O'Connor, P. M., Shanahan, F., Kiely, B., Ross, R. P. & Hill, 
C. (2007). Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile 
strains. J Med Microbiol 56, 940-946. 
 
Ryan, M. P., Meaney, W. J., Ross, R. P. & Hill, C. (1998). Evaluation of lacticin 3147 
and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl 
Environ Microbiol 64, 2287-2290. 
 
Schukken, Y., Chuff, M., Moroni, P., Gurjar, A., Santisteban, C., Welcome, F. & 
Zadoks, R. (2012). The "other" Gram-negative bacteria in mastitis: Klebsiella, 
serratia, and more. The Veterinary clinics of North America Food animal practice 28, 
239-256. 
 
Shpigel, N. Y., Elazar, S. & Rosenshine, I. (2008). Mammary pathogenic Escherichia 
coli. Current opinion in microbiology 11, 60-65. 
 
Srimal, S., Surolia, N., Balasubramanian, S. & Surolia, A. (1996). Titration 
calorimetric studies to elucidate the specificity of the interactions of polymyxin B 
with lipopolysaccharides and lipid A. Biochem J 315 ( Pt 2), 679-686. 
 
Storm, D. R., Rosenthal, K. S. & Swanson, P. E. (1977). Polymyxin and related 
peptide antibiotics. Annual review of biochemistry 46, 723-763. 
122 
 
 
Suda, S., Cotter, P. D., Hill, C. & Ross, R. P. (2012). Lacticin 3147--biosynthesis, 
molecular analysis, immunity, bioengineering and applications. Curr Protein Pept Sci 
13, 193-204. 
 
Vaara, M. (1992). Agents that increase the permeability of the outer membrane. 
Microbiol Rev 56, 395-411. 
 
Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. (2010). Structure--activity 
relationships of polymyxin antibiotics. J Med Chem 53, 1898-1916. 
 
Vidaillac, C., Benichou, L. & Duval, R. E. (2012). In vitro synergy of colistin 
combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56, 
4856-4861. 
 
Wiedemann, I., Bottiger, T., Bonelli, R. R. & other authors (2006). The mode of 
action of the lantibiotic lacticin 3147--a complex mechanism involving specific 
interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 61, 
285-296. 
 
Yahav, D., Farbman, L., Leibovici, L. & Paul, M. (2012). Colistin: new lessons on an 
old antibiotic. Clin Microbiol Infect 18, 18-29. 
 
Yuan, Z. & Tam, V. H. (2008). Polymyxin B: a new strategy for multidrug-resistant 
Gram-negative organisms. Expert opinion on investigational drugs 17, 661-668. 
123 
 
 
Zavascki, A. P., Goldani, L. Z., Li, J. & Nation, R. L. (2007). Polymyxin B for the 
treatment of multidrug-resistant pathogens: a critical review. J Antimicrob 
Chemother 60, 1206-1215. 
 
 
 
 
 
 124 
 
Table 1. MIC data for lacticin 3147, polymyxin B and polymyxin E alone and in combination. FIC figures have been calculated as a result of 
triplicate experiments and indicate asynergy, bpartial synergy, cadditive effects, dindifference, and eantagonism between the combined 
antimicrobials. *FIC index which includes the reduction in lacticin 3147 MIC from the highest level tested to that which achieves an MIC in the 
presence of polymyxin.
Organism 
MIC (µg ml-1) 
Lacticin  
3147 
Polymyxin 
B 
Polymyxin 
E 
Lacticin 3147/ 
Polymyxin B FIC 
Lacticin 3147/ 
Polymyxin E FIC 
Salmonella Typhimurium UK1 924 0.0586 0.0586 924/0.015 1.25d 924/0.0073 1.125d 
Salmonella Typhimurium LT2 231 0.3125 0.4688 No MIC >4e No MIC >4e 
Cronobacter sakazakii DPC 6440 >924 0.3125 0.3125 57.75/0.0781 0.250 (<0.312)*a 57.75/0.0195 0.062 (<0.125)*a 
E. coli 0157:H- 231 0.0586 0.0781 28.875/0.0073 0.250a 28.875/0.0049 0.188a 
E. coli DH5α 462 0.0781 0.0781 28.875/.0098 0.188a 28.875/0.0098 0.188a 
E. coli EC101 462 0.0781 0.0781 14.4375/.0391 0.5a 28.875/0.0098 0.188a 
E. faecium DO 0.9625 >375 >375 0.9625/23.4375 1c 0.9652/23.4375 1c 
B. cereus 8079 3.85 187.5 375 1.925/23.4375 0.62b 3.85/375 2d 
S .aureus 5247 15.4 187.5 >375 7.7/46.875 0.75b 15.4/23.4375 1c 
Tables and Figures 
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Table 2. MIC data for lacticin 3147, and its individual peptides Ltnα and Ltnβ, polymyxin B and polymyxin E alone and in combination. FIC 
figures have been calculated as a result of triplicate experiments and to indicate asynergy and bpartial synergy effects.*Alternative MIC and 
FIC data that allows for fixed levels of polymyxin across antimicrobial combinations, thus allowing for the calculation of the involvement of 
Ltnα and Ltnβ in synergy with polymyxin.
E.coli 0157:H- 
MIC (µg ml-1) 
Lacticin 3147 Polymyxin B Polymyxin E Lacticin 3147/ Polymyxin B FIC 
Lacticin 3147/ 
Polymyxin E FIC 
231 (37.5 µM) 
(α :124.74, Β: 106.26) 0.0586 0.0781 
28.875/0.0073 
28.875 / 0.0147* 
0.250a 
0.376*a 
28.875/ 0.0049 
14.4375 / 0.0195* 
0.188a 
0.312*a 
Ltnα/ Polymyxin B Polymyxin E Ltnα/ Polymyxin B FIC 
Ltnα/ 
Polymyxin E FIC 
187.11 (56.25 µM) 
(1.5 X Ltnα) 0.0586 0.0781 
93.555 / 0.0073 
(6.0 X Ltnα in combin.) 0.625
b 46.7775/ 0.0195 
(6.0 X Ltnα in combin.) 0.500
a 
Ltnβ/ Polymyxin B Polymyxin E Ltnβ/ Polymyxin B FIC 
Ltnβ/ 
Polymyxin E FIC 
495.88 (175 µM) 
(4.7 X Ltnβ) 0.0586 0.0781 
61.9850 / 0.0147 
(4.7 X Ltnβ in combin.) 0.376
a 30.9925 / 0.0195 
(4.7 X Ltnβ in combin.) 0.313
a 
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Fig. 1. Antibiotic disc-based assessment of lacticin 3147 and polymyxin B/E 
sensitivity and synergy. Antibiotic discs infused with polymyxin B and polymyxin E 
were placed on agar plates swabbed with E. faecium DO and E. coli EC101. Lacticin 
3147 (1.2, 1.9 or 2.5 μg) was added to additional discs containing the respective 
polymyxins and to blank, non-polymyxin containing, controls. Results are the 
outcome of duplicate experiments and are expressed as total area of inhibitory 
zone expressed in mm2. 
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Summary 
The lantibiotic lacticin 3147 has been the focus of much research due to its 
broad spectrum of activity against many microbial targets, including drug-resistant 
pathogens. In order to protect itself, a lacticin 3147 producer must possess a cognate 
immunity mechanism. Lacticin 3147 immunity is provided by an ABC transporter, 
LtnFE, and a dedicated immunity protein, LtnI, both of which are capable of 
independently providing a degree of protection. In the study described here, we carry 
out an in-depth investigation of LtnI structure-function relationships through the 
creation of a series of fusion proteins and LtnI determinants that have been the subject 
of random and site-directed mutagenesis. We establish that LtnI is a transmembrane 
protein that contains a number of individual residues and regions, such as those 
between amino acid 20 and 27 and amino acid 76 and 83, which are essential for LtnI 
function. Finally, as a consequence of the screening of a bank of 28,000 strains 
producing different LtnI derivatives, we identified one variant (LtnI I81V) that provides 
enhanced protection. To our knowledge, this is the first report of a lantibiotic immunity 
protein with enhanced functionality. 
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Introduction 
Lantibiotics are post-translationally modified antimicrobial peptides produced 
by Gram positive bacteria. Many lantibiotics are active in nanomolar concentrations 
and have a broad spectrum of activity against many bacteria, including drug-resistant 
pathogens (Chatterjee et al., 2005; Cotter et al., 2005a; Guder et al., 2000; McAuliffe et 
al., 2001; Pag & Sahl, 2002). As a consequence, lantibiotics have been the subject of 
much investigation with respect to clinical and/or food applications (Breukink & de 
Kruijff, 2006; Brumfitt et al., 2002; Cotter et al., 2005a; Galvin et al., 1999; Kruszewska 
et al., 2004; Wiedemann et al., 2001). Because of the potency of lantibiotics, each 
producer must provide immunity against its own lantibiotic.  Lacticin 3147  is a type II 
lantibiotic produced by rare strains of Lactococcus lactis (Suda et al., 2011). The lacticin 
3147 producer employs two systems to provide immunity (Draper et al., 2008; Draper 
et al., 2009; McAuliffe et al., 2000). One system is comprised of an ABC transporter 
complex designated LtnFE, thought to function through the extrusion of lacticin 3147 
from the cytoplasmic membrane. Such immunity transporters have been identified in 
other lantibiotic producers and are generically designated LanFE(G) (Guder et al., 2002; 
Otto et al., 1998; Peschel & Gotz, 1996; Stein et al., 2003; Stein et al., 2005). Immunity 
to lacticin 3147 is also provided by a dedicated immunity protein, LtnI. Generically 
designated LanI, these heterogeneous proteins/lipoproteins can provide protection 
against an associated lantibiotic alone or in combination with LanFE(G) (Klein & Entian, 
1994; Kuipers et al., 1993; McAuliffe et al., 2000; Okuda et al., 2005; Pag et al., 1999). 
Immunity to a number of other lantibiotics, including Pep5, epicidin 280, lactocin S and 
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cytolysin, is provided solely by the corresponding immunity proteins, PepI, EciI, LasI 
and CylI, respectively (Coburn et al., 1999; Heidrich et al., 1998; Skaugen et al., 1997). 
Relatively little regarding the mechanism by which LtnI provides protection to 
lacticin 3147 is known. Although this 116-amino-acid (aa) protein is predicted to be 
membrane associated on the basis of hydrophobicity profiling (McAuliffe et al., 2000), 
to date, other insights into LtnI function have had to be inferred from what is known 
about other LanI proteins. NisI and SpaI, proteins associated with immunity to nisin and 
subtilin, respectively, differ from LtnI in that they are lipoproteins that are linked to the 
membrane by a lipid moiety. These proteins have been investigated in some depth. For 
example, a series of C-terminally truncated NisI proteins were created and expressed in 
L. lactis in order to identify the region of NisI that interacts with nisin. A 21-amino-acid 
C-terminal deletion resulted in the retention of just 14% of the protective effect 
provided by native NisI, whereas longer deletions (up to 74 aa) had no additional 
effect. When the corresponding 21-aa region of SpaI was replaced with that of NisI and 
expressed in L. Lactis, the SpaI’-‘NisI fusion protein provided immunity to nisin, 
confirming the nisin-specific protective capabilities of these C-terminally located amino 
acids (Takala & Saris, 2006).  
Similar investigations have been carried out to identify essential domains within 
PepI, a LanI protein associated with Pep5 immunity (Meyer et al., 1995), and its 
homologue, EciI, which is responsible for epicidin 280 immunity and cross-immunity to 
Pep5 (Heidrich et al., 1998). The introduction of charged amino acids into the N-
terminal hydrophobic 20-amino-acid stretch of PepI impacted on the membrane 
131 
 
localisation of the protein. One such mutant protein, PepI-I17R, conferred substantially 
reduced immunity to Pep5. The addition of an F13D change in this background, slightly 
increased immunity levels compared to I17R alone, but also resulted in an enhanced 
susceptibility to proteolysis (Hoffmann et al., 2004). To investigate the importance of 
the C-terminal domain of PepI, a truncated protein, PepI1-65 that lacked the four C-
terminally located charged amino acids was created. The immunity provided by this 
truncated version was greatly reduced (Pag et al., 1999). A further study focused on 
three other C-terminally truncated versions of PepI; PepI1-63, PepI 1-57 and PepI 1-53. As 
each segment consisting of two positively charged residues next to one negatively 
charged amino acid was removed, the level of protection was further reduced. The 
negative impact on immunity was evident, despite the fact that these proteins 
remained located in the membrane, thereby suggesting that the C terminus of PepI is 
also involved in target recognition. The importance of charge distribution within this C-
terminal region was also apparent from the negative impact on immunity arising from 
the creation of a PepI-K59T derivative (Hoffmann et al., 2004).  
Finally, the structure and function of the LanH protein associated with 
immunity to the type II lantibiotic nukacin ISK-1, NukH (92 amino acids), have been 
extensively investigated (Aso et al., 2005). NukH, although distinct from LanI proteins 
in that it functions as an accessory protein to the ABC transporter immunity system 
NukFEG, has a transmembrane (TM) location. Through the creation of truncated 
versions of NukH fused to an alkaline phosphatase (PhoA) reporter and by evaluation 
of their sensitivity to proteinase K, it was established that NukH contains 3 
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transmembrane domains (TMDs). The PhoA fusion sites of NukH from amino acid 1 to 
33 [NukH(1-33)-PhoA] and amino acids 1 to 92 [NukH(1-92)-PhoA] were shown to be 
extracellularly located, in that they were subject to proteinase K degradation, whereas 
the PhoA domain of NukH(1-64)-PhoA was not, thereby supporting in silico predictions 
that this corresponded to a transmembrane domain (Okuda et al., 2005). To identify 
functional domains within NukH, amino acid substitutions, deletions and truncated 
versions were created. Deletion of either the N terminus (position 1 to 6) or the C 
terminus (position 89 to 92) of NukH did not have any effect on its nukacin ISK-1 
binding capabilities or immunity function. However, substituting the amino acids of the 
internal or external loop for alanines abolished NukH function. It was revealed that the 
external loop was of greatest importance with respect to target binding and that while 
deletion of the transmembrane regions abolished immunity completely, the truncated 
protein was still capable of binding its target (Okuda et al., 2005).  
Here, to address a lack of knowledge with respect to the topology and 
functional domains of LtnI, or indeed, type II immunity proteins in general, a series of 
fusion proteins and site-directed derivatives were created. We also created the first 
bank of randomly mutated LanI proteins and identified the first LanI variant that 
provides enhanced lantibiotic protection. 
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Materials and Methods 
Growth Conditions 
The strains and plasmids utilized during this study are found in Table 1. 
Lactococci were routinely grown at 30˚C without aeration in M17 broth (Oxoid Ltd., 
Basingstoke, Hampshire, England) supplemented with 0.5% (wt/vol) glucose (GM17), 
GM17 supplemented with K2HPO4 (36 mM), KH2PO4 (13.2 mM), sodium citrate 
(1.7 mM), MgSO4 (0.4 mM), (NH4)2SO4 (6.8 mM) and 4.4% glycerol (GM17 freezing 
buffer) without aeration; or GM17 agar unless otherwise stated. Escherichia coli was 
grown in Luria-Bertani (LB) broth (Sambrook et al., 1989) at 37˚C with vigorous 
agitation. Antibiotics were used, where indicated, at the following concentrations: 
Ampicillin (Amp) was used at a concentration of 100 µg ml-1 for E. coli and 
chloramphenicol at a concentration of 10 µg ml-1 for E. coli and 5 µg ml-1 for L. lactis. 
 
General molecular biology techniques 
Plasmid DNA was isolated from E. coli strains using the High Pure plasmid 
isolation kit as recommended by the manufacturer (Roche Diagnostics, Mannhein, 
Germany). Plasmids isolated from L. lactis were isolated in the same way following 
treatment with protoplast buffer (5mM EDTA, 50 U ml-1 mutanolysin, 10 mg ml-1 
lysozyme, 0.75M sucrose, 20mM Tris-HCl pH7.5). Total cell DNA was isolated using 
Roche High Pure PCR template preparation kit (Roche Diagnostics, Mannheim, 
Germany). Chemically competent E. coli Top10 was used as an immediate host for the 
plasmids pNZ44 following manufacturer’s guidelines for transformation. L. lactis strains 
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were made electrocompetent following the procedure described by Holo and Nes 
(Holo & Nes, 1995). In both cases electrotransformation was performed with an Electro 
cell manipulator (BTX-Harvard apparatus). PCR was performed according to standard 
procedures using BioTaq DNA (Bioline), Vent polymerase (New England biolabs), KOD 
DNA polymerase (Novagen) and Pwo DNA polymerase (Roche Diagnostics). For colony 
PCR, genomic DNA was accessed through lysis of cells in 10% Igepal CA-630 (Sigma-
Alrich) at 94˚C for 10 mins. Extraction of DNA from agarose gels were performed using 
the KeyPrep Spin Gel DNA Clean Up Kit (Anachem, Bedfordshire, UK) as recommended 
by the manufacturer. DNA ligations were executed according to established procedures 
using T4 ligase supplied by Roche Diagnostics. Restriction enzymes were also used to 
manufacturer’s guidelines and were supplied by Roche Diagnostics. DNA sequencing 
was performed by MWG Biotech AG or Beckman Coulter genomics. 
 
Random mutagenesis of ltnI 
Plasmid DNA was isolated from E. coli Top10 pNZ44ltnI (Draper et al., 2009) 
using the Maxiprep plasmid kit (Qiagen) to a concentration of approximately 
428 ng μl−1. pNZ44ltnI was then used as template for the Genemorph II random 
mutagenesis kit (Stratagene) according to manufacturer's guidelines. To introduce an 
average of 1 base pair change in the 488-bp cloned fragment, amplification was 
performed in a 50-μl reaction mixture containing approximately 500 ng of target DNA 
(pNZ44ltnI), 2.5 units Mutazyme DNA polymerase, 1 mM dNTPs and 200 ng each of 
primers LtnIRMFor and LtnIRMrev. The reaction was preheated at 96°C for 1 min, then 
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incubated for 25 cycles at 96°C for 1 min, 52°C for 1 min and 72°C for 1 min, and then 
finished by incubating at 72°C for 10 min. Amplified products were purified by gel 
extraction and reamplified with KOD DNA polymerase before being digested with KpnI 
and XbaI, ligated with similarly digested and shrimp alkaline phosphatase-treated 
pNZ44, and introduced into E. coli Top 10. To determine if the correct rate of mutation 
had been achieved, recombinant plasmid DNA was isolated from selected clones and 
sequenced. Transformants were pooled and stored in 80% glycerol at −20°C. Plasmid 
DNA isolated from the mutant bank was used to transform L. lactis MG1363. 
Transformants (approximately 28,000) were isolated from Q trays using a Genetix QPIX 
II-XT colony-picking robot, inoculated into 384-well plates containing GM17 freezing 
buffer, incubated overnight and subsequently stored at −20°C. 
 
Construction of lacZ- and phoA- ltnI gene fusions.  
pMRC01 was used as the template to amplify, by PCR, C-terminally truncated 
ltnI fragments using LtnIxbaF (containing the ribosomal binding site and start codon for 
ltnI) as the forward primer for all constructs. The respective reverse primers are listed 
in Table 2. All lacZ reverse primers (LtnI21B to LtnI114B) contain a BamHI restriction 
site to facilitate in-frame fusion with the lacZ gene of pRMCD70 (Daniels et al., 1998), 
whereas reverse primers for phoA fusions (LtnI21H to LtnI114H) contain a HindIII site 
to facilitate in-frame fusion with phoA of pRMCD28 (Daniels et al., 1998). All constructs 
were electroporated into E. coli CC118, and transformants were selected on LB plates 
containing ampicillin and initially checked using a phoA or lacZ check primer situated 
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upstream of the cloned ltnI gene fragment in conjunction with the appropriate reverse 
primer used to make the constructs. The integrity of the constructs was subsequently 
confirmed by DNA sequencing. 
 
Creation of truncated LtnI proteins 
Plasmid pMRC01 was used as a template to facilitate the creation of truncated 
ltnI genes. The primer 5562R was used to generate all N-terminal deletion mutant 
constructs in combination with the forward primers Nterm14F, Nterm20W and 
Nterm28Y (all containing a PstI site; Table 2). Primers 5563F and Cterm83, Cterm90 and 
Cterm109 were used to generate the C-terminal deletion mutant. In all cases the PCR 
products were digested with the appropriate restriction enzymes, introduced 
downstream of the constitutive P44 promoter in pNZ44 and transformed into E. coli 
Top10 cells. Transformants were selected on LB-Cm plates, further analysed by PCR 
and sequenced to ensure their integrity. Plasmids were then electroporated into L. 
lactis MG1363 to assess the level of immunity provided. 
 
Site-directed mutagenesis in LtnI 
Amino acids in LtnI were changed using the site-directed mutagenesis strategy 
(QuikChange, Stratagene) as described previously (Cotter et al., 2005b) using pNZ44ltnI 
as the template and the primers listed in Table 2. That is, the primers LtnIL1AF/R and 
LtnIL2AF/R were used for constructing pNZltnIL87A and pNZltnIL94A, respectively; and 
pNZ44ltnID57A, pNZ44ltnIR59A were created using the primers LtnID57AF/R and 
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LtnIR59AF/R, respectively, for the single mutants. A double mutant (pNZ44ltnID57A-
R59A) was created using one pair of primers (LtnID57/R59F/R) encompassing both 
mutations. The QuikChange procedure was used according to the manufacturer’s 
instructions with the exception that E. coli Top10 were used as the cloning host. 
Putative mutants were selected on LB-Cm plates, confirmatory PCRs were carried out 
using an appropriate check primer in conjunction with pNZR or 5562R, successful 
mutation was confirmed with DNA sequencing and the immunity provided when these 
plasmids were introduced into MG1363 was assessed.  
 
Agar-based lacticin 3147 sensitivity tests 
Using the Genetix QPIX II-XT colony-picking robot, the mutant bank was 
stamped onto Q trays containing GM17 seeded with various concentrations of a 
skimmed milk-based preparation of lacticin 3147 (lacticin 3147 fermentation, Teagasc 
Moorepark) a 1 mg ml-1 solution of which corresponds to 640 Activity Units (AU) ml-1 
against the lacticin 3147-sensitive target L. lactis HP. Sensitivity to lacticin 3147 was 
indicated by a failure to grow in the presence of 3 mg ml-1 lacticin 3147 powder. 
Enhanced resistance to lacticin 3147 was screened for through exposure to 12 mg ml-1 
(7,680 AU ml-1) lacticin 3147 powder. Sensitivity to lacticin 3147 was also assessed 
using a gradient agar sensitivity test (Hoffmann et al., 2004). Briefly, square petri dishes 
(100x100mm) were filled with 25 ml of GM17 containing 15 mg ml-1 lacticin 3147-milk 
powder, placed at approx a 3o angle and allowed to set. The petri dish was then placed 
in a horizontal position and an additional 25 ml of GM17 was added resulting in the 
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creation of a lacticin 3147 concentration gradient. Diluted bacterial cultures (0.5 
McFarland units) were applied with a sterile cotton swab along the lacticin 3147 
gradient and incubated overnight at 30°C.  
 
Broth-Based lacticin 3147 sensitivity assays   
Broth based growth assays were performed by inoculating L. lactis 
MG1363.pNZ44ltnI strains to give a final inoculum of 105 CFU ml−1 in a volume of 0.2 ml 
in GM17 containing 1.1 µM lacticin 3147 and monitoring optical density at 600 nm 
(OD600) with a Spectromax 340 spectrophotometer (Molecular Devices, Sunnyvale, 
California) over a 16 hr period. Minimum inhibitory concentration (MIC) assays were 
performed as described previously (Draper et al., 2009). 
 
β-Galactosidase and alkaline phosphatase assays.  
β-Galactosidase and alkaline phosphatase assays were carried out as described 
by Miller (Miller, 1972) and Manoil (Manoil, 1991), respectively. Briefly, for LacZ 
constructs, E. coli were grown in 10 ml LB broth until the OD600nm reached ∼0.5, 
collected by centrifugation and resuspended in 1 ml LacZ buffer. Cells were 
permeabilised with 0.1% SDS and chloroform as described by (Israelsen et al., 1995). 
Subsequently, 4 mg ml-1 2-nitrophenyl β-D-galactopyranoside (ONPG) was mixed with 
the permeabilised cells, the mixture was incubated at 30°C until the development of a 
yellow pigment and the reaction was stopped with 1M sodium carbonate (NaCO3). 
Enzymatic activities were calculated using the following formula [(522 × OD420nm of 
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reaction mixture)/(OD600nm of culture × volume per ml of culture used × time of 
reaction)]. Miller activity per ml of culture represents the average of three triplicate 
experiments. To assay PhoA activity, E. coli were grown as for β-galactosidase assays, 
resuspended in 1M Tris pH 9.0, permeabilized as before; phosphatase substrate (10 mg 
ml-1 ) was added; and samples were incubated at 37°C until the development of a 
yellow pigment; the reaction was stopped with 10M sodium hydroxide (NaOH). PhoA 
activity was calculated using the formula; [(1000 × OD420nm of reaction 
mixture)/(OD600nm × volume of culture × time of reaction)]. 
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Results 
In silico analysis of LtnI.  
It was previously reported by McAuliffe et al. that LtnI (116 amino acids in 
length) is likely to be an integrated membrane protein, based on Kyte and Doolittle 
hydrophobicity plots that predict three highly hydrophobic domains (McAuliffe et al., 
2000). We can now report a more extensive bioinformatic analysis, using the TMHMM 
(Krogh et al., 2001), HMMTOP (Tusnady & Simon, 2001), SPLIT (version 4.0) (Juretic et 
al., 2002), SOUSI (Hirokawa et al., 1998) and TMpred (Hofmann & Stoffel, 1993) 
servers, which also strongly predict that these hydrophobic regions correspond to 
three trans-membrane domains (TMDs). All predictions suggest that the N terminus of 
LtnI is located outside of the cell, that TMD1 and TMD3 have an outside-to-inside 
orientation, that TMD2 has an inside to outside orientation and that the C terminus has 
a cytoplasmic location (Fig. 1). A study analyzing the accuracy of 13 TM helix prediction 
methods, including those used in this study, has highlighted the accuracy of TMHMM2 
and SPLIT (version 4.0) (Cuthbertson et al., 2005), and thus, the structures predicted by 
TMHMM2 and SPLIT (version 4.0) were used the templates (Fig. 1(c)) to design all 
subsequent experimentation.  
In silico analysis (PSI-BLAST; http://blast.ncbi.nlm.nih.gov/) has also facilitated 
the identification of genes encoding LtnI-like proteins from within microorganisms 
whose genomes have been sequenced (Fig. 2). This includes a bliI gene that has 
previously been shown to provide protection against lacticin 3147 when expressed 
heterologously (Draper et al., 2009). An alignment of the putative amino acid 
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sequences of the LtnI-like proteins facilitates the identification of conserved regions 
that potentially correspond to regions that are essential to the function of these 
proteins. One notable feature relates to the fact that the putative cytoplasmic loop is 
characterized by a large number of what are mostly charged amino acids that are 
conserved across homologues, represented in LtnI by D57, E58, R59 and T60. 
Furthermore, while previous in silico investigations have predicted the presence of a 
leucine zipper in LtnI (McAuliffe et al., 2000), the identification of leucine zippers can 
be easily assigned incorrectly when the correct orientation of leucines alone is 
employed. Notably, when reassessed using 2ZIP, a server for leucine zipper prediction 
(Bornberg-Bauer et al., 1998), it becomes apparent that LtnI lacks other essential coiled 
coil segments, thus casting doubt over the existence of a leucine zipper domain. Finally 
Batch CD search (a conserved domain search tool) (Marchler-Bauer et al., 2011) fails to 
annotate functional protein domains within LtnI. 
 
Analysis of LtnI membrane topology in E. coli using ltnI-lacZ and ltnI-phoA gene 
fusions.  
We used β-galactosidase (lacZ) and alkaline phosphatase (phoA) gene fusions to 
experimentally probe LtnI membrane topology (Manoil, 1991). The aforementioned 
bioinformatic analysis was used as the basis for constructing a series of constructs 
whereby each of the predicted inside/outside domains, including the 3 TMDs (Fig. 1(c)), 
was fused to LacZ and PhoA. Fusions of this nature can reveal the location of individual 
domains based on the premise that enzymatically active LacZ is only achieved if it is 
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located in the cytoplasm and active PhoA hybrids are only observed if the enzyme is 
located outside the cytoplasmic membrane. The low-copy-vectors pRMCD28 (phoA) 
and pRMCD70 (lacZ) were utilized to fuse truncated forms of ltnI to phoA or lacZ genes 
lacking the first eight codons. These were under the control of a lacI promoter. 
Fourteen hybrids were generated. In these hybrids, LacZ and PhoA were fused to the C-
terminal amino acids A21, F45, K55, L75, G85, C100 and D114 of truncated LtnI 
proteins. β-Galactosidase and phosphatase assays showed that the K55 hybrid had a 
LacZ-positive and PhoA-negative phenotype, indicating that, as predicted, K55 is 
located in the cytoplasm (Fig. 3). Similarly, the G85 fusions behaved as expected (LacZ-
negative, PhoA-positive), indicating that this region is located outside the cytoplasmic 
membrane. A21 fusions have a LacZ- and PhoA-negative phenotype, which may be due 
to the production of a non-functional hybrid protein as a consequence of its small size, 
or may indicate that A21 may be located in the membrane. The C-terminal region D114 
fusions had a PhoA-negative phenotype and a slightly LacZ-positive phenotype, 
suggesting that the C terminus of LtnI is located in the cytoplasm but is in close contact 
with the membrane, in a manner that results in lower LacZ activity. Fusions made 
within putative TM regions (F45, L75 and C100) all have a LacZ- and PhoA- negative 
phenotype, thus indicating that these amino acids are indeed embedded in the 
membrane (Fig. 3).  
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Design and analysis of N-terminal and C-terminal deletions of LtnI.  
To further investigate the importance of different regions, truncated versions of 
LtnI were created. Initially, the N terminus, a region highly conserved between LtnI-like 
proteins, was truncated to exclude residues 1 to 13 of LtnI ( abbreviated ltnI∆NT1-13), 
while a second mutant that lacks this region as well as residues 14 to 19, and a third 
lacking residues 1 to 27 were generated (Fig. 2). The construct pNZ44ltnI∆NT1-13 was 
cloned into MG1363 and was initially tested by well diffusion assay for an immunity 
phenotype. The level of immunity provided by MG1363.pNZ44ltnI∆NT1-13 was 
comparable with that of MG1363.pNZ44ltnI, as was MG1363.pNZ44ltnI∆NT1-19, a fact 
that was confirmed by MIC studies (Table 3). In contrast, MG1363.pNZ44ltnI∆NT1-27 
was as sensitive as the control host strain MG1363, thus demonstrating that the region 
between W20 and N27 inclusive of the N terminus of LtnI is essential for its 
functionality. In contrast, it was apparent that the absence of the C-terminal region of 
LtnI pNZ44ltnI∆CT110-116 did not alter the immunity phenotype, with an MIC of 
1.25µM (identical to that of MG1363.pNZ44ltnI). While the removal of larger regions of 
the C terminus (facilitated by the creation of pNZ44ltnI∆CT90-116 and 
pNZ44ltnI∆CT83-116) resulted in decreased immunity, strains expressing these 
proteins remained quite resistant (MIC 62.5nM) relative to the sensitive host MG1363 
(Table 3).  
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Creation and analysis of site-directed mutants in LtnI 
In order to investigate a role for the previously identified leucine zipper-
associated residues in LtnI, residues L87 and L94 (the 1st and 2nd leucines within the 
motif) were individually converted to an alanine through manipulation of pNZ44ltnI 
and expression in MG1363. A number of conserved residues corresponding to residues 
D57, E58, R59 and T60 in LtnI were also invetigated. One positively charged amino acid 
(R59) and one negatively charged amino acid (D57) within the conserved, putatively 
cytoplasmically-located domain were converted to alanine to assess their importance. 
A double D57A-R59A change was also made (Fig. 4). In all cases, immunity levels were 
equal to those provided by pNZ44ltnI as determined by well diffusion assays (data not 
shown). Subsequently, more sensitive MIC determination tests were carried out. 
However, it was again evident that the changes made did not impact on the level of 
immunity provided (Table 3), thereby revealing that neither the putative leucine 
zipper, nor the two charged residues in the cytoplasmic domain, are essential for 
immunity.     
 
Random mutagenesis of ltnI and identification of essential residues and domains 
 Given the failure of rational site-directed mutagenesis to identify residues that 
are important with respect to the provision of LtnI-mediated immunity, a random 
mutagenesis-based strategy was developed. More specifically, the plasmid pNZ44ltnI 
was isolated and utilized as a template for a GeneMorph II PCR-based reaction that was 
carried out in a manner designed to result in the introduction of at least a 1-bp change 
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in the ltnI amplicons. Ligation of these amplicons into pNZ44 and heterologous 
expression in L. lactis MG1363 led to the creation of a bank of 28,000 strains 
expressing randomly mutated forms of ltnI. Spotting of the bank onto GM17 infused 
with 3 mg ml-1 (1,920 AU ml-1) lacticin 3147-skim milk powder revealed more than 200 
strains that were unable to grow despite PCR confirmation that a copy of the ltnI gene 
was present. Ninety-five representative mutants were selected for DNA sequencing to 
identify the changes responsible for the dysfunction of LtnI immunity (Table 4, Fig. 4). 
In 18 cases, disruption of immunity was as a consequence of a single amino acid 
substitution. These represented 12 distinct mutants, as I6N, E11D and N29S variants 
were each detected on two occasions while D79N was recovered four times (Table 4). 
Of the 12 single amino acid substitutions, 5 occur at the N terminus between amino 
acid positions 4 and 13. The E4G change alters the overall charge of the external N 
terminus of LtnI from a net charge of -2 to -1 by replacing glutamic acid with glycine. 
Conversion of the isoleucine at position 6 to an asparagine replaces a hydrophobic 
residue with a hydrophilic one. While the F9I mutation maintains a hydrophobic moiety 
at this position, it does however, involve the loss of an aromatic ring at this position. 
Similarly, the mutation E11D does not alter the overall charge but does result in the 
loss of a carbene group. The final amino acid to be altered in the external N-terminal 
stretch in LtnI is leucine at position 13, which is converted to a proline.  
Within the transmembrane region there are a total of six changes resulting in a 
complete loss of immunity. The changes in the first membrane spanning domain 
include N29S, G33D, F36I and F36L. The change at N29S maintains the hydrophilic 
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nature of the region but altering this essential amino acid to a serine reduces the 
immunity phenotype. The second change, G33D, introduces a negative charge into the 
native TMD region. Two different changes occur at phenylalanine 36: conversion to an 
isoleucine and conversion to a leucine. Within the second transmembrane domain, two 
mutations, D79N and F82S, resulted in the elimination of activity,. Replacing the 
aspartic acid at position 79 with an arginine represents the loss of a negative charge, 
while replacement of phenylalanine at position 82 and with a hydrophilic serine results 
in the loss of the hydrophobic moiety of this region. The final single amino acid change 
identified related to K110I, whereby the positively charged lysine is replaced by 
isoleucine, thus altering the net charge of the protein at the membrane.  
Thirty-two strains expressing mutated forms of ltnI were sensitive as a 
consequence of frameshift mutations (Table 4; Fig. 4). These represented 16 distinct 
mutations, as M1, Y15, E19, S24, L32 and K56 were each altered on multiple occasions. 
Notably, all detrimental frameshift mutations occurred within codons corresponding to 
regions between residue 1 and 65 but not in more C-terminally located residues. Stop 
codons were introduced in 17 instances, corresponding to 9 different positions as stop 
codons at positions corresponding to K2, E22, K55 and Y69 were identified on more 
than one occasion. In all cases these stop codons occurred within the region between 
residues 2 and 69. It is also noteworthy that while frameshifts will have multiple 
effects, they are comparable to the effects of stop codons, as they indicate that the 
region after the frameshift must have been important if activity has been eliminated. In 
combination, the location of the detrimental ‘frameshift’ and ‘stop’ mutations provides 
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further evidence that the provision of LtnI is not dependent on the presence of intact 
C-terminal domains. 
Finally of the 95 mutants sequenced, there were 12 incidences (10 of which 
were distinct) of 2 to 4 changes, changes that resulted in amino acid changes, 
frameshifts and/or the introduction of stop codons; and thus the specific change 
responsible for inactivity was not apparent. Finally, there were 16 cases where ≥20 
changes were identified in the genes that resulted from excessive mutagenesis of ltnI.  
 
Identification of an LtnI derivative that provides enhanced protection 
An agar-based screening strategy was employed to screen for ltnI derivatives 
that provide enhanced protection resulting in the ability of the host strain to grow in 
the presence of 12 mg ml-1  (7,680 AU ml-1) lacticin 3147-milk powder. A single mutant 
with an ability to survive in the presence of increased levels of lacticin 3147 was 
identified. To ensure that this enhanced protection was as a consequence of the ltnI-
associated change, rather than a spontaneous change within the host’s genome, the 
associated pNZ44ltnI plasmid was isolated, re-introduced into a fresh MG1363 
background and found to again provide enhanced protection. The corresponding ltnI 
gene was sequenced and a mutation predicted to result in an I81V change was 
identified. Residue 81 of LtnI is predicted to be part of the second transmembrane 
domain, close to the interface of the extracellular membrane. To further assess the 
enhanced protection provided by this change, MG1363.pNZ44ltnI and 
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MG1363.pNZ44ltnI(I81V) were grown in the presence and absence of 1.1µM lacticin 
3147. This confirms the enhanced resistance of LtnI(I81V) to the lantibiotic (Fig. 5).   
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Discussion 
The dedicated immunity proteins associated with lantibiotic production are a 
heterogeneous group of proteins of differing size, composition and structure. They are 
target molecule-specific and are highly efficient in their action. NisI, SpaI and PepI are 
anchored to the cytoplasmic membrane, and unusually, NisI has also been found as a 
lipid-free form, presumably scavenging for exogenous nisin (Hoffmann et al., 2004; 
Koponen et al., 2004; Stein et al., 2003; Stein et al., 2005). In contrast, it was previously 
recognized that LtnI was very likely to traverse the membrane (McAuliffe et al., 2000) 
in a manner similar to that predicted for CylI (Coburn et al., 1999) and established for 
NukH (Okuda et al., 2005). Notably, however, none of these proteins show any 
homology to each other. 
In this study, the assessment of LtnI topology suggests that LtnI contains three 
transmembrane regions. This is consistent with the SPLIT (version 4.0) and TMHMM 
algorithms, which have previously been established to be 85% and 83% accurate, 
respectively, in predicting the location of residues (Cuthbertson et al., 2005). The 
biological and in silico data predict the existence of an internal loop between TMD 1 
and TMD 2 and an external loop between TMD 2 and TMD 3. The predicted 
cytoplasmic loop has a large number of positively charged residues, and in general such 
residues act as strong topogenic signals, influencing the conformation of membrane 
proteins in prokaryotes and eukaryotes (Sipos & von Heijne, 1993; von Heijne, 1989; 
von Heijne, 2006). On the basis of an extensive study comparing integral membrane 
proteins from 107 genomes (both prokaryotic and eukaryotic) in which the distribution 
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of the positively charged amino acids, lysine and arginine was analyzed, it was 
suggested that this trend is true for all TM proteins (Nilsson et al., 2005). Our biological 
assessment of topology relied on assays carried out in E. coli. It is thus important to 
note that it has previously been demonstrated that topological data derived from E. 
coli are highly reflective of the situation in lactic acid bacteria (Johnsborg et al., 2003). 
Therefore, it is likely that the topology of LtnI predicted is a true reflection of the 
situation in a lacticin 3147-immune L. lactis isolate. 
Our targeted mutagenesis focused on specific residues and domains within LtnI. 
The importance of two charged amino acids within a highly conserved region of the 
cytoplasmic loop of LtnI was assessed by their substitution, both singly and in 
combination. Interestingly, unlike that observed for PepI, where loss of charged 
residues in the C terminus reduces immunity function (Hoffmann et al., 2004) , here in 
neither case was there a detrimental impact on the associated immunity phenotype, 
establishing that neither of these residues have a role in the immunity function of LtnI. 
While it may be the case that other positively charged residues in this region and/or 
the other topological signals within LtnI are sufficient to ensure the retention of 
functionality, it was notable that random mutagenesis did not reveal essential residues 
within this internal loop. The leucine zipper-like motif located near the C terminus of 
LtnI was also subjected to mutagenesis to investigate if this unusual feature had a role 
in the functionality of LtnI. Site-directed mutagenesis of either the 1st or 2nd leucine had 
no effect on the immunity phenotype, suggesting the zipper motif has no functional 
role in immunity. It appears that predicting the presence of a leucine zipper solely on 
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the basis of bioinformatic tools identifying a distinct pattern of leucines cannot be 
made with confidence, and our findings would seem to indicate that the presence of 
the leucine repeats in LtnI may be coincidental. Truncation of the N and the C terminus 
of LtnI revealed that the extended N terminus plays a key role in the immunity 
phenotype, but that the latter part of the C terminus, as also seen in the case of NukH 
(Okuda et al., 2005), is not essential. Furthermore, the removal of TMD 3 alone or in 
conjunction with the external loop from the C terminus, results in a reduction of 
immunity but does not eliminate immunity. This is a phenomenon also observed for 
NukH, whereby the TMD3 is essential only for a full immunity level (Okuda et al., 2005). 
Interestingly, the last 7 amino acids of LtnI would not appear to make any contribution 
to protection, as pNZ44ltnI∆CT110-116 provided the same level of immunity as 
pNZ44ltnI. However, it is noteworthy that removal of a positive charge within this 
region (K110I) has a more dramatic impact. Such an alteration may have a knock-on 
effect on other, nearby, regions, and/or negatively impact on the native structure of 
the protein.  This is also true for the N terminus of LtnI where removal of the negative 
charge at position 4 results in loss of function. In contrast, although truncation within 
the extended N terminus of LtnI results in inactivity (MG1363.pNZ44ltnI∆NT1-27 is not 
immune but MG1363.pNZ44ltnI∆NT1-20 is), no immunity-eliminating amino acid 
substitutions were identified between position 20 and 27, suggesting that the region as 
a whole, rather than specific amino acids, is important. In contrast, substitutions 
involving charge (E4G) or the loss (F9I) or gain (L13P) of large or secondary structure-
distorting amino acids within the region from amino acids 1 to 13 in the N terminus 
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have a greater impact than the deletion of this entire region. The first of two absolutely 
essential domains identified in this study is therefore within the N terminus, and 
contains a region between W20 and N27 (inclusive) that is essential for immunity and 
notably contains conserved amino acids amongst homologues. 
With respect to the transmembrane regions, it was observed that changes 
resulting in loss of immunity were in most cases found close to the membrane and, in 
all cases, were confined to TMD1 and TMD2. In this regard, the use of a level of 3 mg 
ml-1 (1,920 AU ml-1) lacticin 3147 in agar was effective in identifying only strains in 
which LtnI activity was completely eliminated. From analysis of the various LtnI 
derivatives that have been generated in this study, it is clear that a second defined 
region of LtnI between I76 (where a frameshift eliminates immunity) and P83 (after 
which a truncated derivative retains 50% activity) is of essential importance. It can also 
be inferred that although TMD 3 (F91 to L109) appears to be tolerant of change, its 
presence is essential for optimal activity. As previously mentioned, the TMD3 region of 
NukH is also essential for a full immunity phenotype, and another region of significance 
is the external loop (Okuda et al., 2005). Here we found that it is a region adjacent to 
this loop that appears to be essential for lacticin 3147 immunity. 
Finally, and perhaps most notably, we have identified an alteration that 
provides an immunity protein (LtnI I81V) with an enhanced ability to protect against its 
cognate lantibiotic. Modified lantibiotic immunity proteins with enhanced activity have 
not previously been described. This observation is of significant interest. The 
bioengineering of lantibiotic producers to generate overproducing strains or strains 
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that produce lantibiotic derivatives with enhanced antimicrobial activity has been the 
focus of much attention in recent years (Field et al., 2010). Bacteria producing these 
proteins need to be protected from the bactericidal agent that they are producing, and 
thus, self-protection may ultimately become a limiting factor. It is thus anticipated that 
mechanisms to enhance immunity may in turn facilitate enhanced production.  
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Tables and Figures 
Table 1. Strains and plasmids 
Strains and Plasmids Description Source/reference 
   
E. coli CC118 ∆phoA20 (Manoil, 1991) 
E. coli Top10 Intermediate cloning host Invitrogen 
L. lactis MG1363 Plasmid free, lacticin 3147 sensitive  (Gasson, 1983) 
L. lactis MG1363.pMRC01 MG1363 with lacticin 3147 producing plasmid (Cotter et al., 2003) 
   
pRMCD28 E. coli phoA in pWSK29;Ampr (Daniels et al., 1998) 
pRMCD70 E. coli lacZ in pWSK29;Ampr (Daniels et al., 1998) 
pNZ44 L. lactis P44 promoter in pNZ8048;Cmr (McGrath et al., 2001) 
pNZ44ltnI pNZ44 containing ltnI (Draper et al., 2009) 
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Table 2. Primers used for truncation and site-directed mutagenesis of LtnI and to 
construct LacZ and PhoA fusions. 
NAME Sequence (5’ to 3’)a 
5563F ATGCATGCAACTATACACCTTCTT 
5562R TATAAGCTTTACCATGTGCTATTGAT 
Nterm14F GGGCTGCAGATGTTTTACTCATTAAAAGAGTGGGCG 
Nterm20W GGCTGCAGATGTGGGCGGAAGGTTCAGCAAAC 
Nterm28Y GGGCTGCAGATGTATAATATACTTTTAGGCTTAAGT 
Cterm83 GTCTAGATTAAAATATTATGTCACATATAATTAG 
Cterm90 GTCTAGATTATGGTTGAATTAAATATCC 
Cterm109 GGGAAGCTTTAAAAGACAATAAATCCCACC 
LtnID57AF CCACAAAGATTGGGAAAAAAGGCAGAAAGAACAACTAAAATAAGTT 
LtnID57AR AACTTATTTTAGTTGTTCTTTCTGCCTTTTTTCCCAATCTTTGTGG 
LtnID57Ach CAAAGATTGGGAAAAAAGCA 
LtnIR59AF CCACAAAGATTGGGAAAAAAGATGAAGCAACAACTAAAATAAGTT 
LtnIR59AR AACTTATTTTAGTTGTTGCTTCATCTTTTTTCCCAATCTTTGTGG 
LtnID57/R59F CCACAAAGATTGGGAAAAAAGCAGAAGCAACAACTAAAATAAGTT 
LtnID57/R59R AACTTATTTTAGTTGTTGCTTCTGCTTTTTTCCCAATCTTTGTGG 
LtnIL2AF CTTTATGGCAAAATATGGTTTTTCTGGCCTTGTTGGTGGG 
LtnIL2AR CCATATTTTGCCATAAAGAATGGTTGAATTAAATATCC 
LtnIL2Ach CAACCATTCTTTATGGCA 
LtnIL1AF CCCAAAGGATATGCAATTCAACCATTCTTTATGTTAAAATATGG 
LtnIL1AR CCATATTTTAACATAAAGAATGGTTGAATTCGATATCCTTTGGG 
LtnIL1Ach ATTTCCCAAAGGATATGCA 
pNZF CTAATGTCACTAACCTGCCCCGTTAG 
pNZR GGCTATCAATCAAAGCAACACGTG 
LtnIRMFor GGGGTACCCTACACCTTCTTTGTTATTG 
LtnIRMRev GCTCTAGAGCTTATATTATTTATTATCTTTAATATAT 
LtnIxbaF AAATCTAGACTGGAGGACATAAGAATGAAGAATGAAAAT 
LtnI21B AAAGGATCCCGCCCACTCTTTTAATGAGTA 
LtnI45B AAAGGATCCAAAAACTACACTTGACAT 
LtnI55B AAAGGATCCTTTCCCAATCTTTGTGGAAATTG 
LtnI75B AAAGGATCCTAGAGTAATTAAAACACA 
LtnI85B AAAGGATCCTCCTTTGGGAAATATTAT 
LtnI100B AAAGGATCCGCAAGAAAAACCATATTT 
LtnI114B AAAGGATCCATCTTTAATATATTTTAA 
LtnI21H AAAAAGCTTCGCCCACTCTTTTAATGAGTA 
LtnI45H AAAAAGCTTAAAAACTACACTTGACAT 
LtnI55H AAAAAGCTTTTTCCCAATCTTTGTGGA 
LtnI75H AAAAAGCCTTAGAGTAATTAAAACACA 
LtnI85H AAAAAGCTTTCCTTTGGGAAATATTAT 
LtnI100H AAAAAGCTTATCTTTAATATATTTTAA 
LtnI114H AAAAAGCTTATCTTTAATATATTTTAAAAGAC 
Pho/lac check GCACCCCAGGCTTTACAC 
      aUnderline represents restriction sites. 
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Table 3. MIC of N- and C-terminally truncated derivatives of LtnI. 
Construct expressed in L. lactis MG1363 MIC 
MG1363 (control) 19.5nM 
pNZ44ltnI 1.25µM 
pNZ44ltnID57A 1.25µM 
pNZ44ltnIR59A 1.25µM 
pNZ44ltnID57A-R59A 1.25µM 
pNZ44ltnI∆NT1-13 1.25µM 
pNZ44ltnI∆NT1-19 1.25µM 
pNZ44ltnI∆NT1-27 19.5nM 
pNZ44ltnI∆CT83-116 62.5nM 
pNZ44ltnI∆CT90-116 62.5nM 
pNZ44ltnI∆CT110-116 1.25µM 
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Table 4. Results from sequencing of 96 randomly mutated LtnI proteins that are 
susceptible to lacticin 3147. 
Mutant Change Mutant Change Mutant Change 
1 Start codon disruption 33 F9I 65 >20CHANGES 
2 N29S 34 G33D 66 D57FRAMESHIFT 
3 I6N 35 I80T, F82C 67 S24FRAMESHIFT 
4 K56FRAME SHIFT 36 >20CHANGES 68 T8P, V47FRAMESHIFT 
5 K56FRAME SHIFT 37 K56FRAME SHIFT 69 N7Y,A21V 
6 K110I 38 >20CHANGES 70 S10FRAMESHIFT 
7 E22STOP 39 D79N 71 >20CHANGES 
8 E11D 40 K2STOP 72 W20STOP 
9 K56R, T74S, C107R 41 Start codon disruption 
73 N29S 
10 E11D 42 Y15FRAMESHIFT 74 I6N 
11 >20 CHANGES 43 K55STOP 75 Y15FRAMESHIFT 
12 D79N 44 I76FRAMESHIFT 76 >20CHANGES 
13 F45STOP 45 K56FRAME SHIFT 77 Y15FRAMESHIFT 
14 E22STOP 46 >20CHANGES 78 >20CHANGES 
15 K2STOP 47 E19FRAMESHIFT 79 >20CHANGES 
16 E22K,A25P,S42R, F45FRAMESHIFT 48 A21FRAMESHIFT 
80 Y15FRAMESHIFT 
17 K2STOP 49 Y15FRAMESHIFT 81 >20CHANGES 
18 K55STOP 50 K56FRAME SHIFT 82 S24FRAMESHIFT 
19 L32FRAMESHIFT 51 >20CHANGES 83 >20CHANGES 
20 Y69H, L87STOP 52 D79N 84 K2STOP 
21 >20CHANGES 53 T48FRAMESHIFT 85 K2STOP 
22 S10FRAMESHIFT 54 A21V, N29S, L32STOP 
86 L32STOP 
23 K56FRAME SHIFT 55 A21V, N29S, L32STOP 
87 Y69STOP 
24 F82S 56 V47FRAMESHIFT 88 E19FRAMESHIFT 
25 E22G, T51A, M93R 57 Y69STOP 89 L65FRAMESHIFT 
26 E4G 58 >20CHANGES 90 K18STOP 
27 F36L 59 F36I 91 E19FRAMESHIFT 
28 D79N 60 A21STOP 92 N5Y,A25V, D57FRAMESHIFT 
29 Y15FRAMESHIFT 61 F46FRAMESHIFT 93 >20CHANGES 
30 S16T,M40T 62 K55STOP 94 S24FRAMESHIFT 
31 W20FRAMESHIFT 63 L32FRAMESHIFT 95 >20CHANGES 
32 L13P 64 A21V, N29S, L32STOP 
96 WT (control) 
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Fig. 1.   
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Fig. 1. LtnI topology predictions  
Membrane Topology models of LtnI using Trans-Membrane (TM) prediction sites. 
TMHMM (a) and SPLIT (version 4.0) (b). (a) Red amino acids predicted to be in 
membrane; blue, amino acids inside; pink, amino acids outside. (b) Purple hatched 
boxes indicate amino acids in membrane. (c) On the basis of the study by Cuthbertson 
et al., (Cuthbertson et al., 2005) the findings obtained with different algorithms were 
compared to indicate LtnI transmembrane regions TMHMM, SPLIT (version 4.0), SOUSI 
and TMpred. Protein sequence of LtnI also indicates residues fused to reporter 
enzymes LacZ and PhoA (residues numbered and with asterisks).   
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Fig. 2. Investigation of LtnI homologues  
LtnI and its closest homologues derived from a variety of Bacillus strains. Highlighted 
are the amino acids that were involved in random or site-directed mutagenesis. The 
amino acids between W20 and N27 have also been investigated for homology due to 
the importance of this region in immunity. Where homology is conserved amongst 
homologues alone (highlighted in red) is of particular interest, as conversion of the 
amino acid at this position in LtnI to the corresponding conserved amino acid 
diminishes immunity. 
 
 
 
 
 
 
171 
 
 
 
Fig. 3. .  Activity of LtnI-LacZ and LtnI-PhoA fusions in E. coli CC118. 
Activity of LtnI-LacZ and LtnI-PhoA fusions in E. coli CC118. A21, F45, etc., represent the 
residue of LtnI fused to lacZ or phoA. Activity is representative of the average of three 
independent triplicate experiments. 
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Fig. 4. Prediction of LtnI topology with overview of mutagenesis and truncation 
positions 
Predicted here is the membrane location of LtnI. Indicated are positions at which 
random mutagenesis due to amino acid changes, frameshifts and stop codon 
introduction resulted in diminished immunity, or as for I81V, in which the the amino 
acid change resulted in a functionally enhanced LtnI protein. Positions at which 
truncated LtnI proteins were created are also present. 
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Fig. 5. Growth curve demonstrating the enhanced immunity of LtnI (I81V) 
MG1363.pNZ44 ltnI and MG1363.pNZ44 ltnI (I81V) were grown in the presence and 
absence of 1.1µM lacticin 3147, each strain was grown in triplicate and absorbance 
readings at 600nm taken hourly.  
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CHAPTER IV 
 
 
The spiFEG locus in Streptococcus infantarius subsp. infantarius BAA-
102 confers protection against nisin U. 
 
Lorraine A. Draper, John R. Tagg, Colin Hill, Paul D. Cotter and R. Paul Ross. 
 
 
This chapter was published in Antimicrobial Agents and Chemotherapy 2012, 56:573-8. 
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Summary 
Nisin U is a member of the extended nisin family of lantibiotics. Here we 
identify the presence of nisin U immunity gene homologues in Streptococcus 
infantarius subsp. infantarius BAA-102. Heterologous expression of these genes in 
Lactococcus lactis subsp. cremoris HP confers protection to nisin U and other 
members of the nisin family, thereby establishing that the recently identified 
phenomenon of resistance through immune mimicry also occurs with respect to 
nisin. 
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Introduction 
Lantibiotics are antimicrobial peptides that have been the focus of intense 
research in recent years. These ribosomally synthesised peptides undergo post-
translational modification, resulting in the presence of unusual amino acids such as 
the eponymous lanthionine residues, as well as a variety of other modified 
residues. The nisin family is the most studied of all lantibiotics. Nisin A was initially 
discovered in 1928 (Rogers, 1928; Rogers & Whittier, 1928) and it has been used 
commercially as a food preservative for over 50 years (Lubelski et al., 2008). The 
nisin family has also been investigated for potential applications in clinical and 
veterinary settings (Cao et al., 2007; Fernandez et al., 2008; Wu et al., 2007) since it 
is active against a wide range of pathogens, including many drug-resistant strains 
(Severina et al., 1998). Indeed, it is already commercially employed as an anti-
mastitis agent (Sears et al., 1992). To date, seven natural forms of nisin have been 
identified. Of these, nisin A (Kaletta & Entian, 1989), nisin Z (Mulders et al., 1991), 
nisin Q (Zendo et al., 2003) and nisin F (de Kwaadsteniet et al., 2008) are produced 
by Lactococcus lactis strains, while nisin U, nisin U2 and nisin U3 are produced by 
Streptococcus uberis (Wirawan, 2007; Wirawan et al., 2006). These variants differ 
from each other by as many as 11 residues across the 31-34 amino acid peptides 
(Field et al., 2008). The large differences between the three nisin U’s and the other 
nisins is so significant that it could be argued that they are not, in fact, nisin 
variants, but are rather members of a distinct lantibiotic subfamily (Piper et al., 
2010). As is the case with all lantibiotics, nisin producers possess immunity 
mechanisms which provide protection from auto-lethality. Despite the diversity of 
these peptides, the phenomenon of cross-immunity has been observed in some 
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instances. For example, nisin U-producing strains are immune to nisin U, A and Z 
(Wirawan et al., 2006). Similarly, the nisin A-producing strain is protected from the 
activity of nisin U (Wirawan et al., 2006).  Lantibiotic immunity is provided by one or 
more systems consisting of a dedicated immunity peptide, LanI, or an ABC 
transporter which pumps the lantibiotic out of the cell, designated LanFE(G). A third 
immunity protein, LanH, is also present in some cases and acts as an accessory 
protein to the ABC transporter system (reviewed in (Chatterjee et al., 2005; Draper 
et al., 2008). In the case of the nisin family of lantibiotics, immunity is based on 
both the action of a LanFEG system and LanI protein. Despite the cross-protection 
referred to above, cross-immunity between lantibiotic producers is rare, with only a 
few exceptional examples (Aso et al., 2005; Heidrich et al., 1998). Indeed, cross-
immunity between producers of the closely related nisin A and subtilin peptides 
(63% identity) is not evident. Another unusual phenomenon is immune mimicry, 
whereby non-lantibiotic-producing strains express functional homologues of 
lantibiotic immunity systems. In the only study of this phenomenon to date, 
homologues of immunity genes associated with the lantibiotic lacticin 3147 were 
identified in Bacillus licheniformis DSM 13 and Enterococcus faecium DO. It was 
shown that heterologous expression of these homologues provided protection 
against lacticin 3147 (Draper et al., 2009). The identification of this phenomenon is 
a concern and may represent a means by which populations of bacteria could 
emerge with resistance to specific lantibiotics. Notably, while a number of systems 
involved in acquired (Gravesen et al., 2001; Kramer et al., 2006) and innate 
resistance to nisin have been identified (Collins et al., 2010a; Collins et al., 2010b), 
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systems capable of providing resistance to any of the nisin peptides through 
immune mimicry have not been identified heretofore. 
Here we identify the first incidence of resistance by means of immune 
mimicry with respect to the nisin family. More specifically, genes encoding a 
homologue of the nisin U immunity-providing ABC transporter (NsuFEG) were 
identified within the genome of a non-lantibiotic-producing pathogen Streptococcus 
infantarius subsp. infantarius BAA-102. Although the BAA-102 strain was 
recalcitrant to genetic manipulation, and thus the creation of an knockout mutant 
was not possible, heterologous expression confirms that SpiFEG and NsuFEG can 
protect against the action of nisin U and other members of the nisin family.  
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Results and Discussion 
In silico screen for homologs of nisin immunity determinants  
Immune mimicry is a recently identified phenomenon and thus far the only 
examples relate to the protection afforded against lacticin 3147 by homologues of 
its immunity proteins (Draper et al., 2009). To identify other examples of immune 
mimicry, a PSI-BLAST search (Altschul et al., 1997) was undertaken using the 
National Center for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov) to determine if genes encoding homologues of the 
nisin immunity proteins could be identified in strains incapable of nisin production. 
This screening revealed the presence of the genes predicted to encode the 
components of an ABC transporter similar to that involved in nisin U immunity 
(NsuFEG; (Wirawan et al., 2006)) within the genome of S. infantarius subsp. 
infantarius BAA-102 (Schlegel et al., 2000). The predicted product of STRINF_01307 
(hereafter referred to as spiF) resembled NsuF (67% identity, e-value 2e-83) while 
STRINF_01306 (hereafter annotated as spiE) and STRINF_01305 (hereafter referred 
to as spiG) are predicted to encode proteins that resemble NsuE (50% identity, e-
value 4e-63) and NsuG (51% identity, e-value of 5e-45), respectively. While the 
similarity between SpiFE and NsuFE is only marginally greater than to NisFE, SpiG is 
only 35% identical to NisG. As a result of this discovery, other genes within this 
region of the BAA-102 genome were subjected to an in silico investigation to 
determine if other lantibiotic-associated genes might be present. Notably, the 3 
genes immediately downstream from spiEFG all resembled those encoding the 
individual components of the nisin two-component system, known as NisRK (or 
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NsuRK in the case of nisin U (Wirawan et al., 2006)), which are responsible for 
regulating nisin biosynthesis and immunity (Kuipers et al., 1995) (Fig. 1). More 
specifically, the gene product of STRINF_01304 is 70% identical to the response 
regulator NsuR, with an e-value of 1e-50 (and is here referred to as spiR) and the 
adjacent gene (STRINF_01303; spiR') also encodes an NsuR-like protein. Although 
SpiR and SpiR’ are 67% identical to NisR, the two proteins are predicted to be quite 
different to each other, having only 11% identity. Furthermore, the predicted 
product of STRINF_01302 is 50% identical (e-value 4e-112) to the histidine kinase 
NisK and 43% identical to NsuK (e-value 7e-101) (Fig. 1). Although none of the nisin-
like compounds have multiple LanR proteins associated with their regulation, 
multiple LanR proteins can be found in the lantibiotic operons of RumA, mersacidin 
and cytolysin (Cox et al., 2005; Gomez et al., 2002; Guder et al., 2002). The NisR 
binding motif, a defined sequence of nucleotides by which NisR binds to the 
promoters of NisF and NisA, is referred to as a nis-box (Kleerebezem, 2004). A 
sequence with high similarity to a nis-box is found in the region upstream of spiFEG, 
and theoretically could act as a binding motif for SpiR and/or SpiR'. It was noted 
that the percent GC content of spiFEGRR'K (33.5%) is lower than that observed in 
the entire BAA-102 genome (37.7%), and thus, the possibility that these genes were 
acquired through horizontal transfer cannot be discounted. Analysis of up- and 
downstream genes reveals that none of these possess lantibiotic-associated 
features. Indeed, further analysis of the BAA-102 genome failed to identify any 
other lantibiotic-associated genes. Interestingly with respect to SpiF, a conserved 
domain, the BcrA subfamily (cd03268), was identified, homology between this 
bacitracin associated transporter and SpiG was also revealed. 
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The presence of the spiFEGRR'K genes in S. infantarius subsp. infantarius 
BAA-102 is noteworthy for a number of reasons. S. infantarius, referred to as S. 
bovis biotype II/1 before reclassification (Bouvet et al., 1997), has been isolated 
from the faeces of infants, from clinical specimens associated with endocarditis and 
from food including dairy products and frozen peas (Abdelgadir et al., 2008; 
Hoshino et al., 2005; Schlegel et al., 2000). This species can also contribute to the 
development of cancer, particularly in cases of chronic infection or inflammatory 
disease where the S. infantarius bacterial components interfere with cell function, 
leading to cell transformation and proliferation (Biarc et al., 2004) and is most 
frequently associated with non-colonic digestive tract cancers (Corredoira et al., 
2008). Notably, nisin U has been shown to be effective against a wide range of 
disease-associated streptococci, including Streptococcus pyogenes, Streptococcus. 
salivarius, S. uberis, Streptococcus agalactiae and Streptococcus dysgalactiae, and 
thus, the possibility that a potential target such as S. infantarius may be resistant to 
nisin as a consequence of immune mimicry is worthy of note. 
Heterologous expression of nsuFEG and spiFEG 
S. infantarius BAA-102 is, on the basis of deferred-antagonism assays (for 
method see (Field et al., 2008)), less sensitive to nisin U than a number of other 
Streptococcus species tested (S. pyogenes, Streptococcus mitis and S. agalactiae, 
data not shown). However, despite several attempts, we were unable to 
successfully transform BAA-102 as a prelude to creating isogenic spiFEG knockout 
mutants. As a consequence, we used heterologous expression as a strategy to 
determine whether the newly identified spiFEG genes could encode protection 
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against nisin U. The corresponding nsuFEG genes from S. uberis 42 (Jayarao et al., 
1991; Wirawan et al., 2006) served as a positive control. To facilitate this, genomic 
DNA was extracted from S. uberis as described previously (Draper et al., 2009). The 
nsuFEG genes were amplified using the primer pairs   
[AAAACTGCAGAAGTAGCAACTAGAAAG] and 
[GGGGTACCCTTTTAGGTGGCTAGTATCGC], and the primers for spiFEG were 
[AAAACTGCAGAAAAGTTTGGGACTTCAATG] and 
[GGGGTACCCCTGTCACCTCAATTGTATTTG], where restriction enzyme sites are 
underlined. The resulting gene products and the shuttle expression vector pNZ44 
(McGrath et al., 2001) were digested with the relevant restriction enzymes, ligated 
and introduced into electrocompetent L. lactis HP (via the intermediate host 
Escherichia coli Top10) as described previously (Draper et al., 2009). Following 
confirmation of the integrity of the newly created vectors, deferred-antagonism 
assays were performed to provide an initial insight with respect to the protection 
provided against the producer of nisin U and other nisins (A, Z, F and Q; (Piper et al., 
2010)). These were carried out as described previously, using GM17 and TS agar for 
Lactococcus and Streptococcus, respectively (Field et al., 2008). Relative sensitivity 
was assessed on the basis of zone size (Table 1). No inhibition was apparent when 
the nisin U producer was overlaid with L. lactis HP.pNZ44nsuFEG, thus establishing 
that the nisin U immunity proteins could provide protection when expressed 
heterologously to the otherwise nisin-sensitive HP strain. Notably, the presence of 
pNZ44spiFEG also provided protection against nisin U, with zone sizes decreasing 
substantially. The SpiFEG system is thus capable of providing protection through 
immune mimicry. The ability of pNZ44nsuFEG and pNZ44spiFEG to protect HP 
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against the actions of nisin A (produced by L. lactis NZ9700; (Kuipers et al., 1993)), 
nisin F (produced by L. lactis NZ9800.pCI372nisF; (Piper et al., 2010)), nisin Z 
(produced by L. lactis NZ9800.pCI372nisZ; (Piper et al., 2010)) and nisin Q 
(produced by L. lactis NZ9800.pCI372nisQ; (Piper et al., 2010)) and nisin U3 
(Wirawan, 2007) was also assessed. It was established that heterologous expression 
of nsuFEG in strain HP provides protection against nisin U3 and to a lesser degree 
against nisin A, nisin F, nisin Z and nisin Q, with zone sizes smaller than those 
observed when HP was used as a target (Table 1). The presence of pNZ44spiFEG 
also substantially reduced the sensitivity of the HP strain to nisin Z and nisin U3 
(Table 1). To further assess the level of protection, the same collection of strains 
were employed to carry out a series of agarose-based well diffusion assays (Fig. 2) 
(Derache et al., 2009; Lehrer et al., 1991). In this instance, the antimicrobials were 
present in the form of cell-free supernatant from overnight cultures of the nisin 
producers. The benefit of this approach is that the enhanced rate of diffusion of the 
antimicrobials through agarose (relative to agar) and the use of target cells in early-
log-phase provides greater sensitivity. The results from these assays confirm the 
significantly enhanced resistance of HP.pNZ44nsuFEG to all forms of nisin and of 
HP.pNZ44spiFEG to nisins Z and U. However, in this instance, HP.pNZ44spiFEG also 
displayed significantly enhanced resistance to nisins A, F and Q (Fig. 2). These 
investigations are consistent with those of Wirawan et al. who previously noted 
cross-protection between nisin-producing strains (Wirawan et al., 2006). Given that 
SpiFEG also resembles transporters involved in bacitracin resistance, the relative 
resistance of L. lactis HP and HP.pNZ44spiFEG to this antibiotic was tested via 
antibiotic disc assays (10 IU, Oxoid) (Collins et al., 2010b). These assays revealed 
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that spiFEG do not provide the HP strains with enhanced resistance to bacitracin 
(data not shown). 
Antimicrobial activity assays with purified nisin U 
 To better assess the extent to which SpiFEG provide protection from nisin U, 
broth-based assays with purified nisin U were carried out. To facilitate this, the 
lantibiotic was purified using an approach previously employed to purify nisin A and 
derivatives (Field et al., 2008), but with some slight modifications. Specifically, the 
tryptone-yeast extract-glucose growth medium was supplemented with higher 
levels of glucose (11 g l-1) and β-glycerophosphate (21 g l-1) before the nisin U 
present in cell free culture supernatant was isolated by passing it through 60 g XAD-
16 beads (prewashed with water), washed with 30% ethanol, and finally eluted with 
70% isopropanol. This was combined with the nisin-containing 70% isopropanol 
from the purification of cell-attached nisin as previously described (Field et al., 
2008). Subsequent purification was performed using a 10 g (60 ml) Strata C18-E 
column (Phenomenex, Cheshire, UK) pre-equilibrated with methanol and water. 
The columns were washed with 30% ethanol and the inhibitory activity was eluted 
in 70% isopropanol-0.1% trifluoroacetic acid (TFA). Aliquots (20 ml) were 
concentrated to 2 ml through the removal of isopropanol by rotary evaporation 
before being applied to a Phenomenex C12 reverse-phase high-performance liquid 
chromotography (HPLC) column (Jupiter 4µm proteo 90 Å, 250 X 10.0 mm, 4 µm) 
previously equilibrated with 25% acetonitrile-0.1% TFA. The column was 
subsequently developed in a gradient of 30% acetonitrile (ACN) containing 0.1% 
TFA to 60% ACN-0.1% TFA from 10 to 45 min at a flow rate of 2.0 ml min-1. Fractions 
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containing nisin U were collected post HPLC, acetonitrile removed by rotary 
evaporation and the protein lyophilised by freeze-drying. Mass spectrometry was 
performed with an Axima CFR plus matrix-assisted laser desorption ionization–time 
of flight (MALDI-TOF) mass spectrometer as previously described (Field et al., 2008), 
which confirmed that the final purified product was nisin U. The purified nisin U 
was employed in studies to compare the growth of HP, HP.pNZ44nsuFEG and 
HP.pNZ44spiFEG in the presence of 416 nM nisin U over 4 hrs in broth (Fig. 3). This 
was assessed by inoculating 1 x 107 CFU ml-1 of target cells into fresh broth 
containing nisin U, incubating at 30°C and at intervals removing aliquots, which 
were subject to serial dilution in ¼-strength Ringers’ solution and plated on GM17 
agar. All growth experiments were performed in triplicate from three separate 
overnight cultures and repeated on at least three different days. These assays 
revealed that after 4hrs the numbers of HP expressing nsuFEG and spiFEG were 
significantly (P value < 0·014) greater those of the corresponding HP control (Fig. 3).  
Assessing the relative protection provided through heterologous expression of 
spiFEGRR’K  
We postulated that the products of spiRR’K may sense and respond to the 
presence of nisin to further enhance the expression of spiFEG and nisin resistance. 
However, should such a phenomenon exist, it would be mediated through the nis-
box within the promoter upstream of spiFEG (Pspi). To investigate this possibility, 
heterologous expression was again employed. Pspi-spiFEGRR’K was amplified using 
the primers [GGGGTACCGAAGGTTGGACAGAAGTTTGG] and 
[GCTGCAGACCATGTCGTAAATAGTCGTTTTTTC] and digested with the appropriate 
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restriction enzymes (Fastdigest, Fermentas) (Hayes et al., 1990). This was ligated 
with similarly digested pCI372 (a shuttle vector which, unlike pNZ44, does not 
contain a constitutive promoter to drive expression of cloned genes) and 
transformed into electrocompetent L. lactis HP. A phenotypic assay was performed 
to assess if exposure to sublethal concentrations of nisin A or nisin U enhanced the 
ability of pCI372Pspi-spiFEGRR’K to provide protection from a subsequent challenge 
with concentrated nisin. Specifically, overnight cultures of L. lactis HP.pCI372 and 
HP.pCI372Pspi-spiFEGRR’K were inoculated (3%) into fresh GM17, incubated until 
they reached an OD600 of 0.3, whereupon 1 ml of cells were exposed to a sublethal 
concentrations (0.3µM) of nisin A or nisin U for 1 hr in 1.5 ml tubes at 30°C. The 
cells were then washed in 10mM sodium phosphate buffer and seeded in 1/100-
strength GM17-agarose, into which wells were bored. Approximately 30 µM Nisin A 
and nisin U were incubated into the wells for 3 hrs and subsequently overlaid with 
2X strength GM17-agarose to allow subsequent growth of L. lactis strains (see 
(Derache et al., 2009; Lehrer et al., 1991) for method). Having determined relative 
sensitivity, on the basis of zone size, we found that in no instance did exposure to 
sublethal concentrations of nisin significantly enhance the protection provided by 
pCI372Pspi-spiFEGRR’K to subsequent exposure to higher concentrations of nisin 
(Fig. 4). It should be noted, however, that this does not preclude the possibility that 
SpiRR’K sense and respond to the presence of nisin in their native background. 
 As a consequence of the continued emergence of antibiotic-resistant 
bacteria, the possibility of using ribosomally synthesised antimicrobial peptides 
such as the lantibiotics as alternative chemotherapeutic agents has received 
attention (Piper et al., 2009). Despite nisin having been used for over half a century 
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for food applications, the development of resistance has not become a problem. 
Nonetheless, it has been established that some bacteria possess innate nisin 
resistance mechanisms and that others can become resistant upon exposure to 
nisin in the laboratory (Collins et al., 2010a; Collins et al., 2010b; Kramer et al., 
2006). It is thus a concern that the use of nisin and other lantibiotics for clinical 
applications could also result in the emergence of resistant strains. However, it is 
hoped that by developing a clearer understanding of the various different 
mechanisms by which resistance can emerge, it will be possible to develop 
strategies to counteract such occurrences. The phenomenon of resistance through 
immune mimicry has been described on only one previous occasion (Draper et al., 
2009), and thus, the identification of nisin immunity determinants in the genome of 
BAA-102 is noteworthy. On the basis of these findings, this phenomenon may be 
more common than has previously been appreciated, and the possibility that the 
presence and transfer of such genes could potentially lead to the emergence of 
lantibiotic-resistant strains needs to be considered carefully.  
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Tables and Figures 
 
Nisin variant 
Avg zone size (mm) ± SD 
HP (control) HP.pNZ44nsuFEG HP.pNZ44spiFEG S. infantarius 
A 18.6 (±0.71) 16.3 (±0.71) 17.85 (±1.06) 2.94 (±0.18) 
F 20.6 (±1.00) 17.79 (±0.27) 19.67 (±1.00) 5.84(±0.50) 
Z 24.4 (±0.36) 20.2 (±0.14) 21.85 (±1.62) 4.9(±0.74) 
Q 16.08 (±0.65) 14.8 (±0.28) 15.05 (±1.62) 4.17(±0.75) 
U 8.4 (±0.42) 0  4.7 (±1.27) 0* 
U3 16.06 (±0.18) 0  12.2 (±2.97) 0* 
* denotes no distinct zone but some hazy growth adjacent to nisin producing colony. 
 
Table 1. Deferred-antagonism assay analysis of the protective capabilities conferred 
by NsuFEG and SpiFEG when expressed in L. lactis HP, or the resistance of the 
natural S. infantarius isolate, against the action of a range of natural nisin variant 
producers. Values are an average of triplicate experiments and represent zone size 
i.e. diameter of zone minus diameter of bacterial growth.   
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Fig. 1. Genetic orientation of homologues of the nisin U (a) and nisin-associated 
immunity and regulatory (b) genes found in the strain S. infantarius subsp. 
infantarius. The up- and downstream genes are included, and from BlastP analysis, 
their theoretical functions are as follows; STRINF_01300, UDP-N-acetyl-D-
glucosamine 2-epimerase; STRINF_01301, hypothetical protein; STRINF_01308, 
hypothetical ATP-binding protein; STRINF_01309, hypothetical membrane protein. 
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Fig. 2. Agarose well diffusion assay, whereby L. lactis HP.pNZ44 and strains 
expressing nsuFEG and spiFEG were challenged under adverse growth conditions 
with nisin A, F, Z, Q and U. Asterisks indicate zone diameters which were 
significantly smaller by Student’s t-test (P < 0.0005) than that found in L. lactis HP, 
hence implying the protective capabilities of these genes. 
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Fig. 3. Survival and growth of the strain L. lactis strain HP and strains expressing 
NsuFEG and SpiFEG when challenged with a sublethal level (416 nM) of nisin U. An 
asterisk at T4 indicates the difference between HP.pNZ44 and strains expressing 
immunity genes are statistically significant (Student’s t-test P < 0·014). 
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Fig. 4. L. lactis HP expressing the genes spiFEGRR’K under the control of their native 
promoter in the vector pCI372 was assessed to discover if the immunity could be 
induced in the presence of nisin. L. lactis HP strains were incubated in the presence 
of approximately 10 ng of either nisin A (a, b) or nisin U (c, d) prior to being 
challenged by agarose well diffusion assay with both nisin A (a, c) and nisin U (b, d). 
L. lactis HP.pCI372 alone was included as a control. The data shows that the action 
of the spiFEG genes has not been induced and thus they are not active under these 
conditions.  
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Summary 
Lacticin 3147, produced by Lactococcus lactis, is a member of the lantibiotic 
class of bacteriocins. Lantibiotics are post-translationally modified antimicrobial 
peptides that are active against a broad range of Gram positive targets. The genes 
encoding lacticin 3147 production and immunity are found on two divergent 
operons; ltnRIFE, which is regulated by the promoter Pimm, and ltnA1A2M1TM2J, 
controlled by the promoter Pbac. We used a green fluorescent protein expression 
reporter system to establish if any of the lacticin 3147-associated gene products 
influence Pbac expression. It was revealed that LtnR plays a role as an activator of 
Pbac, in addition to acting as a negative regulator of Pimm. Moreover, Pbac was 
subject to negative regulation by ltnA1 and ltnA2, and the ltnA2 transcript was 
shown to play a part in this repression. Thus, fluctuations in the levels of LtnR and 
ltnA1A2, may serve to maintain lacticin 3147 expression, modification and export at 
a homeostatic level within the cell. 
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Introduction 
Lantibiotics are highly potent antimicrobial peptides that target a broad 
spectrum of Gram positive species, often active in the nanomolar range (Morgan et 
al., 2005b; Wiedemann et al., 2006). Ribosomally synthesised and subject to post-
translational modification that creates unusual residues such as dehydroalanine 
(Dha), lanthionine and β-methyl lanthionine, these peptides are termed lantibiotics 
as they are lanthionine-containing peptide antibiotics (for review see (Chatterjee et 
al., 2005)). Lacticin 3147 is a two-component lantibiotic produced by Lactococcus 
lactis. Both components, Ltnα and Ltnβ, combine in a 1:1 ratio (Morgan et al., 
2005a; Wiedemann et al., 2006) and are active against a wide range of targets, 
including nosocomial pathogens such as methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant enterococci (VRE) (Cotter et al., 2013; Piper et al., 
2009). The immunity and biosynthetic genes associated with lacticin 3147 are 
located on a 60.2Kb lactococcal plasmid called pMRC01 and consist of two 
operons ltnRIFE (immunity) and ltnA1A2M1TM2J (biosynthesis) (Fig.1) (Dougherty et 
al., 1998; Draper et al., 2009; McAuliffe et al., 2000a). LtnR shares homology with a 
number of transcriptional repressors of the PBSX (Xre) family and has been shown 
to negatively regulate the promoter (Pimm) of the ltnRIFE immunity operon 
(McAuliffe et al., 2001). LtnI is an immunity specific transmembrane protein and 
LtnFE form a self-protecting ABC transporter (Draper et al., 2009; Draper et al., 
2012; McAuliffe et al., 2000a). LtnR is thought to bring about this negative 
regulation through binding to the Pimm promoter region. It was established that 
mutation of the ltnR gene in the pMRC01 background resulted in a hyper-immune 
phenotype, whereas overexpression of ltnR resulted in cells with increased 
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sensitivity to lacticin 3147. The biosynthetic and export machinery are found in the 
second lacticin 3147 operon (Fig. 1). The genes ltnA1 and ltnA2, encoding the pre-
pro-peptides of Ltnα and Ltnβ, respectively, are found immediately after the 
promoter Pbac. Downstream from these are ltnM1 and ltnM2, which encode 
enzymes involved in post-translational modification, catalysing the 
dehydration/thioether-formation reactions involved in the creation of the mature 
lantibiotic. Each of the lacticin 3147 pre-peptides is modified by a different 
modification enzyme, LtnM1 is required to produce mature Ltnα, while LtnM2 is 
required to produce mature Ltnβ (McAuliffe et al., 2000b). Located between the 
ltnM genes is ltnT, encoding an ABC transporter that is involved in leader cleavage 
and transport of the lacticin 3147 peptides from the cell. The final member of the 
lacticin 3147 operon is ltnJ, encoding a unique enzyme that is responsible for the 
presence of D-alanine residues in both Ltnα and Ltnβ (Cotter et al., 2005).  
Lacticin 3147 biosynthesis and immunity are therefore under the control of 
two divergent promoters, Pimm and Pbac. While the negative regulation of Pimm by 
LtnR has been demonstrated, to date the nuances relating to control of the Pbac 
promoter have yet to determined. Random mutagenesis of Pbac revealed that the 
only mutations to disrupt expression were localised to the canonical -10 and -35 
regions of the promoter (Field et al., 2007). Additionally, it had been noted that a 
construct that contained the Pbac promoter fused to a β-gal reporter produced 
levels of β-galactosidase activity comparable to those of a construct that also 
contained ltnR. These results suggested that LtnR did not play a role in the 
regulation of Pbac and hence was thought not to be involved in transcription of the 
biosynthetic genes (McAuliffe et al., 2001). It was concluded that Pbac is 
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constitutively expressed, with an intragenic rho-independent attenuator in the form 
of a triple stem loop in ltnM1  suggested as a means of limiting the transcription of 
genes (McAuliffe et al., 2001). This contrasted with the observation that the 
promoters governing the expression of many lantibiotic structural genes are 
regulated, frequently via a two-component signal transduction system. Regulation 
of this kind has been evident in the case of the lantibiotics subtilin, produced by 
Bacillus subtilis, and nisin, produced by L. lactis (Engelke et al., 1994; Klein et al., 
1993). Genes encoding lantibiotic-associated histidine kinases (LanK) and response 
regulators (LanR) have been identified in producers of these lantibiotics. Signal 
transduction is achieved by phosphate transfer from LanK, which is 
autophosphorylated upon recognition of the external signal, to LanR. LanR then 
binds to specific nisin- and subtilin-specific pentanucleotide direct repeat 
sequences, called a nis- and spa-boxes, upstream of the promoter, activating 
transcription. As the signal molecule in this system is the antimicrobial peptide, 
production can be said to be positively auto-regulated through a quorum sensing-
like mechanism (Kleerebezem et al., 1997). In the case of nisin, these nis-box 
sequences are associated with the promoter PnisA, responsible for transcription of 
nisABTCIP, as well as upstream of the immunity genes nisFEG. Similarly, subtilin 
spa-boxes are located upstream of the spaBTC promoter PspaB, upstream of PspaS 
and the gene encoding the subtilin pre-pro-peptide, and upstream of the promoter 
PspaI of the immunity genes spaIFEG (Kleerebezem et al., 2004). Regulation of the 
gene cluster responsible for production of and immunity to another B. subtilis-
associated lantibiotic, mersacidin, is through binding of the MrsR1 response 
regulator to the promoter governing lantibiotic production. In addition, upon 
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recognition of mersacidin, a two-component system MrsR2/MrsK2 regulates the 
immunity associates ABC transporter, MrsFGE. MrsR2/MrsK2 are also thought to 
have a role in mersacidin production to synchronize biosynthesis and immunity 
(Schmitz et al., 2006). In contrast, the regulatory systems associated with some 
other lantibiotics involve a single regulatory protein. Such regulatory proteins 
include MutR (Qi et al., 1999), LasX (Rawlinson et al., 2002) and EpiQ (Peschel et al., 
1993). In fact, LasX has a dual role in that it regulates the two divergent operons 
within the lactocin S gene cluster (lasAMNTUVPJW [lasA–W] and [lasXY]), 
simultaneously acting as an activator of PlasA – W transcription and as a repressor of 
P lasXY transcription.  
Our understanding of the regulation of lantibiotic biosynthesis has led to the 
development of the nisin controlled expression (NICE) system (Mierau & 
Kleerebezem, 2005), highlighting the benefits that can be reaped from in-depth 
knowledge of promoters and their regulation. Furthermore, since production levels 
can act as a bottleneck to the commercialisation of lantibiotics, a detailed 
characterisation of the promoters involved in expression can potentially lead to 
manipulations that can enhance lantibiotic manufacture. Here we compare the 
strength of the lacticin 3147 promoter, Pbac, with that of a range of known 
lactococcal promoters and establish that this promoter is regulated by genes within 
the lacticin 3147 cluster. This improved understanding of Pbac regulation has the 
potential to ultimately facilitate improved lacticin 3147 biosynthesis. 
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Materials and methods 
Bacterial strains and growth conditions 
Bacterial strains and plasmids used in this study are listed in Table 1. L. lactis 
strains were grown M17 broth (Oxoid) supplemented with 0.5% glucose (GM17) or 
GM17 agar at 30°C without aeration. E. coli was grown in Luria–Bertani (LB) broth 
with vigorous shaking or agar at 37°C. Antibiotics were used where indicated at the 
following concentrations: chloramphenicol at 5 μg ml-1 for L. lactis and 10 μg ml-1  
for E. coli; erythromycin was used at 300 μg ml-1  in E. coli and was combined with 
chloramphenicol in L. lactis at a concentration of 5 μg m-1 l for both antibiotics.   
Plasmid creation 
Plasmids pNZ25, pNZ32 and pNZbac were created as follows: the high-copy 
cloning vector pNZ44 was digested with restriction enzymes BglII and NcoI (Roche 
Diagnostics), sites for which are found either side of the P44 promoter, resulting in 
its removal. The plasmid backbone was subsequently isolated by gel extraction 
using a GeneJET gel extraction kit (Thermo Scientific) according to manufacturer’s 
guidelines, and treated with shrimp alkaline phosphatase step. Promoters PCP25 and 
P32 were created by annealing two complementary oligonucleotides (Table 2). 
Briefly, 10 µg of each oligo was reconstituted in 50mM Tris-HCl, 10mM MgCl, 
100mM NaCl, 1mM dithioerythritol and 1mM EDTA, were combined and heated to 
95°C for 5 mins followed by cooling to 25°C over 1hr. Approximately 1 µg of the 
now annealed oligos were phosphorylated using polynucleotide kinase (Roche) 
according to manufacturer’s guidelines. The promoter Pbac was amplified by PCR 
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from genomic DNA from the strain L. lactis MG1363.pMRC01, using KOD DNA 
polymerase (Novagen) using the primers Pbac F and Pbac R (listed in Table 2). Total 
cell DNA was isolated using an Invitrogen PureLink® Genomic DNA Kit. Promoters 
were subsequently ligated into the promoterless pNZ44 vector backbone using T4 
Ligase supplied by Roche Diagnostics, and transformed into chemically competent 
E. coli Top 10 (Invitrogen) as an intermediate host. Following verification by DNA 
sequencing (Source BioScience), plasmids were isolated using a High Pure plasmid 
isolation kit as recommended by the manufacturer (Roche Diagnostics) and 
digested using the restriction enzymes PstI and XbaI (Roche Diagnostics). The gfp+ 
gene was amplified from the plasmid pNZ8150gfp+ using the primers gfp+For and 
gfp+Rev and was subsequently digested with PstI and XbaI and ligated into the 
vectors pNZ25, pNZ32, pNZ44 and pNZbac and transformed into E. coli Top 10. 
Following verification of DNA sequences, pNZ25gfp+, pNZ32gfp+, pNZ44gfp+ and 
pNZbacgfp+ were transformed into L. lactis strains made electrocompetent 
according to the procedure described by Holo and Nes (Holo & Nes, 1995). 
Gene deletions and their complementation 
Deletion of ltnA1A2 from MG1363.pMRC01 was carried out using a 
combination of splicing by overlap extension PCR (Horton et al., 1990) and a 
double-crossover recombination event as described previously (Cotter et al., 2003) 
using the primers ltnA1A2soeA, ltnA1A2soeB, ltnA1A2soeC and ltnA1A2soeD. To 
express ltnA2 and ltnR in trans, the genes were amplified by PCR using KOD 
polymerase using the primers ltnA2 F and ltnA2 R for ltnA2 and ltnR F and ltnR R for 
ltnR (listed in Table 2). These products were digested with PstI and XbaI and ligated 
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into similarly digested pNZ44 under the control of the P44 promoter. The P44 
promoter and ltnA2 or ltnR were amplified from pNZ44ltnA2 and pNZ44ltnR as 
described previously using primers P44 For and ltnA2 R/ltnR R (listed in Table 2), 
digested with SphI and XbaI and ligated into similarly digested pNZEm (described in 
Table 3). After transformation into E. coli Top 10, plasmid isolation and verification 
of DNA sequence integrity, the plasmids pNZEmP44R and pNZEmP44A2 were 
electroporated into the corresponding L. lactis ΔltnR.pNZbacgfp+ and 
ΔltnA1A2.pNZbacgfp+ strains. To create pNZEmP44A2PP-, the entire 
plasmid pNZEmP44A2 was amplified by PCR using Phusion High-Fidelity DNA 
polymerase (New England Biolabs) and primers ltnA2PP- F and ltnA2PP- R, which 
introduced a stop codon immediately after the start codon of ltnA2 (for primers see 
Table 2). PCR products were DpnI treated in order to remove the 
methylated pNZEmP44A2 template and the resulting plasmids were transformed 
into E. coli Top 10 prior to DNA sequencing to confirm integrity of the resulting 
plasmids. pNZEmP44A2PP- was then electroporated into L. lactis 
MG1363.pMRC01ΔA1A2.pNZbacgfp+. 
Growth and fluorescence assays  
Broth-based assays were performed by inoculating L. lactis strains 
containing the appropriate plasmids to give a final inoculum of 2X107 CFU ml-1 in a 
volume of 0.2 ml in GM17 and monitoring the optical density at 600 nm (OD600) to 
analyse bacterial growth or to quantify fluorescence (excitation: 435 nm, emission: 
520 nm) in a Spectromax 340 spectrophotometer (Molecular Devices, Sunnyvale, 
CA) over a 23 hr period. 
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In silico analysis 
Multiple alignments were performed using the ClustalW2 (Larkin et al., 
2007) tool found at the EMBL-EBI website (Goujon et al., 2010). Repeat and 
palindrome elements of the promoters were identified using Lasergene GeneQuest 
software version 7.0 (DNASTAR, Madison, WI, USA). 
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Results 
In silico analysis of Pimm and Pbac 
In silico analysis of the Pimm/Pbac promoter regions revealed a number 
repeats and palindromes (Fig. 2). These consensus sequences are similar to sites 
bound by transcriptional regulators other than members of the Xre family, of which 
LtnR is a member. More specifically, there are two sites that resemble the E. coli Fur 
(ferric uptake regulation protein)-box sequence (Fur1) and another than resembles 
a Bacillus subtilis Per-box sequence (Fur2). In Figure 3 the percentage identity to 
the proposed operator sequences of Pimm/Pbac are displayed along with the aligned 
consensus binding sequence for the transcriptional regulator Xre, the Fur1 and Fur2 
boxes referred to above and the two putative operator sequences found in Pimm 
and Pbac. Alignments were performed using ClustalW2 (Larkin et al., 2007). The 
operator sequences of the lacticin 3147 gene cluster more closely resemble Fur 
consensus sites than the previously reported Xre-like consensus sequence within 
Pimm (84.21% versus 80.00% respectively) (McAuliffe et al., 2001). While it is 
apparent that LtnR shows greater homology to the consensus sequence of Xre 
proteins (31.03%) than to that of Fur proteins (16.00%), it is notable that a single 
Fur protein (locus tag: llmg_1023), which bears 35% identity to this consensus 
sequence, is present within the strain L. lactis MG1363. On the basis of finding 
multiple binding sites associated within Pimm/Pbac, further investigations were 
carried out to determine whether Pbac is regulated as suggested by the presence of 
these various repeat regions.  
  
212 
 
A comparison of the strength of Pbac relative to other lactococcal promoters in 
MG1363 
The Pbac promoter associated with lacticin 3147 production was previously 
suggested to be constitutive in nature (McAuliffe et al., 2001). The strength of Pbac 
activity relative to some known lactococcal constitutive promoters was assessed 
using green fluorescent protein (GFP) as a reporter. The lactococcal promoters used 
for this comparison include a promoter similar to PCP25 with a L. lactis optimised 
ribosomal binding site (RBS) (Jensen & Hammer, 1998), a truncated version of the 
promoter P32 (van der Vossen et al., 1987) and the P44 promoter, as found in the 
plasmid pNZ44 (McGrath et al., 2001). To facilitate this, the P44 promoter in pNZ44 
was replaced by PCP25, P32 and Pbac to create pNZ25, pNZ32 and pNZbac. The gfp+ 
gene was cloned into these three plasmids, as well as pNZ44. A comparison of 
expression levels in L. lactis MG1363 revealed that while the presence of the PCP25, 
P32 and P44 promoters resulted in the production of GFP+, no GFP+ production was 
evident from the Pbac-containing vector (Fig. 4). Among the vectors that successfully 
brought about GFP+ production, comparably high levels of expression were 
observed as a consequence of PCP25 and P44 driven transcription, while levels were 
approximately 25% lower when P32 was used.    
 
Pbac exhibits strong promoter activity in the presence of pMRC01 
As the promoter Pbac is naturally found within the lacticin 3147 associated 
operon, further experiments were carried out to determine if expression from this 
promoter on pNZbacgfp+ would be affected in a strain containing the other lacticin 
3147-associated determinants present on pMRC01. Thus pNZbacgfp+, along with 
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pNZ25gfp+, pNZ32gfp+ and pNZ44gfp+ (for comparative purposes), were 
electroporated into competent L. lactis MG1363.pMRC01 cells. A significant 
increase in GFP+ production was observed when pNZbacgfp+ is co-localised with 
pMRC01. The level of GFP+ expressed by Pbac is approximately double that 
observed for the constitutive promoters PCP25 and P44 (Fig. 5) when expressed in L. 
lactis MG1363 (Fig. 4). Moreover, the expression of GFP+ from the vectors pNZ25, 
pNZ32 and pNZ44 is unaltered by the presence of pMRC01 and remains consistent 
with that observed previously in L. lactis MG1363.  
Mutation of ltnR or ltnA2 impacts on Pbac activity  
As production of GFP+ from pNZbacgfp+ occurred as a consequence of the 
presence of pMRC01, we hypothesised that there may be elements within the 
lacticin 3147 operon that regulate Pbac. In order to investigate this further, 
pNZbacgfp+ was introduced into a series of L. lactis MG1363.pMRC01 derivatives in 
which lacticin 3147-associated genes had been deleted in a non-polar manner. 
These strains lacked ltnR, ltnA1, ltnA1A2, ltnM1, ltnM2 or ltnJ. The relative GFP+ 
production from these strains was assessed at 18 hrs (Fig. 6, Fig. 7). These 
investigations established that the presence of ltnR is essential for Pbac activity. In 
addition, Pbac is considerably up-regulated in the absence of ltnA1 and ltnA2 
(∆ltnA1A2). This phenomenon was not as obvious in the absence of ltnA1 alone, 
suggesting that the additional absence of ltnA2 is of key importance (Fig. 6). 
Deletion of the genes ltnM1, ltnM2 and ltnJ did not alter levels of GFP+ relative to 
those evident in the MG1363.pMRC01 strain (Fig. 7). 
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Complementation of ltnA2 and ltnR 
As the absence of ltnM2, which is required for the post translational of Ltnβ, 
does not impact on Pbac activity transcription levels, it was evident that mature Ltnβ 
is not responsible for the lack of Pbac activity from the ΔltnA1A2 strain. This was 
also apparent when it was established that externally added purified Ltnβ peptide 
had no effect on expression (data not shown). We speculated that the regulation of 
Pbac was dependent either on the presence of the unmodified pre-pro-peptide, or 
that the ltnA2 RNA was involved. In order to investigate this, two ltnA2-containing 
plasmids were generated and their ability to complement the hyper-GFP+ 
producing phenotype in the ΔltnA1A2 background was assessed. One of these 
contained an intact ltnA2 gene and the second, ltnA2PP-, was designed such that a 
stop codon was introduced immediately after the start codon. It was established 
that the presence of the ltnA2 transcript alone is sufficient to reduce GFP+ 
production, with no significant difference (Student’s t-test P <0.4) between ltnA2 or 
ltnA2PP-(Fig. 6).  In contrast, re-introduction of ltnR in trans did not complement the 
ΔltnR phenotype (data not shown). 
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Discussion 
Previous investigations, involving fusion of the promoter to β-gal in the 
vector pAK80 and expression in L. lactis MG1363, indicated that Pbac is 
constitutively expressed (McAuliffe et al., 2001) However with no comparison to 
any known constitutive promoter(s) and the contrasting use of a of low copy 
plasmid it makes comparisons to the current study difficult. Here we gain a more in 
depth insight into lacticin 3147 promoter function via the expression of gfp+ in the 
presence of pMRC01 and mutated derivatives.  
This study established that LtnR has a dual role in regulation. It was 
previously known that LtnR has a role in repressing transcription from the immunity 
associated Pimm promoter (McAuliffe et al., 2001), but we have identified a second 
role as an activator of expression from Pbac. This was apparent since there was no 
transcription from Pbac in the gfp+ containing reporter plasmid in the absence of 
ltnR. Although complementation of this gene was attempted, Pbac activity did not 
change from that observed in the ΔltnR strain. This is consistent with the previous 
finding that ltnR over-expression did not complement the immunity related ΔltnR 
phenotype (McAuliffe et al., 2001). 
Both ltnA1 and ltnA2 also appear to play a role in regulation. In the absence 
of ltnA1 alone slightly higher levels of GFP+ production are observed, but, when 
both genes are deleted, GFP+ levels increase dramatically, suggesting that the 
presence of ltnA2 is particularly important. Notably, exogenously added Ltnβ did 
not compensate for this phenotype. The absence of ltnM2, and in turn modified 
Ltnβ, had no impact on expression from Pbac. Thus, either the unmodified Ltnβ pre-
pro-peptide or the ltnA2 transcript must be involved in regulation. Results of ltnA2 
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complementation studies revealed that indeed the transcript alone was sufficient 
to reduce GFP+ expression levels. While further work is required to assess the role 
of ltnA1 and ltnA2, the cumulative results of this study suggests that LtnR and at 
least ltnA2 mRNA contribute to co-ordinating expression from the lacticin 3147 
gene cluster, maintaining immunity, biosynthesis and the post-translational 
modification process in equilibrium.  
An examination of the Pbac promoter revealed a putative operator site, with 
a set of three heptanucleotide repeats and a set of three hexanucleotide repeats 
also overlap the two divergent promoters, Pimm and Pbac. The location of these is 
such that they overlap the -35 and-10 regions of Pbac and thus suggest that they are 
potential targets of regulation. Regulation via the presence of inverted repeats and 
palindromes located in the promoter has been reported in many cases (Roy & 
Falkow, 1991; Yuan & Wong, 1995). Indeed, with respect to bacteriocin regulation, 
a pair of inverted repeats are thought to be the binding site of SapR, the response 
regulator component of the SapRK two-component system, involved in the 
regulation of expression of sakacin A and its immunity genes from two divergent 
operons (Axelsson & Holck, 1995). A palindrome and series of inverted repeats have 
also been implicated in the regulation of a newly discovered and as yet unnamed 
lantibiotic produced by Bifidobacterium longum DJO10A (Lee et al., 2011), while a 
set of heptanucleotide repeats is also associated with LasX-mediated regulation of 
lactocin S (Rawlinson et al., 2002). Palindromic sequences (operators) have been 
identified in B. subtilis as the binding sequences of Xre repressor proteins 
(McDonnell & McConnell, 1994), the family of repressors to which LtnR belongs. 
One such palindromic sequence has previously been identified in Pimm (McAuliffe et 
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al., 2001). However, this putative LtnR binding site within Pimm more closely 
resembles that of the core Xre binding consensus sequence (McDonnell & 
McConnell, 1994) than the palindrome identified in Pbac. PBSX/Xre family 
transcriptional regulators are more typically repressor proteins than activators 
(Wood et al., 1990). Hochschild and Dove describe how activation and repression 
through the same DNA-bound regulator and RNA polymerase may elicit different 
effects at different promoters (Hochschild & Dove, 1998). In one instance, they 
refer to a study which reveals that the sequence of the promoter (specifically, the 
degree of similarity of the −35 region sequence to the consensus) determines the 
regulatory outcome (Monsalve et al., 1997). In contrast to Pbac, the -35 region of 
Pimm is seen to greatly diverge from the lactococcal -35 consensus sequence (Fig. 2) 
(De Vos & Simons, 1994). This may serve to explain how the same LtnR protein can 
serve as both an activator and repressor while binding at these adjacently 
positioned promoters. 
The intragenic region encompassing the two promoters of the lactocin S 
gene cluster is characterised by the presence of 3 repeats, thought to act as a 
binding recognition site for LasX. The co-located promoters Pimm and Pbac also 
possess two distinct 3 repeat motifs and in addition, Pimm has an Xre consensus-like 
operator associated with it. Here, we also identify a palindrome within Pbac which 
may also serve as a recognition and binding site for LtnR. In fact another 
transcriptional Fur-type regulator, found in Borrelia burgdorferi, which classically 
controls expression of genes involved in iron uptake and iron storage by binding to 
a Fur-box DNA consensus sequence (Andrews et al., 2003), is seen to bind two 
distinct consensus motifs similar to that proposed for LtnR (Katona et al., 2004). Fur 
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proteins have also been associated with the regulation of many other genes in 
addition to those directly related to iron metabolism. It has been revealed that Fur 
participates in a wide variety of functions including, for example, shock response, 
defence against oxygen radicals, chemotaxis, metabolic pathways, 
bioluminescence, swarming, production of toxins and other virulence factors (for 
review see (Escolar et al., 1999)). Fur has also been associated with regulation of 
the bacteriocin colicin V (Chehade & Braun, 1988). LtnR does not share any notable 
homology with Fur proteins to the degree it does with the Xre family of regulators. 
However, it is still plausible that it may bind, in a manner similar to the Fur-like 
proteins, to the two such Fur-like binding sequences identified here. With the 
identification of a Fur protein within L. lactis MG1363 it would be of interest to 
determine whether it has any involvement in lacticin 3147 regulation under 
circumstances such as responses to shock or oxidative stress.  
On overviewing the various constructs designed and investigated in this 
study, we can reveal, in accordance with the presence or absence of ltnR and 
ltnA1A2, a clear rationale of their intercellular roles. We hypothesise that the dual 
role of LtnR as both an activator and repressor co-ordinates the biosynthesis and 
immunity of lacticin 3147, and that ltnA1 and ltnA2 play a role in modulating 
biosynthesis so as to maintain lantibiotic production at a homeostatic level. We 
propose that the cell initiates lacticin 3147 biosynthesis/immunity by initiating 
expression from Pimm, which in fact was previously described as being constitutive in 
nature in the absence of the regulatory protein LtnR (McAuliffe et al., 2001) (Fig. 
8(a)). This allows production of LtnR and the lacticin 3147 immunity proteins, LtnI, F 
and E. The immune cell is now prepared for the presence of the bactericidal 
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lantibiotic; LtnR now binds to Pimm and represses its own production and that of the 
immunity genes (Fig. 8(b)). Concomitantly LtnR binds to Pbac, stimulating activation 
of lacticin 3147 biosynthetic, modification and transport gene expression (Fig. 8(c)). 
In order to prevent an overload of lacticin 3147 pre-pro-peptide within the cell 
ltnA2 (and perhaps to be determined, ltnA1) transcript interacts with LtnR or the 
Pbac promoter and reduces activation to a homeostatic level (Fig. 8(d)). This allows 
the cell sufficient time to complete the essential post-translational modifications 
characteristic of a lantibiotic. As modified Ltnα and Ltnβ are not involved in the 
regulation of Pbac, we can conclude that there is a correlated effort between 
fluctuating levels of intracellular LtnR and ltnA1A2 transcript with Pimm and Pbac 
regulation. This results in a steady state of lacticin 3147 immunity, biosynthesis and 
modification that ultimately lead to export of fully modified Ltnα and Ltnβ from the 
cell. While the nuances of the contribution of ltnA1 need to be finalised, the relative 
contribution of LtnR and ltnA2 have revealed that Pbac is a regulated promoter, 
rather than a constitutive one. With further analysis it may be possible to 
manipulate this system in order to maximise lacticin 3147 production. 
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Tables and Figures 
Table 1. Strains used in this study 
L. lactis MG1363 Strain Relevant characteristics Reference 
MG1363 L. lactis devoid of lacticin 3147 operon (Lac-) (Gasson, 1983) 
pNZ25gfp+ Lac-;PCP25 expression of gfp+ This study 
pNZ32gfp+ Lac-;P32 expression of gfp+ This study 
pNZ44gfp+ Lac-;P44 expression of gfp+ This study 
pNZbacgfp+ Lac-;Pbac expression of gfp+ This study 
pMRC01.pNZ25gfp+ Lac+; PCP25 expression of gfp+ This study 
pMRC01.pNZ32gfp+ Lac+; P32 expression of gfp+ This study 
pMRC01.pNZ44gfp+ Lac+; P44 expression of gfp+ This study 
pMRC01.pNZbacgfp+ Lac+; Pbac expression of gfp+ This study 
pMRC01 ΔA1A2 pMRC01 ΔltnA1A2 This study 
pMRC01 ΔA1 pMRC01 ΔltnA1 (Cotter et al., 2003) 
pMRC01 ΔR pMRC01 ΔltnR (Deegan, 2007) 
pMRC01 ΔM1 pMRC01 ΔltnM1 (Field et al., unpublished) 
pMRC01 ΔM2 pMRC01 ΔltnM2 (Field et al., unpublished) 
pMRC01 ΔJ pMRC01 ΔltnJ (Cotter et al., 2005) 
pMRC01 ΔA1A2.pNZ44gfp+ Lac 
ΔltnA1A2; P44 expression of gfp+ This study 
pMRC01 ΔA1A2.pNZbacgfp+ Lac 
ΔltnA1A2; Pbac expression of gfp+ This study 
pMRC01 ΔA1.pNZ44gfp+ Lac 
ΔltnA1; P44 expression of gfp+ This study 
pMRC01 ΔA1.pNZbacgfp+ Lac 
ΔltnA1; Pbac expression of gfp+ This study 
pMRC01 ΔR.pNZ44gfp+ Lac ΔltnR; P44 expression of gfp+ This study 
pMRC01 ΔR.pNZbacgfp+ Lac ΔltnR; Pbac expression of gfp+ This study 
pMRC01 ΔM1.pNZ44gfp+ Lac 
ΔltnM1; P44 expression of gfp+ This study 
pMRC01 ΔM1.pNZbacgfp+ Lac 
ΔltnM1; Pbac expression of gfp+ This study 
pMRC01 ΔM2.pNZ44gfp+ Lac 
ΔltnM2; P44 expression of gfp+ This study 
pMRC01 ΔM2.pNZbacgfp+ Lac 
ΔltnM2; Pbac expression of gfp+ This study 
pMRC01 ΔA1A2.pNZbacgfp+.pNZEmP44A2 
pMRC01ΔA1A2.pNZbacgfp+;P44 ltnA2 
expression  This study 
pMRC01ΔA1A2.pNZbacgfp+.pNZEmP44A2
pp- pMRC01ΔA1A2.pNZbacgfp+;P44 ltnA2
PP- 
expression This study 
pMRC01 ΔA1A2.pNZbacgfp+.pNZEmP44R 
pMRC01 ΔA1A2.pNZbacgfp+;P44 ltnR 
expression This study 
Other Strains    
E. coli Top10 Intermediate cloning host Invitrogen 
E. coli EC101 Rep+ cloning host (Law et al., 1995) 
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Table 2. Primers used in this study 
 
Oligo/Primer Sequence 
PCP25 F gatctCTTTGGCAGTTTATTCTTGACATGTAGTGAGGGGGCTGGTATAATCACATAAGGAGGATATATc 
PCP25 R catggATATATCCTCCTTATGTGATTATACCAGCCCCCTCACTACATGTCAAGAATAAACTGCCAAAGa 
P32 F gatctTTTGTGAGCTTGGACTAGAAAAAAACTTCACAAAATGCTATACTAGGTAGGTAAAAAAATATT 
CGGAGGAATTTTGAAc 
P32 R catggTTCAAAATTCCTCCGAATATTTTTTTACCTACCTAGTATAGCATTTTGTGAAGTTTTTTTCTAGTC 
CAAGCTCACAAAa 
Pbac F GAAGATCTTATATACAGAGTTACTAATAGAA 
Pbac R TGCCATGGTTTTTTGTTCATGATA 
ltnA1A2soeA ATCTGCAGAATTTAAAAAATCACA 
ltnA1A2soeB AGATACTTCTTCCAACCA 
ltnA1A2soeC TGGTTGGAAGAAGTATCCTGAGTCTCATGGAGGAA 
ltnA1A2soeD ACGAATTCAGGGATATTCCTCAT 
ltnR F CTGCAGCATAGATAGGAGGAAAATGTTTG 
ltnR R GGTCTAGAAAAGGTATTGATATTTTCATTC 
ltnA2 F AACTGCAGTTAATAACAAATTTTTAATTAATTAAG 
ltnA2 R GCTCTAGATTACTCCTAATTAACAAGCACGTG 
ltnA2pp- F GCTTTACGATGTAAGAAAAAAATATGAAAAAGAATGACA 
ltnA2pp- R TGTCATTCTTTTTCATATTTTTTTCTTACATCGTAAAGC 
P44 For GGGCATGCGTTAGTTGAAGAAGGTTTTTATATTAC 
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Table 3. Plasmids used in this study 
 
Plasmids  Relevant characteristics  Reference 
pNZ25 CmR; high-copy vector;PCP25 promoter This study 
pNZ32 CmR; high-copy  vector;P32 promoter This study 
pNZ44 CmR; high-copy vector;P44 promoter (McGrath et al., 2001) 
pNZbac CmR; high-copy vector;Pbac promoter This study 
pNZEm EmR; high-copy vector;Pnis promoter Margolles et al., unpublished 
pNZ44ltnA2 pNZ44 expression of ltnA2  This study 
pNZ44ltnR pNZ44 expression of ltnR This study 
pNZEmP44A2 Em
R; P44 expression of ltnA2 This study 
pNZEmP44R Em
R; P44 expression of ltnR This study 
pNZEmP44A2
PP- Em
R; P44 expression of untranslated 
ltnA2 pre-pro-peptide 
This study 
pNZ8150gfp+ Source of gfp+ gene Field et al., unpublished 
pVE6007 CmR; temperature-sensitive (Maguin et al., 1992) 
pORI280 RepA-, LacZ+ (Leenhouts et al., 1996) 
pORI280ltnA1A2soe pORI280 containing spliced ltnISOEAD fragment  This study 
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Fig. 1. The 12.6kb lacticin 3147 gene cluster. Two promoters Pimm and Pbac are 
located at the interface of the two divergent operons: ltnRIFE and ltnA1A2M1TM2J, 
which are responsible for the biosynthesis, immunity and export of the final 
lantibiotic. 
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Fig. 2. Overview of the ltnR-A1 intragenic region. The -10 and -35 elements of the 
promoters Pimm and Pbac are indicated (and underlined). Red triangles indicate the 
transcriptional start sites. The translational start sites for LtnR and Ltnα pre-pro-
peptide are shown indicated with a black arrow and the predicted corresponding 
ribosome binding sites (RBS). Two sets of three direct repeats are displayed boxed 
in yellow and blue. An inverted repeat in Pimm and a palindrome present in Pbac are 
boxed in red with inverted arrows. 
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Fig. 3. The putative operator sites identified within Pimm and Pbac are aligned with 
consensus sequence homologues (a). These include the Xre binding consensus 
sequence and two sequences termed here as Fur1 and Fur2, to which a Fur (ferric 
uptake regulation protein) homologue binds. Nucleotides in red are common across 
all operators, those in green indicated identity between Pimm/Pbac and the Fur 
operators and yellow identifies those bases in common with the Xre consensus 
binding sequence. The percentage identity of sequences to the Pimm and Pbac 
putative operators has also been included (b). The percentage to which LtnR is 
identical to Xre and Fur protein consensus sequences is also presented (c). 
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Fig. 4. Expression of gfp+ in L. lactis MG1363 via a variety of known constitutive 
promoters i.e. P25, P32 and P44, present in or replacing P44 in the vector pNZ44. A 
corresponding plasmid pNZbacgfp+ harbouring the lacticin 3147 associated 
promoter Pbac, is compared to these constitutive promoters and it is revealed that 
its level of expression is comparable to that of a negative control L. lactis MG1363 
strain devoid of the gfp+ gene.  
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Fig. 5. Expression of gfp+ via the plasmids pNZ25, pNZ32, pNZ44 and pNZbac in L. 
lactis MG1363.pMRC01. The strain L. lactis MG1363.pNZbacgfp+ was included for 
comparative purposes, as were two control strain L. lactis MG1363 and L. lactis 
MG1363.pMRC01 devoid of the gfp+ gene.  
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Fig. 6. An overview of GFP+ production by pNZbacgfp+ in the presence or absence 
of pMRC01 and derivatives lacking ltnA1, ltnA1A2 or ltnR after 18hrs in L. lactis 
MG1363. Complementation of ltnA2 in the ∆ltnA1A2 background gene, using an 
intact (via pNZEmP44A2) or mutated ltnA2 (via pNZEmP44A2PP-) was also investigated 
(*Student's t-test P < 0.4). The presence or absence of ltnA1 and its transcript 
(indicated by a yellow circle and wavy line), ltnA2 and its transcript (indicated by a 
red circle and wavy line) and ltnR (indicated by the circled letter R) are displayed 
above, along with a representation of the observed Pbac strength, where a bold 
arrow implies increased activity and no arrow indicates lack of expression.  
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Fig. 7.  An overview of GFP+ expression by pNZbacgfp+ in the presence of pMRC01 
and the various deletions therein after 18 hrs in L. lactis MG1363. The presence or 
absence of LtnR (circled R) and ltnA1A2 (indicated by a red circle) are displayed 
above along with a representation of the observed Pbac activity, where no arrow 
indicates no expression. 
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Fig. 8.  Hypothesis of internal LtnR and ltnA2 fluctuations and their impact on 
promoter regulation. In the absence of lacticin 3147 the cell first switches on 
immunity (a). LtnIFE confer immunity and ltnR suppresses LtnRIFE production (b). 
LtnR also activates lacticin 3147 production (c). The presence of ltnA2 and perhaps 
also ltnA1 (to be confirmed) reduces expression of lacticin 3147 genes to protect 
the cell against overproduction and allows time for modification of the lantibiotic 
pre-pro-peptides (d).                              
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Lantibiotics are ribosomally synthesised antimicrobial peptides produced by 
many Gram positive bacteria. They are distinguished by the presence of the unusual 
amino acids lanthionine and methyl-lanthionine, which are responsible for the 
characteristic bridges observed in these peptides. Lacticin 3147 and nisin are two 
well-studied lantibiotics produced by Lactococcus lactis. They display activity 
against a wide spectrum of Gram positive microorganisms at concentrations in the 
nanomolar range. The genes encoding the two peptide antimicrobial lacticin 3147 
are located on two divergent operons on the plasmid pMRC01, whereas the genes 
responsible for nisin and its natural variants are found on a single operon in several 
strains of L. lactis and S uberis. In order to protect themselves from the bactericidal 
agent they produce, lantibiotics have to employ a resistance or, more accurately, a 
self-immunity mechanism. In the case of lacticin 3147 and nisin, this is achieved 
through the action of a dedicated ABC transporter (LanFE(G)) and a separate 
immunity specific protein (LanI). Given the potency of lacticin 3147 and nisin, it 
would seem that these antimicrobials represent genuine alternatives to 
conventional antibiotics. Obstacles that could prevent the commercialisation of 
lantibiotics include the fact that the potential mechanisms through which resistant 
strains could emerge have not been extensively investigated as well as the 
relatively small concentrations of lantibiotic generated by some producers. 
 Chapter I of this thesis reviews the lantibiotic resistance mechanisms 
employed by bacteria. Many of these are innate, rather than acquired, mechanisms 
Thesis Summary 
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of resistance that protect the cell wall and cell membrane of strains under attack 
from lantibiotics and other antimicrobials with a similar mode of action. Naturally 
acquired resistance seems quite rare but those that have been identified are also 
discussed.  
Chapter II addresses the possibility of overcoming limitations in producing 
large quantities of lantibiotic by combining the peptides with other antimicrobials. 
This is somewhat similar to the hurdle technology employed in food protection in 
that bacteria are generally more susceptible to the combined effect of more than 
one antibacterial agent. Ultimately, this study highlights the fact that polymyxin 
B/polymyxin E (colistin) and lacticin 3147 function synergistically. This was apparent 
from checkerboard assays that were performed against a number of Gram positive 
and Gram negative species. The resultant fractional inhibitory concentration (FIC) 
index values established that, while partial synergy was detected against Gram 
positive targets, synergy was obvious against Gram negative species, including 
Cronobacter and E. coli. Combining lacticin 3147 with low levels of a polymyxin 
could thus provide a means of broadening the target specificity of the lantibiotic, 
while reducing the concentrations of the individual antimicrobials. With the 
potential of lacticin 3147 as an anti-mastitic agent having already been established 
with respect to Gram positive species, this application highlights a means of also 
targeting Gram negative species, such as E. coli, that are also associated with the 
disease. 
Chapter III describes an in-depth investigation of the lacticin 3147 immunity 
peptide LtnI. Characterisation of structure-function relationships in LtnI was 
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achieved through the creation of a series of fusion peptides and random and site 
directed mutagenesis of ltnI. The results are consistent with in silico predictions 
that LtnI is a transmembrane protein and reveals the presence of regions, such as 
those between amino acid 20-27 and 76-83, which are essential for LtnI function. 
Finally, as a consequence of the screening of a bank of 28,000 strains producing LtnI 
variants, we identified one (LtnI I81V) that provides enhanced protection. To our 
knowledge, this is the first report of a lantibiotic immunity protein with enhanced 
functionality. This enhanced knowledge may be of benefit when overcoming 
hurdles relating to the discovery of derivatives with enhanced activity, or increasing 
levels of lantibiotic production, which might otherwise lead to the growth of the 
producing strain being inhibited.  
Chapter IV describes the presence of nisin U immunity gene homologues in 
Streptococcus infantarius subsp. infantarius BAA-102. Nisin U is a member of the 
extended nisin family of lantibiotics. Heterologous expression of the BAA-102 
spiFEG genes (homologues of the nisin U immunity specific ABC transporter 
nsuFEG) in L. lactis subsp. cremoris HP conferred protection to nisin U and other 
members of the nisin family. This is an example of immune mimicry, a phenomenon 
in which non-lantibiotic producing strains express functional homologues of 
lantibiotic immunity systems. This study established that this mechanism of 
resistance, only recently identified for lacticin 3147, also occurs with respect to 
nisin. Immune mimicry has the potential to pose a real problem if lantibiotics are to 
be employed in a clinical setting, and so a greater understanding of this 
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phenomenon may allow the identification of strategies to prevent such resistance 
from developing.  
Chapter V investigates the regulation of lacticin 3147 production. It was 
formerly believed that expression of the lacticin 3147 biosynthetic genes was 
constitutive, even though most lantibiotic systems are regulated. We demonstrated 
that, in fact, the regulatory protein LtnR, previously associated with repression of 
itself and the immunity genes, also acts as an activator of the Pbac promoter and 
plays a role in the expression of the biosynthetic, modification and transport genes.  
Different levels of expression are observed depending on the absence or presence 
of specific genes of the lacticin 3147 gene cluster. While ltnR is required to obtain 
the intermediate/homeostasis levels of expression associated with the un-mutated 
pMRC01 plasmid, the absence of ltnA1 and ltnA2 results in a greatly heightened 
level of expression. As the modification genes ltnM1 and ltnM2 are not involved in 
this enhanced expression, it would seem that either the unmodified pre-pro-
peptides or gene transcripts act as the regulatory elements. The expression of 
different forms of ltnA2 in pMRC01ΔA1A2, resulting in translated and untranslated 
versions of the ltnA2 gene, revealed that the transcribed but untranslated gene also 
complemented this phenomenon. While the contribution of ltnA1 has yet to be 
defined, these results do suggest a role for ltnA2 and ltnR in repression and 
activation of Pbac, respectively. It would seem that these mechanisms are employed 
such that a balance between production and immunity can be maintained, whereby 
the expression, processing and export of the ltnA1 and ltnA2 gene products are 
regulated to ensure that the cell is not overloaded. Investigating the processes 
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involved in regulating the Pbac promoter may facilitate the production of greater 
levels of lacticin 3147 and, in such a situation, the improved immunity provided by 
the enhanced version of LtnI discovered here may be useful.  
Overall, this thesis makes several contributions to our knowledge of 
lantibiotics, particularly in the area of potential applications in clinical settings.  The 
major limitations in developing clinical applications for lantibiotics include 
production levels, efficacy against selected pathogens and the issue of resistance 
development. All three areas are addressed in this thesis. A thorough 
understanding of regulatory controls (Chapter V) and associated immunity 
mechanisms (Chapter III) may be useful in addressing production levels.  
Alternatively, the need for enhanced production could be avoided through the use 
of antimicrobial combinations (Chapter II). In addition, an awareness of the threats 
associated with the emergence of resistance through immune mimicry can allow 
researchers to develop strategies to prevent this phenomenon from leading to the 
dissemination of lantibiotic resistance (Chapter IV). Given the dearth of novel 
antibiotics and the continuing threat posed by antibiotic resistance development, 
lantibiotics (and other bacteriocins) present a realistic alternative, worthy of further 
investigation. This thesis represents a significant advance in our knowledge, and 
brings the likely deployment of lantibiotics in the clinic a little bit closer. 
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Saturation mutagenesis of selected residues of the
a-peptide of the lantibiotic lacticin 3147 yields a
derivative with enhanced antimicrobial activity
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Cotter,3,4* Colin Hill1,3** and R. Paul Ross3,4
1Department of Microbiology, University College Cork,
Cork, Ireland.
2Faculty of Food Science and Engineering, ‘Dunarea de
Jos’, University of Galati, Galati, Romania.
3Alimentary Pharmabiotic Centre, University College
Cork, Cork, Ireland.
4Teagasc Food Research Centre, Moorepark, Fermoy,
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Summary
The lantibiotic lacticin 3147 consists of two ribosoma-
lly synthesized and post-translationally modified
antimicrobial peptides, Ltna and Ltnb, which act syn-
ergistically against a wide range of Gram-positive
microorganisms. We performed saturation mutagen-
esis of specific residues of Ltna to determine their
functional importance. The results establish that Ltna
is more tolerant to change than previously suggested
by alanine scanning mutagenesis. One substitution,
LtnaH23S, was identified which improved the specific
activity of lacticin 3147 against one pathogenic strain,
Staphylococcus aureus NCDO1499. This represents
the first occasion upon which the activity of a
two peptide lantibiotic has been enhanced through
bioengineering.
Introduction
Lantibiotics [lanthionine-containing antibiotics (Schnell
et al., 1988)] are a member of the family of antimicrobial
peptides termed bacteriocins (Willey and van der Donk,
2007; Bierbaum and Sahl, 2009). In lantibiotics, dehy-
droalanine (Dha) and dehydrobutyrine (Dhb) residues
are formed through the dehydration of serine and threo-
nine respectively. The eponymous lanthionine (Lan) and
b-methyllanthionine (MeLan) residues are enzymatically
introduced when a covalent (thio-ether) bridge forms
between a neighbouring cysteine and one of these
unsaturated amino acids. These post-translational modi-
fications confer structure and function to the previously
inactive precursor peptide. Lantibiotics have been the
subject of intensive studies as a result of their broad
target range, potent activity and their potential as safe,
natural food additives or as chemotherapeutic agents
(Cotter et al., 2005b; Galvez et al., 2007; Piper et al.,
2009a).
Lacticin 3147 is a lantibiotic produced by the food-
grade bacterium Lactococcus lactis spp. lactis DPC3147.
It is active against a variety of clinically significant
Gram-positive organisms, including methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococcus strains (VRE) and penicillin-resistant Pneu-
mococcus, in addition to foodborne pathogens such as
Listeria monocytogenes and Bacillus cereus (Lawton
et al., 2007b; Piper et al., 2009b; Carroll et al., 2010).
Lacticin 3147 is a two peptide lantibiotic and thus both
peptides, Ltna and Ltnb, are required for full antimicrobial
activity (Wiedemann et al., 2006). Lacticin 3147 is active
at single nanomolar concentrations through a dual
mechanism in which Ltna first interacts with the cell
wall precursor lipid II to inhibit peptidoglycan synthesis.
It is proposed that the resulting Ltna : lipid II complex
then interacts with Ltnb to facilitate pore-formation
(Wiedemann et al., 2006). An unusual feature of lacticin
3147 is the presence of three D-alanines (D-Ala) that
are enzymatically derived from ribosomally introduced
L-serines (Cotter et al., 2005c). Lacticin 3147 is one of
only two examples of prokaryotic gene-encoded peptides
in which such modified residues have been identified
(Skaugen et al., 1994).
Two peptide lantibiotics remain relatively uncommon.
To date only seven other lacticin 3147-like antimicrobials
have been characterized; staphylococcin C55 (Navaratna
et al., 1999), plantaricin W (Holo et al., 2001), Smb
(Yonezawa and Kuramitsu, 2005), BHT-A (Hyink et al.,
2005), haloduracin (McClerren et al., 2006; Lawton et al.,
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2007a), lichenicidin (Begley et al., 2009; Dischinger et al.,
2009) and a predicted pneumococcin (Majchrzykiewicz
et al., 2010). The a peptides of the two peptide lantibiotics
cluster with the mersacidin-like peptides (Cotter et al.,
2005a), with the exception of the enterococcal cytolysin
(Cox et al., 2005). Despite their different overall struc-
tures, alignment of the mersacidin-like peptides with those
from the more distantly related lacticin 481 subgroup
(Fig. 1) reveals the presence of a conserved stretch of
amino acids, (C)TXS/TXD/EC, a motif encompassing a
conserved ring that has been suggested to comprise the
core site for lipid II binding (Breukink and de Kruijff, 2006;
Cotter et al., 2006). Significantly, this region represents
the first point of contact between mersacidin and the
bacterial cell and is thus believed to contain core amino
acids that are essential with regard to the functionality of
these peptides (Hsu et al., 2003).
Lantibiotics represent one possible solution to combat
the emergence of multi-drug resistant strains (Boucher
et al., 2009). The fact that lantibiotics are gene-encoded
and ribosomally synthesized has facilitated the develop-
ment of versatile expression systems capable of produc-
ing novel derivatives. This approach has generated
information about the structure-function relationships of
lantibiotics, as well as allowing one to screen for the
enhancement of chemical and antimicrobial properties
(Field et al., 2010a). A description of the role of each
individual amino acid or domain will be required for a
rational approach to design new, improved lantibiotics. To
this end, an attempt has been made to predict the identity
of essential and variable residues across both peptides of
lacticin 3147 using alanine scanning mutagenesis (Cotter
et al., 2006). However, the consequences of changing a
residue to alanine do not always reflect the overall
tolerance/intolerance of a specific residue to change. To
address this issue, saturation mutagenesis of the lipid
II-binding component of lacticin 3147, i.e. Ltna, was per-
formed. We focused on the residues of Ltna that are not
involved in bridge formation and while this approach fre-
quently confirmed the relevance of the alanine scanning
approach with regard to the importance of specific amino
acids, a limited number of substitutions were found to be
tolerated at positions previously designated as being intol-
erant of change. We also noted that amino acids highly
conserved across related lantibiotics are not necessarily
inviolate. More significantly, we identified the first deriva-
tive of a two peptide lantibiotic with increased potency
against a strain of clinical significance.
Fig. 1. Alignment of the unmodified sequence of structural peptides of the mersacidin-like lantibiotic subgroup (Mersacidin Subgroup), which
includes single-peptide members and the closely related a peptides of two peptide lantibiotics, and the lacticin 481-like lantibiotic subgroup
(Lacticin 481 Subgroup). The sequence of Ltna is italicized. Dark grey boxes indicate residues that are fully conserved across both sub-
groups, medium grey indicates residues that are highly conserved across both subgroups, while light grey indicates partially conserved
residues. The putative lipid II binding motif conserved among the mersacidin and lacticin 481 lantibiotic subgroups (with the exception of (C),
which is not found in the lacticin 481 subgroup) is given at the bottom of the alignment.
Site-saturation mutagenesis of Ltna 565
© 2013 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 6, 564–575
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Results and discussion
Saturation mutagenesis was performed using a PCR-
based approach and a two-plasmid expression system
was subsequently applied in generation of banks of Ltna
mutants (Field et al., 2007), with a particular focus on
mutants that retained at least some bioactivity against the
sensitive indicator strain L. lactis HP (Table 1). As the aim
of the current study was to confirm whether individual
residues are tolerant or intolerant of change, no attempt
was made to distinguish between mutations that impact
on production and those that impact on specific activity.
Targeting of ‘essential’ residues in Ltna for
site-saturation mutagenesis
The conversion of a number of Ltna residues to alanine
resulted in the abolition of bioactivity (Cotter et al., 2006);
as such, these residues were designated as being ‘essen-
tial’ for bioactivity of lacticin 3147. These include residues
proposed to be involved in the interaction with Ltnb (F6,
S7, W12, N14), putative lipid II binding residues (L21,
E24) and two tryptophans (W18 and W28). Despite not
being conserved (Fig. 1), the replacement of F6 and W12
with alanine was previously found to eliminate bioactivity
(Cotter et al., 2006). Here saturation mutagenesis estab-
lished that conservative substitutions are tolerated at
position 12 (Fig. 2), with bioactivity decreasing relative
to the size of the newly incorporated residue (Trp >
Tyr > Phe; Table 1). However, a critical role was confirmed
for F6 with respect to bioactivity (Cotter et al., 2006)
(Table 1). Based on previous observations (Jing et al.,
2003; Sanderson and Whelan, 2004), there is a likelihood
that aromatic amino acids in membrane-acting peptides
such as these are likely to be situated at the lipid-water
interface and promote hydrophobic interaction with the
cytoplasmic membrane. Thus, replacing the native
residue with any amino acid other than another aromatic
residue could be expected to have a detrimental effect on
antimicrobial activity (Cotter et al., 2006).
Position S7 is subject to a two-step post-translational
modification to form D-alanine (Cotter et al., 2005c).
Despite the natural presence of an alanine at the corre-
sponding location in Blia and the fact that only Ltna, and
potentially Saca (Suda et al., 2011), possess a D-alanine
at this location (Fig. 1), an S7A mutant was previously
found to be inactive (Cotter et al., 2005c; Cotter et al.,
2006). Here we confirm the negative consequences of
such a S7A change and note that many other substitu-
tions also result in the elimination of bioactivity. However,
in line with previous investigations, S7T (dehydrated to
Dhb, data not shown) and S7G substitutions (Cotter
et al., 2005c) were both found to result in active mutants
(Table 1), confirming a limited tolerance to change
(Fig. 2).
The previously generated N14A mutant lacked bioac-
tivity (Cotter et al., 2006), in accordance with the complete
conservation of N14 among lantibiotic a peptides (Fig. 1).
This suggested a pivotal role for this residue in the syn-
ergistic interaction between both component peptides
(Cotter et al., 2006). However, it is now apparent that
some substitutions are tolerated to some degree, includ-
ing replacements with positively charged residues
arginine or lysine (Table 1).
Despite the variability of L21 across the mersacidin and
lacticin 481 subgroups and the presence of alanine at
the corresponding location in the closely related C55a
(Fig. 1), a LtnaL21A mutant was previously found to be
inactive (Cotter et al., 2006; O’Connor et al., 2007). Thus,
this position was previously designated as being essen-
tial. However, site-saturation of L21 found that two
Fig. 2. Tolerance of residues of Ltna to change as determined by (A) alanine scanning, with the assumption that lack of bioactivity on substi-
tution with alanine (or glycine in the case of a native alanine) indicates an immutable residue, while retention of bioactivity suggests that other
residues could be tolerated at the specific position, and (B) saturation mutagenesis, with those that retain bioactivity only when the native
residue is present designated as immutable residues, and those retaining bioactivity on substitution with one or more other residues classified
as tolerant to change. Grey circles indicate tolerant positions while black circles indicate immutable positions. White circles represent residues
involved in bridge formation, which were not targeted in this study.
566 D. Field et al.
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conservative substitutions are tolerated, L21M and L21V,
and perhaps surprisingly, a L21Y mutant retained a
small amount of bioactivity (Table 1). The retention of
bioactivity by the L21V mutant is notable in that it renders
Ltna more similar to other a peptides (SmbB, BHT-Aa and
Blia; Fig. 1). The results of saturation mutagenesis at
positions N14 and L21 highlight the risk of relying solely
on alanine scanning as an indication of tolerance to
change (Fig. 2).
E24 is highly conserved among the mersacidin and
lacticin 481 subgroups (Fig. 1) and LtnaE24A showed no
bioactivity (Cotter et al., 2006). When the corresponding
residues in mersacidin (Szekat et al., 2003), actagardine
(Boakes et al., 2009) and Hala of haloduracin (Cooper
et al., 2008) were substituted with Ala (and also to Gln in
the case of HalaE22), all antimicrobial activity was also
lost. HalaE22Q was also deficient with regard to the inhi-
bition of peptidoglycan formation by the enzyme PBP1b,
which uses lipid II as a substrate for glycan polymerization
(Oman et al., 2011). Unsurprisingly, on saturation muta-
genesis of LtnaE24, the only mutant to retain activity,
albeit low levels, is one in which the negative charge at
this position is maintained (E24D; Table 1). This is con-
sistent with previous findings (Deegan et al., 2010) and
renders the peptide more similar to many members of the
lacticin 481 subgroup (Fig. 1). This observation contra-
dicts a previous investigation that designated E24 as intol-
erant of change (Cotter et al., 2006) (Fig. 2). However,
while a preference for the native glutamate is apparent, it
can be said that a negatively charged residue at this
position of Ltna is of critical importance.
Despite their variable nature across the mersacidin-like
peptides (Fig. 1), bioactivity was abolished when W18
and W28 were converted to alanine (Cotter et al., 2006).
It was noted that on saturation mutagenesis of position
W18, none of the Ltna mutants identified retained detect-
able bioactivity (Table 1). In contrast, a W28Y mutant
retained bioactivity, albeit at a reduced level compared to
the wild-type, in disagreement with the anticipated intol-
erance to change at this location (Cotter et al., 2006)
(Table 1; Fig. 2).
Targeting of ‘variable’ residues in Ltna for
site-saturation mutagenesis
Many Ltna residues were classified as variable in that
they could be altered to alanine (or glycine in the case of
native alanines) without resulting in complete loss of bio-
activity (Cotter et al., 2006). These include the N-terminal
variable residues (T3, N4, L8, T5), ring B variable resi-
dues (D10, Y11, G13, N15, G16, A17) and C-terminal
variable residues (H23, M26, A27, K30). It should be
noted that some changes which were previously found to
be tolerated (Cotter et al., 2006) did not yield bioactive
strains on this occasion, presumably as a consequence of
the reduced activity associated with the expression
system used in this study.
Residues T3 and T5 of Ltna are both dehydrated to Dhb
in mature lacticin 3147. Given the degree to which the
previously generated T3A mutant retained bioactivity
(Cotter et al., 2006), coupled with the fact that a threonine
at this position is not conserved across the a peptide
group (Fig. 1), it is perhaps not surprising that four bioac-
tive mutants, T3M, N, Y and D, were identified on satura-
tion mutagenesis of this residue (Table 1). Interestingly,
none of these substitutions were residues present at the
corresponding locations in other members of the group
(Fig. 1). The retention of low levels of bioactivity by T5A,
which renders the peptide more similar to Bhaa, was
replicated (Cotter et al., 2006), and two additional bioac-
tive mutants were identified (T5V, L; Table 1). Signifi-
cantly, T5V rendered Ltna more similar to the related a
peptides SmbB and BHT-Aa (Fig. 1).
Because some activity was retained upon conversion of
N4 to alanine (Cotter et al., 2006) and the residue at this
position varies across the a peptide group (Fig. 1), N4
was previously categorized as being non-essential with
respect to the bioactivity of lacticin 3147. Three active
mutants were identified (Table 1), two of which involved
substitutions which rendered the peptides more similar to
other a peptides (A, Pnma; V, SmbB and BHT-Aa)
(Fig. 1). Similarly, L8 is variable across the group and a
L8A mutant previously displayed bioactivity (Cotter et al.,
2006). In accordance with this, an additional bioactive
mutant was detected (L8E; Table 1).
Previous mutagenesis of the residues within ring B of
Ltna suggested that this region is tolerant of change in
that six of the nine corresponding mutants retain bioactiv-
ity when altered to alanine (Cotter et al., 2006). The first of
these residues, the negatively charged residue D10, is not
conserved across the a peptide group (Fig. 1) and five
active mutants were identified (Table 1). In particular, the
retention of bioactivity following substitution with another
negatively charged residue, D10E, was anticipated in light
of the natural presence of a glutamate at the correspond-
ing position of Pnma (Fig. 1). Despite the non-production
of a D10K mutant previously (Deegan et al., 2010), it
seems that the presence of a negative charge here is not
essential, given that a D10H mutant still retained some
bioactivity.
In the case of four of the five aromatic residues in Ltna
(F6, W12, W18 and W28), conversion to alanine com-
pletely eliminated bioactivity (Cotter et al., 2006). The
exception, Y11A, displayed greatly reduced bioactivity.
This aromatic residue also varies across the a peptide
group (Fig. 1). Indeed, five mutants with reduced bioac-
tivities were identified (Table 1), including substitutions
that rendered Ltna more similar to other members of the
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group: Y11A (Pnma), Y11V (SmbB, bhtA-alpha) and Y11R
(Bhaa) (Fig. 1).
G13A was previously found to retain a considerable
level of bioactivity (Cotter et al., 2006), even though
glycine is conserved in all a peptides (Fig. 1). It was
suggested that alanine alone, because of its similarity to
the native glycine, could be tolerated (Cotter et al., 2006).
However, saturation mutagenesis established the toler-
ance of the G13 residue to a variety of substitutions,
ranging from other hydrophobic residues (G13A), to non-
conservative hydrophilic neutral (G13N and G13Q) and
charged residues (G13H and G13R) (Table 1). It should
be noted that the bioactivity level of all G13 mutants was
much reduced when compared to wild-type.
Residue G16 is even more highly conserved than
G13, being fully conserved across both the mersacidin-
like peptides (except RumB) and lacticin 481-like pep-
tides (Fig. 1). This hyper-conserved nature, and the
reduced and absent bioactivity of G16A (Cotter et al.,
2006) and G16E (Field et al., 2007), respectively, sug-
gested that G16 is less tolerant of change than its G13
counterpart. This was indeed the case as only one addi-
tional substitution retained detectable bioactivity (G16S,
in which the Ser residue remains unmodified; data not
shown) (Table 1). Similarly, on saturation mutagenesis of
the corresponding glycine in mersacidin (G9), only three
bioactive mutants were identified, including G9A and
G9S (Appleyard et al., 2009). The corresponding posi-
tion in nukacin ISK-1 (G5) has been shown by saturation
mutagenesis to be essential to bioactivity (Islam et al.,
2009).
Residues N15 and the previously discussed N14 are
noteworthy due to the contrasting consequences on con-
version to alanine, with N15A retaining significant bioac-
tivity (Cotter et al., 2006). Saturation mutagenesis of N15
revealed eight mutants that retained bioactivity (Table 1),
including the previously described N15A. In line with
previous studies (O’Connor et al., 2007; Deegan et al.,
2010), an N15K mutant, which more closely resembles
the related C55a, SmbB, BHT-Aa, Hala and Pnma pep-
tides (Fig. 1), exhibited relatively high levels of bioactivity
(Table 1). A N15S substitution that alters Ltna to more
closely resemble rumB, plantaricin C, michiganin and
actagardine and many of the lacticin 481 peptides (Fig. 1)
was also tolerated (Table 1).
Residue A17 is expected to be amenable to substitution
based on its variation among related peptides (Fig. 1) and
the fact that high activity was observed on substitution
with glycine (Cotter et al., 2006). In keeping with this
hypothesis, site-saturation at this position yielded a
number of active mutants (Table 1). Surprisingly, no resi-
dues found at the corresponding locations in other group
members were identified. We did not detect a previously
described mutation, A17N, that makes Ltna more closely
resemble Saca and which has little impact on bioactivity
(O’Connor et al., 2007).
Although M26 is conserved in six out of eight a peptides
(Fig. 1), the retention of some activity on substitution with
alanine led to its classification as a residue that is ame-
nable to change (Cotter et al., 2006). Indeed, following
saturation mutagenesis, many active substitutions were
identified (Table 1), including M26L that more closely
resembles some members of the lacticin 481 subgroup.
While an M26I mutant was only slightly active, mutation of
the corresponding residue (V22) in nukacin ISK-1 to iso-
leucine resulted in a variant with increased potency (Islam
et al., 2009).
In keeping with its designation as a variable residue
(Cotter et al., 2006), and its non-conserved nature
(Fig. 1), position A27 was found to be very tolerant of
change when subjected to site-saturation mutagenesis
(Table 1) (Cotter et al., 2006). In fact, site-saturation muta-
genesis of LtnaA27 yielded the greatest number of bioac-
tive mutants. A change to arginine, which is found in the
equivalent position in SmbBa and BHT-Aa, resulted in a
mutant that retained much of its bioactivity. A change to
valine, which renders the peptide more similar to Plwa,
had a more damaging impact. The identification of an
A27S variant was interesting given that previous attempts
to construct this mutant in order to generate a derivative of
Ltna that more closely resembled C55a were unsuccess-
ful (O’Connor et al., 2007). We established that this
mutant retained close to wild-type levels of bioactivity
(Table 1), and like A27T, remained in an unmodified form
(data not shown). The A27S variant also displayed levels
of bioactivity comparable to those of the wild-type against
S. thermophilus NCDO2525 and L. lactis AM2 (data not
shown). A27S was purified in order to determine its spe-
cific activity (see below).
Ltna has a net neutral charge (two positive residues,
H23 and K30; and two negative; D10 and E24). While
alanine substitution of the negatively charged residues
had a relatively major impact, changing the positively
charged amino acids had a lesser effect (Cotter et al.,
2006). Indeed, a previously described derivative substi-
tuting alanine for both positive residues still retained
considerable bioactivity (Deegan et al., 2010). The H23
location also merited attention by virtue of being the only
position in the region of Ltna within the predicted lipid II
binding domain (residues 19–25), which retained bioac-
tivity on conversion to alanine. Furthermore, both H23 and
K30 are variable across the mersacidin-like peptides
(Fig. 1). Saturation mutagenesis indicated many permis-
sible substitutions for these positively charged residues
(Table 1). In two instances they were replaced by other
positively charged amino acids (K30R and H23R).
Mutants where the substitution mimics a natural variation
between Ltna and the other a peptides (Fig. 1) were
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identified, namely H23V (SmbB, BHT-Aa and Hala),
K30N (Plwa, Hala and Blia) and K30Q (BHT-Aa).
Although it has previously been established that both
H23D- and K30D-producing strains are bioactive (Deegan
et al., 2010), these mutants were not identified in the
current study, suggesting that they were not created or
were not among those tested.
It was apparent that Ltna H23S- and H23T-producing
mutants retained close to wild-type levels of bioactivity
against S. aureus NCDO1499, a clinical isolate involved
in bovine mastitis, S. thermophilus NCDO2525 and
L. lactis AM2 (data not shown). As a consequence of this
bioactivity, coupled with our inability to detect these pep-
tides by CMS, it was postulated that production of these
peptides may be reduced and thus that specific activity
may be relatively high. On that basis, the H23T and H23S
peptides were selected for purification and further analy-
sis. Following purification, masses of 3269 and 3255 Da
were ascertained for H23T and H23S, respectively, indi-
cating that both hydroxyl residues remained in an unmodi-
fied form. Significantly, a serine residue is naturally
present at the corresponding positions in both mersacidin
and plantaricin C (Fig. 1), which in the case of mersacidin
is known to be modified to Dha.
Peptide purification and specific activity studies
Reverse Phase-High Performance Liquid Chromatogra-
phy (RP-HPLC) of H23S, H23T and A27S confirmed pep-
tides of the expected mass, with the exception of an
additional peak corresponding to 3285 Da for H23T, which
was indicative of oxidation. This occurred despite the use
of a variety of strategies designed to minimize this phe-
nomenon. As a result its specific activity could not be
accurately assessed. Accordingly, only purified H23S and
A27S were utilized for specific activity studies.
The MICs of Ltna A27S against L. lactis AM2 and
S. thermophilus NCDO2525, both alone and when com-
bined with Ltnb, are higher than those of Ltna and the
wild-type Ltna–Ltnb combination (Table 2). H23S-Ltnb
had a MIC of 0.0313 mM against S. thermophilus
NCDO2525, similar to the wild-type Ltna–Ltnb combina-
tion (Table 2). The MICs of the two Ltna peptides were
also identical when determined in isolation against
S. thermophilus NCDO2525. It was noteworthy that the
H23S variant alone is twofold more active than its wild-
type counterpart against L. lactis AM2 but, when com-
bined with Ltnb, had a MIC the same as that of wild-type
Ltna–Ltnb (Table 2). This is only the second example
where one of the peptides of a two peptide lantibiotic
exhibits increased solo specific activity relative to the
parental molecule. The first such peptide, LtnbR27A, dis-
played a twofold increased specific activity against
L. lactis HP when compared to Ltnb alone (Deegan et al., Tab
le
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2010). However, in that case an eightfold decreased spe-
cific activity was observed when LtnbR27A was combined
with its sister peptide Ltna against HP. Most notably,
further MIC-based investigations revealed that when
LtnaH23S is combined with Ltnb, their combined specific
activity (0.25 mM) was twofold greater than the natural
lacticin 3147 (0.50 mM) against S. aureus NCDO1499
(Table 2), thus making it the first example of the applica-
tion of bioengineering to successfully enhance the activity
of lacticin 3147, or indeed any two peptide lantibiotic.
Prompted by this finding, further MIC-based analysis of
LtnaH23S combined with Ltnb against a wider selection of
indicator strains including other staphylococcal isolates
(S. aureus Newman, S. aureus Farm 1), enterococci
(E. casseliflavus 5053, E. faecium 5119) and L. lactis HP
revealed that in each case, a twofold decrease in specific
activity compared to wild-type Ltna–Ltnb was apparent
(Table 2). LtnaH23S alone did not show enhanced solo
activity against any of the targets. Thus, although
LtnaH23S exhibits enhanced specific activity, both alone
and in combination with Ltnb, this enhanced activity is
very much a strain specific phenomenon.
Conclusion
Only a small number of bioengineered lantibiotics had
been created prior to 2005, including derivatives with
enhanced antimicrobial activity (Liu and Hansen, 1992;
Kuipers et al., 1996; Wiedemann et al., 2001; Yuan et al.,
2004; Rink et al., 2007), derivatives with enhanced prop-
erties including improved solubility and stability (Liu and
Hansen, 1992; Rollema et al., 1995; Yuan et al., 2004), or
ones which enabled researchers to gain an appreciation of
structure/function relationships (Chan et al., 1996; van
Kraaij et al., 1997; 2000; Chen et al., 1998; Wiedemann
et al., 2001; Szekat et al., 2003). These pioneering studies
suggested that lantibiotic peptides are quite adaptable
and it was evident that further bioengineering-based
approaches could be rewarding. Some recent examples
have been successful with regard to the generation and
identification of lantibiotic derivatives with improved anti-
microbial and/or physicochemical properties (Rink et al.,
2007; Field et al., 2008; 2012; Appleyard et al., 2009;
Islam et al., 2009; Field et al., 2010b; Rouse et al., 2012).
The two peptide lantibiotics have been the subject of
much interest as they offer many possibilities with respect
to the design of new, and possibly more potent, antimi-
crobials. To facilitate the rational design of such peptides,
we performed saturation mutagenesis on one of the two
lacticin 3147 peptides. There are already encouraging
signs that Ltna would make an excellent candidate for
bioengineering considering the significant number of resi-
dues (16/30) that retained bioactivity following alanine
scanning mutagenesis (Cotter et al., 2006), and the fact
that it can function in combination with the b peptide from
another two peptide lantibiotic (O’Connor et al., 2007).
This flexibility is coupled with the fact that the involvement
of two peptides facilitates the examination of distinct func-
tional domains in isolation (Morgan et al., 2005). While
both Ltna and Ltnb each possess solo activity, Ltna is
significantly more active than Ltnb. Thus, Ltna derivatives
can be more easily assessed in isolation, as well as in
combination with Ltnb. It has been speculated that once
the basis of the mutual interaction between the a and b
peptides is revealed, theoretically the a peptide could be
directed to other more strain-specific targets than lipid II
(Breukink and de Kruijff, 2006), while continuing to inter-
act with the b peptide to facilitate pore formation.
To this end, site-saturation mutagenesis was performed
on all residues of Ltna other than those involved in bridge
formation, facilitating a more comprehensive determina-
tion of the tolerance of Ltna to change than that provided
by alanine scanning (Fig. 2). It was apparent that a number
of positions in particular were more amenable to change
(N14, L21) than was previously predicted (Cotter et al.,
2006). Furthermore, a limited number of mostly conserva-
tive changes were tolerated at positions previously desig-
nated as intolerant (S7, W12, E24 and W28) (Cotter et al.,
2006). Significantly, despite the conserved nature of posi-
tions G13, G16 and M26, it was found that within lantibiot-
ics a high degree of conservation does not necessarily
mean that change at this location is not tolerated.
Additionally, during this process, a H23S substitution
was found to improve the specific activity of lacticin 3147
against a strain of S. aureus responsible for bovine mas-
titis, and that of the Ltna peptide alone against L. lactis
AM2. While the bioengineering of lantibiotics has pro-
duced some successes and the activity of a number of
one peptide lantibiotics has been enhanced, this is the
first description of a bioengineered two-peptide lantibiotic
with an improved specific activity. The fact that such
enhanced combinations have not been described previ-
ously most likely stems from the requirement for two pep-
tides to act synergistically for full activity. This imposes a
greater structural constraint on each peptide, and thus
alterations made to enhance the interaction of the a
peptide with its cell target for instance may have a nega-
tive impact on its ability to function synergistically with the
b peptide. One might have predicted that the H23S altera-
tion could enhance lipid II binding as a consequence of
the peptide more closely resembling mersacidin, whose
activity is solely based on lipid II binding without pore
formation. However, the fact that the solo activity of Ltna
H23S against S. aureus is not improved confirms that the
enhanced activity is dependent on the presence of Ltnb.
We speculate that this change must either improve the
Ltna–Ltnb interaction at the target site or that an
enhanced Ltna–lipid II interaction may require a Ltnb-
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induced conformational change. Future work will focus on
the elucidation of the mechanistic basis for the strain-
specific enhanced activity of lacticin 3147 H23S relative to
lacticin 3147.
In summary, through the study of > 200 mutants, this
systematic mutagenesis has provided significant informa-
tion on the key residues that contribute to the bioactivity of
lacticin 3147, which should prove valuable for the rational
design of novel lantibiotics with improved properties. Fur-
thermore, while the vast majority of mutants were less
potent, the high number of derivatives that were produced
in this study can also be interpreted as a test of the in vivo
promiscuity of the enzymatic machinery, showing that the
biosynthetic pathway of lacticin 3147 has a relatively
relaxed specificity when it comes to mutants of Ltna.
Perhaps most importantly, a Ltna–H23S change was
found to improve the specific activity of lacticin 3147
against a strain of S. aureus, representing the first
instance in which an enhanced bioengineered derivative
of a two peptide lantibiotic has been identified.
Experimental procedures
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this study are listed in
Table S1. L. lactis and Enterococcus strains were grown in
M17 broth (Oxoid) supplemented with 0.5% glucose (GM17)
or GM17 agar at 30°C and 37°C respectively. Escherichia coli
was grown in Luria–Bertani broth with vigorous shaking or
agar at 37°C. S. aureus strains were grown in Mueller-Hinton
broth (Oxoid) at 37°C. S. thermophilus NCDO2525 was
grown in Litmus Milk (Difco BD, USA) before routine subcul-
turing in M17 broth supplemented with 0.5% lactose (LM17) at
37°C. Chloramphenicol and tetracycline were used at 5
and 10 mg ml-1, respectively, for L. lactis (unless other-
wise stated) where required and at 20 and 10 mg ml-1,
respectively, for E. coli. Xgal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) was used at a concentration of 40 mg ml-1.
Site-saturation mutagenesis
Oligonucleotide pairs (Table S2) were designed to replace
each target ltnA1 codon with the NNK triplet, which should
result in the substitution of the relevant residue with all 19
possible alternatives (Cwirla et al., 1990; Scott and Smith,
1990). Plasmid pDF01 was used as template DNA for satu-
ration mutagenesis and PCR amplification was performed as
previously described (Field et al., 2008). Following plasmid
amplification and introduction into the intermediate E. coli
MC1000 host, plasmid DNA from a pooled bank of pDF01
derivatives (each corresponding to a targeted amino acid)
was isolated using a Roche High Pure Plasmid Isolation Kit.
DNA sequence analysis with pCI372FOR (MWG Biotech,
Germany) confirmed randomization at the relevant codon.
PbacA1A2 (containing bioengineered ltnA1 genes, the
partner ltnA2 gene and the associated promoter region Pbac)
was re-amplified using the primers pPTPLA1A2FOR and
pPTPLA1A2REV and template DNA isolated from the indi-
vidual mutagenized pDF01 pools. Amplified products were
purified as before, digested with BglII and XbaI (Roche),
ligated with similarly digested and shrimp alkaline phos-
phatase (Fermentas)-treated pPTPL and introduced by elec-
troporation into E. coli MC1000. Transformants were pooled
and stored in 80% glycerol at -20°C. Plasmid DNA isolated
from each mutant bank was introduced by electroporation
into the strain L. lactis MG1363 pOM44 to facilitate expres-
sion of the bioengineered Ltna peptide (in the presence of
unaltered Ltnb) for further analysis. A total of 144 transform-
ants were chosen at random and inoculated into 96-well
plates containing GM17 chloramphenicol and tetracycline
(5 mg ml-1 each), incubated overnight and stored at -20°C
after addition of 80% glycerol. Mutants were identified by MS
analysis and, in instances where the nature of the change
remained ambiguous after MS or a peptide could not be
detected, sequencing with TETK P1. All bioactive derivatives
in each bank were identified. Ten representative inactive
derivatives were chosen from each bank for further analysis,
with loss of activity attributed to the particular substitution, an
insertion, numerous mutations or the introduction of a stop
codon. Varying levels of success were observed in the iden-
tification of unique inactive derivatives. Steps were taken to
ensure that the companion peptide was unmutated (by MS
and/or sequencing) in all cases.
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS)
Colony mass spectrometry (CMS) was performed with an
Axima TOF2 MALDI-TOF mass spectrometer (Shimadzu
Biotech, Manchester, UK) as previously described (Field
et al., 2010b). For purified peptide, a small amount of lyophi-
lized peptide resuspended in 70% IPA 0.1% TFA was used for
analysis.
Bioassays for antimicrobial activity
Deferred antagonism assays were performed as previously
described (Field et al., 2007). For high throughput screening
of the Ltna site-saturation banks against L. lactis HP,
deferred antagonism assays were performed by spotting
strains using a 96-pin replicator (Boekel) on GM17 agar
plates. Zone size was measured with callipers and calculated
as the diameter of the zone of clearing minus the diameter of
bacterial growth.
Minimum inhibitory concentration determinations were per-
formed as described previously (Wiedemann et al., 2006),
with incubation for 16 h at 30°C (L. lactis) or 37°C (S. aureus,
S. thermophilus and Enterococci). The MIC was read as the
lowest peptide concentration causing inhibition of visible
growth.
RP-HPLC purification of lacticin 3147 and
Ltna derivatives
Reverse phase-high performance liquid chromatography
(RP-HPLC) was used to obtain pure lacticin 3147 and Ltna
derivatives as previously described (Suda et al., 2011).
572 D. Field et al.
© 2013 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 6, 564–575
253
Acknowledgements
Work in the authors’ laboratory is supported by the Irish
Government under the National Development Plan; by the
Irish Research Council for Science Engineering and Technol-
ogy (IRCSET); by Enterprise Ireland; and by Science Foun-
dation Ireland (SFI), through the Alimentary Pharmabiotic
Centre (APC) at University College Cork, Ireland, which is
supported by the SFI-funded Centre for Science, Engineering
and Technology (SFI-CSET) and provided P.D.C., C.H and
R.P.R. with SFI Principal Investigator funding.
Conflict of interest
None declared.
References
Appleyard, A.N., Choi, S., Read, D.M., Lightfoot, A., Boakes,
S., Hoffmann, A., et al. (2009) Dissecting structural and
functional diversity of the lantibiotic mersacidin. Chem Biol
16: 490–498.
Begley, M., Cotter, P.D., Hill, C., and Ross, R.P. (2009) Iden-
tification of a novel two-peptide lantibiotic, lichenicidin, fol-
lowing rational genome mining for LanM proteins. Appl
Environ Microbiol 75: 5451–5460.
Bierbaum, G., and Sahl, H.G. (2009) Lantibiotics: mode of
action, biosynthesis and bioengineering. Curr Pharm Bio-
technol 10: 2–18.
Boakes, S., Cortes, J., Appleyard, A.N., Rudd, B.A., and
Dawson, M.J. (2009) Organization of the genes encoding
the biosynthesis of actagardine and engineering of a
variant generation system. Mol Microbiol 72: 1126–1136.
Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E.,
Gilbert, D., Rice, L.B., et al. (2009) Bad bugs, no drugs: no
ESKAPE! An update from the Infectious Diseases Society
of America. Clin Infect Dis 48: 1–12.
Breukink, E., and de Kruijff, B. (2006) Lipid II as a target for
antibiotics. Nat Rev Drug Discov 5: 321–332.
Carroll, J., Draper, L.A., O’Connor, P.M., Coffey, A., Hill, C.,
Ross, R.P., et al. (2010) Comparison of the activities of
the lantibiotics nisin and lacticin 3147 against clinically
significant mycobacteria. Int J Antimicrob Agents 36: 132–
136.
Chan, W.C., Leyland, M., Clark, J., Dodd, H.M., Lian, L.Y.,
Gasson, M.J., et al. (1996) Structure-activity relationships
in the peptide antibiotic nisin: antibacterial activity of frag-
ments of nisin. FEBS Lett 390: 129–132.
Chen, P., Novak, J., Kirk, M., Barnes, S., Qi, F., and Caufield,
P.W. (1998) Structure-activity study of the lantibiotic
mutacin II from Streptococcus mutans T8 by a gene
replacement strategy. Appl Environ Microbiol 64: 2335–
2340.
Cooper, L.E., McClerren, A.L., Chary, A., and van der Donk,
W.A. (2008) Structure-activity relationship studies of the
two-component lantibiotic haloduracin. Chem Biol 15:
1035–1045.
Cotter, P.D., Hill, C., and Ross, R.P. (2005a) Bacterial lanti-
biotics: strategies to improve therapeutic potential. Curr
Protein Pept Sci 6: 61–75.
Cotter, P.D., Hill, C., and Ross, R.P. (2005b) Bacteriocins:
developing innate immunity for food. Nat Rev Microbiol 3:
777–788.
Cotter, P.D., O’Connor, P.M., Draper, L.A., Lawton, E.M.,
Deegan, L.H., Hill, C., and Ross, R.P. (2005c) Posttrans-
lational conversion of L-serines to D-alanines is vital for
optimal production and activity of the lantibiotic lacticin
3147. Proc Natl Acad Sci USA 102: 18584–18589.
Cotter, P.D., Deegan, L.H., Lawton, E.M., Draper, L.A.,
O’Connor, P.M., Hill, C., and Ross, R.P. (2006) Complete
alanine scanning of the two-component lantibiotic lacticin
3147: generating a blueprint for rational drug design. Mol
Microbiol 62: 735–747.
Cox, C.R., Coburn, P.S., and Gilmore, M.S. (2005) Entero-
coccal cytolysin: a novel two component peptide system
that serves as a bacterial defense against eukaryotic and
prokaryotic cells. Curr Protein Pept Sci 6: 77–84.
Cwirla, S.E., Peters, E.A., Barrett, R.W., and Dower, W.J.
(1990) Peptides on phage: a vast library of peptides for
identifying ligands. Proc Natl Acad Sci USA 87: 6378–
6382.
Deegan, L.H., Suda, S., Lawton, E.M., Draper, L.A., Hugen-
holtz, F., Peschel, A., et al. (2010) Manipulation of charged
residues within the two-peptide lantibiotic lacticin 3147.
Microb Biotechnol 3: 222–234.
Dischinger, J., Josten, M., Szekat, C., Sahl, H.G., and
Bierbaum, G. (2009) Production of the novel two-peptide
lantibiotic lichenicidin by Bacillus licheniformis DSM 13.
PLoS ONE 4: e6788.
Field, D., Collins, B., Cotter, P.D., Hill, C., and Ross, R.P.
(2007) A system for the random mutagenesis of the two-
peptide lantibiotic lacticin 3147: analysis of mutants pro-
ducing reduced antibacterial activities. J Mol Microbiol
Biotechnol 13: 226–234.
Field, D., Connor, P.M., Cotter, P.D., Hill, C., and Ross, R.P.
(2008) The generation of nisin variants with enhanced
activity against specific gram-positive pathogens. Mol
Microbiol 69: 218–230.
Field, D., Hill, C., Cotter, P.D., and Ross, R.P. (2010a) The
dawning of a ‘Golden era’ in lantibiotic bioengineering. Mol
Microbiol 78: 1077–1087.
Field, D., Quigley, L., O’Connor, P.M., Rea, M.C., Daly, K.,
Cotter, P.D., et al. (2010b) Studies with bioengineered
Nisin peptides highlight the broad-spectrum potency of
Nisin V. Microb Biotechnol 3: 473–486.
Field, D., Begley, M., O’Connor, P.M., Daly, K.M., Hugen-
holtz, F., Cotter, P.D., et al. (2012) Bioengineered nisin a
derivatives with enhanced activity against both Gram posi-
tive and Gram negative pathogens. PLoS ONE 7: e46884.
Galvez, A., Abriouel, H., Lopez, R.L., and Ben Omar, N.
(2007) Bacteriocin-based strategies for food biopreserva-
tion. Int J Food Microbiol 120: 51–70.
Holo, H., Jeknic, Z., Daeschel, M., Stevanovic, S., and Nes,
I.F. (2001) Plantaricin W from Lactobacillus plantarum
belongs to a new family of two-peptide lantibiotics. Micro-
biology 147: 643–651.
Hsu, S.T., Breukink, E., Bierbaum, G., Sahl, H.G., de Kruijff,
B., Kaptein, R., et al. (2003) NMR study of mersacidin
and lipid II interaction in dodecylphosphocholine micelles.
Conformational changes are a key to antimicrobial activity.
J Biol Chem 278: 13110–13117.
Site-saturation mutagenesis of Ltna 573
© 2013 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 6, 564–575
254
Hyink, O., Balakrishnan, M., and Tagg, J.R. (2005) Strepto-
coccus rattus strain BHT produces both a class I two-
component lantibiotic and a class II bacteriocin. FEMS
Microbiol Lett 252: 235–241.
Islam, M.R., Shioya, K., Nagao, J., Nishie, M., Jikuya, H.,
Zendo, T., et al. (2009) Evaluation of essential and variable
residues of nukacin ISK-1 by NNK scanning. Mol Microbiol
72: 1438–1447.
Jing, W., Hunter, H.N., Hagel, J., and Vogel, H.J. (2003) The
structure of the antimicrobial peptide Ac-RRWWRF-NH2
bound to micelles and its interactions with phospholipid
bilayers. J Pept Res 61: 219–229.
van Kraaij, C., Breukink, E., Rollema, H.S., Siezen, R.J.,
Demel, R.A., De Kruijff, B., and Kuipers, O. (1997) Influ-
ence of charge differences in the C-terminal part of nisin on
antimicrobial activity and signaling capacity. Eur J Biochem
247: 114–120.
van Kraaij, C., Breukink, E., Rollema, H.S., Bongers, R.S.,
Kosters, H.A., de Kruijff, B., and Kuipers, O. (2000) Engi-
neering a disulfide bond and free thiols in the lantibiotic
nisin Z. Eur J Biochem 267: 901–909.
Kuipers, O.P., Bierbaum, G., Ottenwalder, B., Dodd, H.M.,
Horn, N., Metzger, J., et al. (1996) Protein engineering of
lantibiotics. Antonie Van Leeuwenhoek 69: 161–169.
Lawton, E.M., Cotter, P.D., Hill, C., and Ross, R.P. (2007a)
Identification of a novel two-peptide lantibiotic, haloduracin,
produced by the alkaliphile Bacillus halodurans C-125.
FEMS Microbiol Lett 267: 64–71.
Lawton, E.M., Ross, R.P., Hill, C., and Cotter, P.D. (2007b)
Two-peptide lantibiotics: a medical perspective. Mini Rev
Med Chem 7: 1236–1247.
Liu, W., and Hansen, J.N. (1992) Enhancement of the chemi-
cal and antimicrobial properties of subtilin by site-directed
mutagenesis. J Biol Chem 267: 25078–25085.
McClerren, A.L., Cooper, L.E., Quan, C., Thomas, P.M.,
Kelleher, N.L., and van der Donk, W.A. (2006) Discovery
and in vitro biosynthesis of haloduracin, a two-
component lantibiotic. Proc Natl Acad Sci USA 103:
17243–17248.
Majchrzykiewicz, J.A., Lubelski, J., Moll, G.N., Kuipers, A.,
Bijlsma, J.J., Kuipers, O.P., and Rink, R. (2010) Production
of a class II two-component lantibiotic of Streptococcus
pneumoniae using the class I nisin synthetic machinery
and leader sequence. Antimicrob Agents Chemother 54:
1498–1505.
Morgan, S.M., O’Connor, P.M., Cotter, P.D., Ross, R.P., and
Hill, C. (2005) Sequential actions of the two component
peptides of the lantibiotic lacticin 3147 explain its antimi-
crobial activity at nanomolar concentrations. Antimicrob
Agents Chemother 49: 2606–2611.
Navaratna, M.A., Sahl, H.G., and Tagg, J.R. (1999) Identifi-
cation of genes encoding two-component lantibiotic pro-
duction in Staphylococcus aureus C55 and other phage
group II S. aureus strains and demonstration of an asso-
ciation with the exfoliative toxin B gene. Infect Immun 67:
4268–4271.
O’Connor, E.B., Cotter, P.D., O’Connor, P., O’Sullivan, O.,
Tagg, J.R., Ross, R.P., and Hill, C. (2007) Relatedness
between the two-component lantibiotics lacticin 3147 and
staphylococcin C55 based on structure, genetics and bio-
logical activity. BMC Microbiol 7: 24.
Oman, T.J., Lupoli, T.J., Wang, T.S., Kahne, D., Walker, S.,
and van der Donk, W.A. (2011) Haloduracin alpha binds the
peptidoglycan precursor lipid II with 2:1 stoichiometry. J Am
Chem Soc 133: 17544–17547.
Piper, C., Cotter, P.D., Ross, R.P., and Hill, C. (2009a) Dis-
covery of medically significant lantibiotics. Curr Drug
Discov Technol 6: 1–18.
Piper, C., Draper, L.A., Cotter, P.D., Ross, R.P., and Hill, C.
(2009b) A comparison of the activities of lacticin 3147 and
nisin against drug-resistant Staphylococcus aureus and
Enterococcus species. J Antimicrob Chemother 64: 546–
551.
Rink, R., Wierenga, J., Kuipers, A., Kluskens, L.D., Driessen,
A.J., Kuipers, O.P., and Moll, G.N. (2007) Dissection and
modulation of the four distinct activities of nisin by muta-
genesis of rings A and B and by C-terminal truncation. Appl
Environ Microbiol 73: 5809–5816.
Rollema, H.S., Kuipers, O.P., Both, P., de Vos, W.M., and
Siezen, R.J. (1995) Improvement of solubility and stability
of the antimicrobial peptide nisin by protein engineering.
Appl Environ Microbiol 61: 2873–2878.
Rouse, S., Field, D., Daly, K.M., O’Connor, P.M., Cotter, P.D.,
Hill, C., and Ross, R.P. (2012) Bioengineered nisin deriva-
tives with enhanced activity in complex matrices. Microb
Biotechnol 5: 501–508.
Sanderson, J.M., and Whelan, E.J. (2004) Characterisation
of the interactions of aromatic amino acids with diacetyl
phosphatidylcholine. Phys Chem Chem Phys 6: 1012–
1017.
Schnell, N., Entian, K.D., Schneider, U., Gotz, F., Zahner, H.,
Kellner, R., and Jung, G. (1988) Prepeptide sequence of
epidermin, a ribosomally synthesized antibiotic with four
sulphide-rings. Nature 333: 276–278.
Scott, J.K., and Smith, G.P. (1990) Searching for peptide
ligands with an epitope library. Science 249: 386–390.
Skaugen, M., Nissen-Meyer, J., Jung, G., Stevanovic, S.,
Sletten, K., Inger, C., et al. (1994) In vivo conversion of
L-serine to D-alanine in a ribosomally synthesized polypep-
tide. J Biol Chem 269: 27183–27185.
Suda, S., Lawton, E.M., Wistuba, D., Cotter, P.D., Hill, C., and
Ross, R.P. (2011) Homologues and bioengineered deriva-
tives of LtnJ vary in their ability to form D-alanine in the
lantibiotic lacticin 3147. J Bacteriol 194: 708–714.
Szekat, C., Jack, R.W., Skutlarek, D., Farber, H., and
Bierbaum, G. (2003) Construction of an expression system
for site-directed mutagenesis of the lantibiotic mersacidin.
Appl Environ Microbiol 69: 3777–3783.
Wiedemann, I., Breukink, E., van Kraaij, C., Kuipers, O.P.,
Bierbaum, G., de Kruijff, B., and Sahl, H.G. (2001) Spe-
cific binding of nisin to the peptidoglycan precursor lipid II
combines pore formation and inhibition of cell wall biosyn-
thesis for potent antibiotic activity. J Biol Chem 276:
1772–1779.
Wiedemann, I., Bottiger, T., Bonelli, R.R., Wiese, A., Hagge,
S.O., Gutsmann, T., et al. (2006) The mode of action of the
lantibiotic lacticin 3147 – a complex mechanism involving
specific interaction of two peptides and the cell wall pre-
cursor lipid II. Mol Microbiol 61: 285–296.
Willey, J.M., and van der Donk, W.A. (2007) Lantibiotics:
peptides of diverse structure and function. Annu Rev
Microbiol 61: 477–501.
574 D. Field et al.
© 2013 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 6, 564–575
255
Yonezawa, H., and Kuramitsu, H.K. (2005) Genetic analysis
of a unique bacteriocin, Smb, produced by Streptococcus
mutans GS5. Antimicrob Agents Chemother 49: 541–548.
Yuan, J., Zhang, Z.Z., Chen, X.Z., Yang, W., and Huan, L.D.
(2004) Site-directed mutagenesis of the hinge region of
nisinZ and properties of nisinZ mutants. Appl Microbiol
Biotechnol 64: 806–815.
Supporting information
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Table S1. Strains and plasmids used in this study. UCC,
University College Cork; NCDO, National Collection of Dairy
Organisms.
Table S2. Oligonucleotides utilised in this study. Pho indi-
cates 5′ phosphate. Boldface represents randomized nucle-
otides (N = A + C + G + T, K = G + T, M = A + C). Underlined
sequences represent restriction sites.
Site-saturation mutagenesis of Ltna 575
© 2013 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 6, 564–575
256
